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Abstract  
Recreational running is a type of physical activity with proven health benefits, including 
improvements in aerobic fitness and cardiovascular function. Recreational running is 
reported as one of the most popular physical activities among Australians, with 7.4% of the 
population participating. As with any physical activity, there are health-related risks, with 
musculoskeletal injuries the most commonly observed injury in runners, specifically, Achilles 
tendon injuries and bone stress injuries. Running-related injuries are complex conditions, 
and their development depends on the interaction of multiple factors. These include extrinsic 
factors, such as training, lifestyle habits, and intrinsic factors, such as sex, age and genetic 
predisposition. Musculoskeletal injuries are recurrent in nature, preventing runners from 
their regular physical activity and therefore affect their health. An increased understanding 
of factors that contribute to the development of the injuries may, therefore, assist with injury 
prevention strategies, reduce injury rates and potentially encourage more people to exercise 
regularly. This study aimed to investigate the health, training and lifestyle habits of Australian 
recreational runners, identifying the most common running-related injuries and associated 
risk factors, and explore genetic variants associated with Achilles tendon injuries and bone 
stress injuries using a genome-wide association study (GWAS) approach.  
The project utilised an online survey platform and versatile promotional approaches in order 
to recruit recreational runners across Australia. A 25-month recruitment campaign resulted 
in a dataset of 4,720 completed survey responses. This study demonstrated that our cohort 
of recruited Australian recreational runners met recommended physical activity guidelines; 
and health risk factors such as smoking, overweight and hypertension were not typical. 
Moreover, the commencement of a running program was associated with significant weight 
loss. In addition, this study identified significant differences in running habits of male and 
female runners, with men were more likely to run more than six sessions per week and at a 
faster race pace than female recreational runners. In relation to injuries, an Achilles tendon 
injury was the most commonly reported injury, with its occurrence associated with being 
male, older in age, and faster race pace and stretching. The second most commonly 
reported injury was a bone stress injury, and its occurrence was associated with younger 
age, obesity, and longer weekly running distance and stretching.   
Whilst a large-scale survey (4,720 participants) was achieved (Chapters 2 and 3), and 
despite numerous adjustments and targeted recruitment strategies, our recruitment into the 
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GWAS were smaller than expected. The data and findings presented in Chapters 4 and 5 
are from this initial explorative study of genetic association with Achilles tendon injuries and 
bone stress injuries. Challenges of recruitment for large-scale genetic studies are also 
discussed throughout this thesis. 
The GWAS component of the presented study comprises 1,099 analysed samples achieving 
only 23.1% and 95.8% of our case-control recruitment targets, respectively. The genetic 
data analyses were of an explorative nature as the sample size was not sufficient for 
reaching the significance levels required for the GWAS. The case-control analysis of the 
genetic variants associated with Achilles tendon injuries identified several putative genes 
(TCF7L1, DOCK4 and TLE1), which were linked to the Wnt signalling pathway. The study 
failed to replicate the results of previously reported genetic associations with Achilles tendon 
injuries, except two results of polymorphisms which were a putative replication (rs1110495 
in the intragenic region (6:51914974) and rs12722 in COL5A1 gene). These results should 
be interpreted with caution due to the imputed nature of the data. The second case-control 
analysis of genetic association with bone stress injuries identified only one genetic variant 
in the gene TMEM135, whose protein function may contribute to the development of these 
injuries. Attempts to replicate previously shown genetic associations did not confirm those 
findings, except one putative replication for rs2051748 in CALCR gene. However, identified 
associations have to be taken with caution due to the small sample size of the study and 
risk of false-positive results. 
In conclusion, this study demonstrated that Australian recreational runners had a body mass 
index within the healthy weight range, seemed to be meeting the recommended physical 
activity guidelines and were non-smokers. The identified sex differences in training habits 
may contribute to the promotion of recreational running depending on biological sex. The 
described factors associated with running-related injuries, specifically Achilles tendon 
injuries and bone stress injuries contributed to the body of knowledge about the 
development of running-related injuries and potentially would advance injury preventive 
strategies. The analyses of the genetic data provided new information about potentially 
important genetic markers and pathways, which may contribute to the development of 
running-related injuries and further our understanding of the pathophysiology behind these 
injuries. The collected phenotypic and genomic data may also contribute to the future 
research of these injuries, data meta-analysis and a better understanding of the genetics of 
multifactorial conditions.   
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1.1 The role of physical activity in health 
First acknowledgements of the important role of physical activity in health can be traced to 
ancient times and are represented by the development of medical gymnastics in China and 
the integration of physical activity in educational programs and establishment of the culture 
of athletic festivals in Greece. However, physical activity was unpopular during the Dark 
Ages, although it was a practical component of religion during the Middle Ages (MacAuley, 
1994). Until the twentieth century, physical activity was viewed sceptically due to its potential 
danger to health when practised vigorously. When several epidemiological studies 
conducted in the early twentieth century found a positive association between physical 
activity and life longevity, and it regained the acknowledgement as a beneficial practice for 
health (Lee et al., 2012; MacAuley, 1994).  
Development of research methods and accumulation of large health datasets across the 
world have allowed researchers to perform a thorough assessment of the current physical 
activity levels in different populations and their role in mortality rates from non-communicable 
diseases. A systematic review of long-term benefits of physical activity showed negative 
relationships between physical activity and weight gain or obesity, the occurrence of 
coronary heart disease and the risk of type 2 diabetes (Reiner, Niermann, Jekauc, & Woll, 
2013). Physical activity was also negatively related to the incidence of dementia and 
Alzheimer’s disease; however, these studies were based on weak evidence, due to the 
absence of longitudinal studies of people without these conditions at the baseline 
assessments (Reiner et al., 2013).  
Regular physical activity contributes to the primary and secondary prevention of several 
chronic diseases, including cardiovascular disease, diabetes, hypertension and obesity 
(Warburton, Nicol, & Bredin, 2006). Physical inactivity causes 6-10% of the burden of 
disease worldwide and 9% of premature mortality (Lee et al., 2012; Physical Activity 
Guidelines Advisory Committee, 2008; Reiner et al., 2013). Currently, the World Health 
Organisation (WHO) recommends either 150 minutes of moderate-intensity aerobic physical 
activity or 75 minutes of vigorous-intensity physical activity throughout the week, based on 
strong evidence of health benefits and reductions in mortality rates (World Health 
Organisation, 2010).  
Although the role of physical activity is proven in the maintenance of a healthy lifestyle and 
in the reduction in risks of various diseases, it is also accompanied by certain risks that must 
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be considered, in particular, musculoskeletal injuries. The incidence of these acute and 
overuse injuries varies depending on the type of sport or activity. This risk can be further 
determined by the intensity, frequency of exercise and history of previous injury (Melzer, 
Kayser, & Pichard, 2004). Regular physical activity at the recommended level is widely 
known to be beneficial to cardiovascular health (O'keefe & Lavie, 2013). However, there is 
a U-shaped relationship between exercise and cardiac health and morbidity. At one end of 
the U-curve, physical inactivity and sedentary lifestyle were associated with a higher risk of 
cardiovascular disease (CVD) (Myers, 2003; Richardson, Kriska, Lantz, & Hayward, 2004). 
In contrast, the other end of the U-curve relates to long-term excessive exercise, which may 
lead to cardiac damage and therefore increase risks of sudden cardiac arrest and 
cardiovascular disease mortality (O'keefe & Lavie, 2013). The majority of the sudden deaths 
associated with training can be explained by an existing cardiovascular abnormality (Melzer 
et al., 2004). Overall, health risks related to physical activity are mainly associated with the 





1.2 Physical activity in Australia 
According to the ‘Australian Burden of Disease Study’, physical inactivity is one of the top 
five factors contributing to the burden of disease (Australian Institute of Health and Welfare, 
2016b). Physical activity guidelines developed by the Australian Department of Health 
comprise recommendations of the WHO and are distinguished for four age groups 
(Department of Health, 2012). Whilst the first three age groups describe the young 
population, under 18 years, the fourth age group is comprised of individuals aged between 
18 and 64 years. For this (fourth) age group, it is recommended to accumulate 150 to 300 
minutes of moderate intensity physical activity or 75 to 150 minutes of vigorous intensity 
physical activity per week. 
According to a report from the National Health Survey (2014-2015), 57.7% of Australian men 
and 53.3% of Australian women aged between 18 and 64 years met recommended physical 
activity guidelines (Australian Bureau of Statistics, 2016a).  Approximately 79% of Australian 
adults participated in physical activity at least once per week with similar levels of 
participation for men and women across the life stages (Australian Sports Commission, 
2016). According to the most recent report from the Australian Bureau of Statistics, the three 
most popular physical activities among Australians were walking for exercise (19.2%), 





1.3 Health benefits and risks of running and jogging 
Running or jogging is a low cost and an easily implemented activity with proven health 
benefits involving improvements in aerobic fitness and cardiovascular function (Oja et al., 
2015). A longitudinal study, the ‘Copenhagen City Heart Study’, showed that jogging was 
associated with a significantly lower all-cause mortality over a 35-year follow up period 
(Schnohr, Marott, Lange, & Jensen, 2013). Another large longitudinal study of 55,137 adults 
showed that people who incorporated running in their training had 30% and 45% lower risks 
of all-cause and CVD mortality, respectively (Lee et al., 2014). Interestingly, running at lower 
doses per week, and slower speeds still was associated with reduced mortality risks, and 
persistent running over time was associated with mortality reduction (Lee et al., 2014). 
Running is a sport with a relatively high incidence rate of lower extremity injuries, varying 
between 19% and 79% (van Gent et al., 2007). Approximately 80% of running-related 
injuries are overuse injuries mainly concerning lower limb, particularly the Achilles tendon, 
knee and foot (Walther, Reuter, Leonhard, & Engelhardt, 2005). Acute injuries that occurred 
while running are less common. A systematic review of the main running-related injuries 
reported that the most common injuries were: medial tibial stress syndrome (known as a 
bone stress injury) (13.6-20%), Achilles tendinopathy (9.1-10.9%) and plantar fasciitis (4.5-
10%) (Dias Lopes, Hespanhol Junior, Yeung, & Pena Costa, 2012). Overuse injuries have 
multifactorial aetiology; the development of these injuries depends on intrinsic (non-
modifiable) factors, including sex, age, systemic disorders and genetic predisposition, and 
also extrinsic (modifiable) factors such as training loads and lifestyle-related factors. Risk 
factors of overuse injuries have been classified and reported in various prospective studies 
and systematic reviews, however, the interrelationship between extrinsic and intrinsic risk 
factors and their relative contribution to the development of overuse injuries remains unclear. 
 
1.3.1 Risk factors of running-related injuries 
1.3.1.1 Physical characteristics of runners 
Age is a non-modifiable factor and has been studied in relation to the injury risk in multiple 
cohorts. Two systematic reviews indicated age as a risk factor of running injuries with the 
conflicting evidence; some studies reported higher age as a risk factor and other studies 
referred to the greater age as a protective factor against injuries (van der Worp et al., 2015; 
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van Gent et al., 2007). Sex is an intrinsic factor which also demonstrated conflicting 
associations with development of certain types of overuse injuries, but no significant 
association with injury occurrence in total (Hart, 1994; van der Worp et al., 2015; van Gent 
et al., 2007; Walter, Hart, McIntosh, & Sutton, 1989). Evaluations of body mass index as a 
risk factor of running injuries also showed inconsistent results, these results possibly were 
affected by the relatively small numbers of overweight and obese runners in the studies (Van 
Mechelen, 1992). However, a study of risk factors of running-related injuries in novice 
runners showed that the increase of the body mass index by 1 kg/m2 was associated with 
an increased hazard risk of the running-related injury in males (Buist, Bredeweg, Lemmink, 
Van Mechelen, & Diercks, 2010).  
 
1.3.1.2 Anatomic and biomechanical characteristics of runners 
Certain alignment defects may be important factors in developing overuse injuries (Van 
Mechelen, 1992). Varus or valgus knee alignment, significant leg length discrepancy, high 
Q-angle and foot anomalies were associated with higher risk of injuries in several studies 
(Korpelainen, Orava, Karpakka, Siira, & Hulkko, 2001a; Taunton et al., 2003; Wen, Puffer, 
& Schmalzried, 1998; Williams Iii, McClay, & Hamill, 2001). Muscle weakness or imbalance 
in the strength of muscle groups may also increase the risk of injuries in runners 
(Fredericson et al., 2000; Niemuth, Johnson, Myers, & Thieman, 2005). Running 
biomechanics are dictated by lower limb anatomy, particularly joints of the foot and ankle 
(Dugan & Bhat, 2005). It has been shown that altered biomechanics played a major role in 
the development of the exercise-related lower leg pain (Willems, Witvrouw, De Cock, & De 
Clercq, 2007). A study that analysed biomechanical and anthropometric variables of groups 
of injured and uninjured runners found that runners whose stride patterns incorporated lower 
levels of impact forces had reduced risk of injuries (Hreljac, Marshall, & Hume, 2000). 
Several studies showed that retraining of the running gait and cadence led to a significant 
reduction in pain (Barton et al., 2016; Esculier et al., 2017; Roper et al., 2016).  
1.3.1.3 Training characteristics and running habits 
A review of running-related musculoskeletal injuries showed that overtraining and the 
presence of the previous injury were the most significant predictors of the overuse injuries 
(Hart, 1994). Two large studies on recreational runners reported that running over 64 km 
per week was a risk factor for running-related injuries (Macera et al., 1989; Walter et al., 
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1989). Weekly frequencies of running sessions were also studied as a risk factor and 
demonstrated contradictory results: one study reported that frequencies of three to seven 
times per week for men and seven times per week for women were associated with risk of 
injury (Walter et al., 1989). However, another study demonstrated that one session per week 
was a risk factor for injury for women (Taunton et al., 2003). A systematic review of 
determinants of lower extremity running injuries in distance runners reported conflicting 
evidence for the association of training increase with the risk of injury (van Gent et al., 2007). 
A previous injury occurring in the preceding 12 months has been identified as the main 
predictor of running injury. This association might be due to incomplete recovery from the 
previous injury (Saragiotto et al., 2014; Walter et al., 1989). Stretching is another factor that 
has been studied in association with running-related injuries and has shown ambiguous 
results (Hreljac, 2005). A critical review investigated associations between stretching and 
injury risk and reported that prospective studies that showed beneficial effects of stretching 
incorporated other interventions, whereas prospective studies that investigated stretching 
alone did not find any significant difference in injury rates. Moreover, the trend was towards 
higher injury rates in people who stretch before exercise (Shrier, 1999).  
Running shoes provide support and cushioning and play an essential role in shock 
absorption while running and hence, injury prevention (Van Mechelen, 1992). In 2008, a 
systematic review of commonly prescribed running shoes with heel elevation demonstrated 
that these prescriptions were not evidence-based (Richards, Magin, & Callister, 2009). 
Advancements in shoe technology and running biomechanics research led to the expansion 
of barefoot running and development of minimalist footwear (Rixe, Gallo, & Silvis, 2012). 
Thus, it was hypothesised that minimalist shoes would allow runners to disperse impact 
forces more efficiently than runners in conventional shoes. A clinical trial of full and partial 
minimalist footwear on 103 recreational runners showed that injury rates among runners 
wearing these minimalist types of footwear were higher than among runners wearing neutral 
footwear (Ryan, Elashi, Newsham-West, & Taunton, 2014). However, another study of 
1,332 American male soldiers compared injury risks between soldiers wearing traditional 
and minimalist running shoes and did not identify any significant difference (Grier et al., 
2016). As the midsole thickness and other shoe characteristics affect running biomechanics 
and therefore, injury risk (Law et al., 2018), the choice of the running footwear may be an 
important contributing factor. Orthotics influence the biomechanical control of the foot, 
aiming to improve running and provide additional cushioning for the foot (McKenzie, 
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Clement, & Taunton, 1985; Nigg, Nurse, & Stefanyshyn, 1999). Appropriately prescribed 
orthotics may assist in injury prevention and are often considered to have a role in the 
treatment of the injury. However, poorly constructed orthotics have been linked to increased 
incidence of injury (McKenzie et al., 1985). 
 
1.3.1.4 Lifestyle habits 
Certain lifestyle habits, including smoking status and alcohol consumption, may have a 
negative impact on physical activity and running. A study of smoking habits among runners 
showed that 50% of smokers that participated in the study had given up smoking since 
starting to run (Ortega & Aguilar-Blanco, 2006). Although smoking is not a common habit 
among physically active people, the majority of the studies that investigated risk factors of 
running-related injuries found a negative association between smoking and injuries 
(Kraemer et al., 2012; Van Middelkoop, Kolkman, Van Ochten, Bierma‐Zeinstra, & Koes, 
2008). According to a systematic review on risk factors of running-related injuries, there was 
limited evidence of the association between alcohol consumption associated and injuries 
(van Gent et al., 2007). 
Studies have shown the most prevalent running-related injuries are medial tibial stress 
syndrome, Achilles tendinopathy and plantar fasciitis (Dias Lopes et al., 2012). Due to many 
contradictory conclusions about risk factors and their impact on running-related injuries in 
the literature, the two most prevalent injuries of lower limbs have been selected for a detailed 





1.4 Achilles tendinopathy 
1.4.1 Achilles tendon anatomy 
Anatomically, tendons are the structures which connect muscles and bones and transmit 
the force from muscle to bone and enable joints to move. Tendons are essential to 
accommodate sustained loads (Sharma & Maffulli, 2005). The Achilles tendon is the largest 
and the strongest tendon in the human body and plays a fundamental role in locomotion. It 
is formed by the confluence of gastrocnemius and soleus muscles and connects to the 
calcaneus (Figure 1.1). Tenocytes and tenoblasts constitute 95% of cells within the tendon. 
Tenocytes are elongated fibroblast type cells and responsible for collagen secretion. 
Tenoblasts are variable in shapes and arranged in long parallel chains (Longo, Ronga, & 
Maffulli, 2009b). Collagen constitutes 90% of the tendon’s extracellular matrix. The most 
common is the collagen type I and the second common is collagen type II. Overall, collagen 
accounts for 65-80% of the dry tendon mass, with 1-2% of the dry tendon mass being elastin 
(Padhiar et al., 2010). The principal role of collagen fibres is to resist tension and at the 
same time, allow for a certain degree of compliance. A hierarchical structure of the tendon 
resolves the contradiction between these tendon’s functions (Figure 1.2) (Benjamin, Kaiser, 
& Milz, 2008). Tendons have significantly less vascular supply comparing to muscles and 
therefore have 7.5 times lower oxygen consumption than muscles (Benjamin et al., 2008; 
Sharma & Maffulli, 2005). Laser Doppler flowmetry showed that blood flow is distributed 
evenly along the tendon and is lower near the insertion to calcaneal (Kader, Saxena, Movin, 
& Maffulli, 2002). Innervation of the tendon is superficial, and nerves follow blood vessels 
along the tendon (Padhiar et al., 2010). 
 





Figure 1.2 Hierarchical organisation of tendon structure (adapted from 




1.4.2 Achilles tendon pathology 
Achilles tendinopathy is the most common clinical diagnosis of Achilles disorders and 
accounts for 55-65% of Achilles tendon injuries, with the highest incidence among runners, 
track and field athletes, volleyball, tennis and soccer players (Järvinen, Kannus, Maffulli, & 
Khan, 2005). According to a systematic review on running-related musculoskeletal injuries 
in 3,276 runners, the prevalence of Achilles tendinopathy has been estimated between 6.2% 
and 9.5% (Dias Lopes et al., 2012). However, other studies of runners have demonstrated 
a prevalence rate of Achilles tendinopathy varying between 11% and 24% (Wasielewski & 
Kotsko, 2007). The term ‘tendinopathy’ is an umbrella term for the description of tendon 
conditions encompassing pain, swelling and impaired performance (Maffulli, 1998; Padhiar 
et al., 2010). Whilst inflammatory cytokines have been observed in the pathological tendons, 
their expression seemed to differ from a traditional inflammatory response. Some studies 
demonstrated that the expression of these cytokines may be a response of tendon cells to 
mechanical stimuli (Kjaer, Bayer, Eliasson, & Heinemeier, 2013; Li et al., 2004). This also 
may be a sign of imbalance between synthesis and degradation processes, which may lead 
to tendon disorganisation. Clinically, Achilles tendinopathy develops as a result of strenuous 
physical activity with a continuous overload of the tendon and is typically characterised by 
pain and swelling around the tendon and morning stiffness. (Padhiar et al., 2010). As load 
that is applied to the tendon can be both anabolic and catabolic, repetitive energy storage 
and release, and excessive compression may be key factors in the development of 
tendinopathy. Even though overload is the main pathological component, it is modulated by 
other factors including genetics, sex, age and biomechanics (Cook & Purdam, 2009).  
A continuum model of tendon pathology, which was proposed in 2009, has three stages: 
reactive tendinopathy, tendon disrepair and degenerative tendinopathy (Figure 1.3) (Cook 
& Purdam, 2009). The first stage develops as a reaction to acute overload and can be 
distinguished by changes in and extracellular matrix structure and cell shape, yet collagen 
integrity is maintained. The second stage is described as an attempt at tendon healing 
through the increased production of collagen and proteoglycans and is characterised by 
greater disorganisation of the matrix. The tendon itself may be swollen, and its vascularity 
increased. The third stage is characterised by potentially irreversible changes in cell and 




Figure 1.3 Continuum model of tendon pathology.  
  
Although Achilles tendon rupture can be a result of untreated Achilles tendinopathy, typically 
spontaneous Achilles tendon ruptures occur without any preceding symptoms (Cook & 
Purdam, 2009). Achilles tendon ruptures may be associated with participation in sports. 
Histopathologic analysis of ruptured tendon showed obvious degenerative changes which 
might be caused by a sedentary lifestyle. Therefore, spontaneous tendon ruptures can be 
caused by asymptomatic degeneration of the tissue and following sudden movement (Figure 




Figure 1.4 Pathophysiologic mechanisms of an Achilles tendon injury development 
(adapted from (Järvinen et al., 2005)). 
 
For treatment decisions, tendon pathology stages may be divided into two groups: 
reactive/early tendon disrepair and late tendon disrepair/degenerative. Conservative 
treatment and modification of the load may be suggested for the first stage, whereas the 
second stage may require surgery after failed conservative interventions (Cook & Purdam, 
2009). However, the recovery process in the tendon is slow due to poor blood flow and slow 
synthesis of collagen (Kader et al., 2002). Overall, tendon’s response to treatment is very 
slow, both in regards to improving load capacity and resolving pain (Cook & Purdam, 2009). 
The key priority in the management of Achilles tendinopathy is therefore, prevention.  
Aetiological factors of Achilles tendinopathy are also divided into intrinsic and extrinsic, with 
the interaction leading to the symptoms and further progress of the tendinopathy. Intrinsic 
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risk factors include demographic non-modifiable factors (sex, age and height), genetic 
susceptibility; and local anatomic factors: leg length discrepancy, malalignment and 
decreased flexibility. Extrinsic factors comprise weight and body mass index (BMI), 
therapeutic agents (corticosteroids, antibiotics), poor environmental conditions (cold 
weather, icy surface), and sport-related factors, involving training patterns, technique and 
equipment (Järvinen et al., 2005; Padhiar et al., 2010). 
 
1.4.3 Modifiable risk factors of Achilles tendinopathy 
1.4.3.1 Weight characteristics, body mass index and lipid profile. 
A case-control study of 60 patients with mid-portion Achilles tendinopathy and 60 uninjured 
controls matched by age, sex and BMI showed that patients with Achilles tendinopathy had 
higher levels of triglycerides (TG), lower levels of high-density lipoprotein cholesterol (HDL-
C) and higher TG:HDL-C ratio. These lipid profiles are typical for insulin resistance 
syndrome and usually described as dyslipidemia. This finding suggests that serum lipids 
may be involved in the development of Achilles tendinopathy (Gaida, Alfredson, Kiss, Bass, 
& Cook, 2010; Gaida et al., 2009). Another study investigated fat distribution on male and 
female patients with asymptomatic Achilles tendinopathy. Ultrasound examinations of 
Achilles tendon in 298 participants identified a higher pathology rate among men than 
women (17/127, 13% versus 8/171, 5%). Males with asymptomatic Achilles tendon 
pathology had elevated waist to hip ratio, were older, had higher central/peripheral fat mass 
and larger waist circumferences (above 83cm) compared to individuals without tendon 
pathology. This pattern of fat tissue distribution around the abdominal area is usually 
associated with metabolic syndrome and may be linked to the previously reported 
association between dyslipidemia and Achilles tendinopathy. Surprisingly, women with 
asymptomatic Achilles tendon pathology had lower central to peripheral fat mass ratios 
compared to women without pathology, which could be explained by the effect of oestrogen 
on body fat distribution, a factor that was not investigated in this study (Gaida et al., 2010). 
A recent study comparing patients with Achilles tendinopathy aged over 65 years old to 
matching uninjured controls showed a significantly higher prevalence of diabetes, higher 
BMI and a higher level of sport participation in the injured group (Abate, Salini, & Schiavone, 
2015). These findings are consistent with other studies that indicate susceptibility in those 
with chronic comorbidities. The types of exercises undertaken by the participants (speed 
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walking, jogging and tennis) were relatively high-risk in nature and may have been beyond 
the loading capacity of the tendon in ageing individuals (Abate et al., 2015). The link between 
an adverse lipid profile and tendinopathy could be explained by the adipokine modulation of 
certain enzymes’ production, which are important for tenocyte functioning. Additionally, 
chronic low-grade inflammation, which is typical for obesity, may affect the tendon healing 
process. At the same time, tendon healing is also disrupted by low concentrations of immune 
cells that tend to migrate into adipose tissue (Abate, Oliva, Schiavone, & Salini, 2012). A 
systematic review of 17 articles on the link between lipid profile and tendon health showed 
a strong association between tendon pathology and high lipid parameters (Tilley, Cook, 
Docking, & Gaida, 2015).  
 
1.4.3.2 Running habits and training characteristics 
A review of running-related risk factors of Achilles tendon injuries showed that running 
distances and number of years trained had contradictory results in different studies but 
overall did not demonstrate any significant effects on the development of Achilles tendon 
injuries (Lorimer & Hume, 2014). A systematic review of running-related musculoskeletal 
injuries reported that excessive load generated in the gastrocnemius and soleus muscles 
was the main stimulus for the development of Achilles tendinopathy (Dias Lopes et al., 
2012).  
The majority of runners prefer to run on hard terrains, such as bitumen and cement. Soft 
terrains, particularly sand, were reported as a risk factor of Achilles tendinopathy 
development, whereas asphalt had a protective effect against this injury; this effect might be 
related to the higher range of motion of the foot during running on the sand (Knobloch, Yoon, 
& Vogt, 2008).  
Correction with orthotics alters the biomechanics of the foot and helps to relieve heel pain, 
reduce strain on the Achilles tendon and reduce the risk of the Achilles tendon injury (Farris, 
Buckeridge, Trewartha, & McGuigan, 2012; Kader et al., 2002). Shoe adaptations with 
special insoles may help to prevent Achilles tendon injuries (Peters, Zwerver, Diercks, 
Elferink-Gemser, & van den Akker-Scheek, 2015). Stretching is typically thought to be a 
preventive method against sports injuries; however, there is no conclusive evidence for its 
positive or negative effect (Peters et al., 2015). McCrory et al. showed that runners with 
Achilles tendon injuries were less likely to incorporate stretching in their training routine, but 
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unfortunately the study survey didn’t include questions about time relationship between 
stretching practice and injury occurrence (McCrory et al., 1999).  
 
1.4.3.3 Lifestyle habits 
Smoking is a well-known risk factor for a wide range of diseases, such as multiple types of 
cancer and CVD (Erhardt, 2009; World Health Organization, 2006), and was considered as 
a potential risk factor of Achilles tendinopathy in a number of studies (Kraemer et al., 2012; 
Owens et al., 2013). However, in these studies results were contradictory, as Kraemer et al. 
found a negative association between Achilles tendinopathy and positive smoking status, 
suggesting that physically active people were less likely to have a smoking habit. Owens et 
al. reported no significant association between smoking status and Achilles tendinopathy. 
Although studying smoking as a risk factor for exercise-related disorders or injuries is 
complicated (due to negative association between smoking and physical activity), this risk 
factor should be taken into account in relation with tendon injuries. 
A study of 450 cases of Achilles tendinopathy in a large military cohort found that moderate 
alcohol use was associated with an increased risk of Achilles tendinopathy. However, this 
finding was weak, as the magnitude of the OR was modest (OR=1.33, CI: 1.00-1.74) and 
this association could be explained by the alcohol-related risk-taking behaviour which may 
lead to an injury, and alcohol’s influence on metabolic and inflammatory factors that may 
contribute to the tendon pathology (Owens et al., 2013).  
 
1.4.3.4 Medications affecting tendon tissue 
Corticosteroid injections were introduced as a therapy for inflammatory conditions in 1950. 
At that time Achilles tendinopathy was thought to be accompanied by inflammation and 
therefore treated by corticosteroid injections. However, further research revealed adverse 
effects of local steroid injections. The first comprehensive literature review of direct 
corticosteroid injections into Achilles tendon and also peritendinous injections revealed that 
intratendinous injections should be abandoned due to the high incidence of subsequent 
tendon rupture (Mahler & Fritschy, 1992). The main conclusion of the review was that local 
corticosteroid injections can mask symptoms of the degenerative state of the tendon and 
therefore expose the tendon to the trauma (Mahler & Fritschy, 1992). Although chronic 
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Achilles tendinopathy is a non-inflammatory disorder, corticosteroid and nonsteroidal anti-
inflammatory drug injections are proposed as part of the conservative management of 
Achilles tendinopathy (Longo et al., 2009b). The controversy regarding the efficacy of these 
injections and possible adverse effects raises questions over the use of corticosteroids and 
makes it a considerable risk factor of Achilles tendon injuries.  
Anabolic steroids are used to promote muscle growth and tissue repair, but adverse side 
effects were demonstrated by several studies on animals (Inhofe, Grana, Egle, Min, & 
Tomasek, 1995). A review by Laseter et al. showed that anabolic steroids intake had 
significant side effects, including dysplasia of tendon fibrils (Laseter & Russell, 1991).  
Fluoroquinolone antibiotics were introduced in the 1980s and are used to treat respiratory 
infections caused by Gram-negative and anaerobic bacteria. Fluoroquinolone antibiotics 
inhibit fibroblast metabolism through the stimulation of their matrix-protease activity and also 
reduce collagen and proteoglycan synthesis (Williams, Attia, Wickiewicz, & Hannafin, 2000). 
In Denmark, a population-based cohort study of fluoroquinolone antibiotics administration 
demonstrated that individuals had three times higher risk of Achilles tendon rupture within 
90 days of using fluoroquinolone antibiotics when compared to the background population 
(Sode, Obel, Hallas, & Lassen, 2007). An Italian population case-control study used health 
services databases and investigated the influence of fluoroquinolone antibiotics and 
corticosteroids on the development of different Achilles tendon injuries. This study showed 
that patients treated with fluoroquinolone antibiotics are at 1.7-fold increased risk of Achilles 
tendon injuries as a whole and in particular at a 4.1-fold increased risk of Achilles tendon 
ruptures. Moreover, simultaneous exposure to corticosteroids may multiply the risk of 
Achilles tendon injuries by 10 times (Corrao et al., 2006). A literature review of Achilles 
tendon injury cases among patients prescribed fluoroquinolone antibiotics showed strong 
evidence of the adverse effect on the tendon (Khaliq & Zhanel, 2003).  
 
1.4.4 Non-modifiable risk factors of Achilles tendinopathy 
1.4.4.1 Physical characteristics of recreational runners with Achilles tendinopathy 
Physical characteristics, such as age and sex, are considered as non-modifiable traits, and 
commonly reported and investigated as factors of multifactorial conditions, such as Achilles 
tendinopathy. Thus, ageing increases collagen and decreases glycosaminoglycan 
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concentrations in tendons (Longo et al., 2009b), therefore reducing tendon elasticity and 
forcing an increased load on muscles. However, a cross-sectional study of the risk factors 
of Achilles tendinopathy in 178 master athletes (aged over 35) carried out by Longo et al. 
did not find any association between age, sex, weight or height and the development of 
Achilles tendinopathy (Longo et al., 2009a). A systematic review of the pathogenesis of 
Achilles tendinopathy analysed data from 68 articles. In 19 of these articles, age was 
reported as a factor affecting the tendon matrix in different ways (Magnan, Bondi, Pierantoni, 
& Samaila, 2014). In a retrospective study of 2002 running injuries, males younger than 34 
years old were less likely to develop Achilles tendinopathy (Taunton et al., 2002). 
Additionally, Hirshmuller et al. showed that older age was a risk factor for midportion Achilles 
tendinopathy among 634 long-distance runners (Hirschmüller et al., 2012). 
Men report Achilles tendinopathy more often than women. However, considering differences 
in physical activities between the sexes, it is hard to evaluate sex as an independent factor 
(Magnan et al., 2014). A study of high school runners aged 13-18 failed to find any 
association between biological sex and the development of Achilles tendinopathy (Tenforde 
et al., 2011).  
 
1.4.4.2 Biomechanical and anatomic characteristics 
Biomechanical characteristics of muscles and joints, such as strength, flexibility and range 
of motion, are frequently discussed as being intrinsic risk factors for Achilles tendinopathy. 
A systematic review of biomechanical risk factors for Achilles tendinopathy in runners 
identified a high foot arch as a protective factor against Achilles tendinopathy, whereas large 
peak braking force was the variable with the most negative effect on the tendon health 
(Lorimer & Hume, 2014). A study of 89 runners showed that weak plantar flexion and lower 
plantar flexion average power were typical characteristics of runners with Achilles 
tendinopathy (McCrory et al., 1999). Several studies demonstrated that malalignment and 





1.4.4.3 Genetic polymorphisms associated with Achilles tendinopathy 
Genetic variations are sequence alterations in deoxyribonucleic acid (DNA) among 
individuals, these may account for differences in phenotype and also health/disease status. 
One of the most commonly investigated types of genetic variation is the single nucleotide 
polymorphism (SNP), a variation in a single nucleotide located at a specific position in the 
DNA (Wright, 2005). Genetic variations occurring in more than 1% of a population are 
considered useful polymorphisms for genetic linkage analysis. To date, the majority of 
genetic studies have employed a candidate gene approach to find genetic polymorphisms 
in genes that might influence tendon structure and its development and therefore either 
predispose to or protect from, the development of Achilles tendinopathy. Genetic 
predisposition has long been proposed as a contributor to the development of Achilles 
tendinopathy. Early studies assessed the genetic association between ABO blood type and 
tendon injuries, described in several investigations of Finnish and Hungarian patients 
(Leppilahti, Puranen, & Orava, 1995; Maffulli, Reaper, Waterston, & Ahya, 2000). However, 
further research did not support this link with ABO blood group (Mokone, Schwellnus, 
Noakes, & Collins, 2006). However, other genes located in the same region of chromosome 
9q as the ABO blood group gene were implicated, as further detailed below. Furthermore, 
Table 1.1 summarizes all genes and genetic polymorphisms that have currently been 
investigated in association with Achilles Tendinopathy.   
Examination of chromosome region 9q revealed the presence of two tendon-related genes: 
tenascin-C (TNC) and collagen, type V, alpha 1 (COL5A1) (Mokone et al., 2005; Mokone et 
al., 2006). Studies found an association of polymorphic variants of TNC and COL5A1 genes 
with the development of Achilles tendinopathy. Tenascin-C regulates cell-matrix interaction 
in the tendon. TNC contained a polymorphism in intron 17 where the number of GT 
dinucleotide repeats ranged from 3 to 21, and 95% of the alleles contained 12 to 17 GT 
repeats. In this range, the most common alleles contained 12 and 14 repeats, and the least 
common alleles were of 13 and 17 repeats. Those runners, who were homozygous or 
heterozygous for the underrepresented alleles of TNC, were 6.2 times less likely to develop 
an Achilles tendon injury (Mokone et al., 2005) indicating that these variants of TNC may be 
protective from Achilles tendinopathy. COL5A1 encodes the pro-a1 (V) chain of the type V 
collagen. Two variants of the COL5A1 gene were associated with an increased risk of 
Achilles tendinopathy. In contrast, the third variant was underrepresented in runners with 
Achilles tendinopathy and therefore, was associated with a reduced likelihood of Achilles 
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tendinopathy development (Mokone et al., 2006). A follow-up study published by the same 
research group from South Africa in collaboration with researchers from Australia replicated 
previously shown associations linking COL5A1 gene variants to Achilles tendinopathy in 
both Australian and South African populations (September, 2009). These studies 
demonstrate the relevance of the TNC and COL5A1 gene polymorphisms in genetic 
predisposition to Achilles tendinopathy. 
Other studies have assessed the contribution of haplotypes constructed from candidate 
polymorphisms in an effort to find interactions between genes or gene products. A 
collaborative study investigated collagen, type XXVII, alpha 1 (COL27A1) gene 
polymorphisms in conjunction with TNC, as COL27A1 is located in the same region of 
chromosome 9q as the TNC gene. Type XXVII collagen, encoded by COL27A1, is 
responsible for the critical structural framework and tensile strength of the interstitial 
matrices. Although there were no significant associations between the polymorphisms in 
COL27A1 and Achilles tendinopathy, a GCA haplotype (a set of genetic variants located on 
a single chromosome), constructed from one COL27A1 polymorphism (rs946053) and two 
TNC polymorphisms (rs13321, rs2104772), showed a significant association with Achilles 
tendinopathy (Saunders et al., 2013). The study of COL5A1 and MIR608 polymorphisms in 
South African and Australian cohorts, found that a variant of COL5A1 contains a putative 
polymorphic micro-RNA binding site. The results showed that polymorphisms rs71746744, 
rs16399, rs1134170 in COL5A1, and a polymorphism rs4919510 in MIR608, which encodes 
a small microRNA 608, were all independently associated with Achilles tendinopathy, 
suggesting a role for these four variants in the messenger ribonucleic acid (mRNA) stability 
and the consequent type V collagen synthesis (Abrahams, Laguette, Prince, & Collins, 
2013). A follow-up study of the same polymorphisms in a British cohort did not find any 
independent association between studied COL5A1, MIR608 or IL-1B (interleukin 1β) 
variants and Achilles tendinopathy as was shown in Australian and South African cohorts 
(Brown et al., 2016). However, an inferred allele combination constructed from COL5A1 
SNPs rs12722, rs3196378 and rs71746744 was associated with the risk of Achilles tendon 
pathology (Brown et al., 2016).  
A further study conducted on South African study participants analysed polymorphisms in 
the gene encoding for matrix metalloproteinase 3 (MMP3), which is involved in the regulation 
of extracellular matrix homeostasis. Three of the investigated polymorphisms in the MMP3 
gene (rs679620, rs591058, rs650108) showed strong association with Achilles tendinopathy 
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and the most underrepresented haplotype in patients with Achilles tendinopathy indicated 
that this variant was protective against Achilles tendinopathy (Raleigh, 2009). Moreover, 
since MMP3 genotyping had been done on the same cohort as COL5A1 reported by 
September et al. (September, 2009), this study presented allelic combinations of MMP3 
rs679620 and COL5A1 rs12722, which are associated with a lower risk of Achilles 
tendinopathy. Type V collagen is a substrate for MMP3, hence genetic variants in COL5A1 
and MMP3 genes could account for differences in the interactions between the proteins 
(Raleigh, 2009). Further investigation of MMP3 gene’s polymorphisms showed that an 
inferred haplotype of four SNPs (rs3025058, rs679620, rs591058 and rs650108) was 
associated with Achilles tendinopathy in an Australian cohort (Gibbon et al., 2016). 
Polymorphisms in COL12A1 (rs240736, rs970547) and COL14A1 (rs4870723, rs1563392) 
were investigated as they both encode for proteins involved in the biological processes of 
fibrillogenesis and, like tenascin-C, in the modulation of the tendon response to mechanical 
stress (September et al., 2008). Additionally, one study of two cohorts from South Africa and 
Australia investigated polymorphisms in the three genes coding for type XI collagen that is 
homologous to type V collagen in function and structure (Hay et al., 2013). Type XI collagen 
is usually expressed in cartilage, but also in developing tendons. Several polymorphisms 
(COL11A1 rs3753841 and rs1676486, COL11A2 rs1799907) have been associated with 
lumbar disc herniation and rheumatoid arthritis. Whilst none of the polymorphisms were 
independently associated with Achilles tendinopathy, the construction of a pseudohaplotype 
consisting of three polymorphisms in COL11A1 and the COL5A1 polymorphism 
rs71746744, revealed a significant association with Achilles tendinopathy. It was 
hypothesized that the interaction of genes encoding for type V and XI collagens could 
modulate the risk of Achilles tendinopathy, allowing for the possibility that the effects of type 
XI collagen variants in the developing tendon may affect the structural or functional 
properties of the mature tendon (Hay et al., 2013).  
Genes involved in tendon homeostasis and particularly in the extracellular matrix have also 
been investigated for their association with Achilles tendinopathy risk (El Khoury et al., 
2013). The ADAMTS (A Disintegrin And Metalloproteinase with ThromboSpondin motifs) is 
a family of proteinases, which are involved in the extracellular matrix homeostasis, and 
reported to be more highly expressed in pathological tendons than in healthy tendons. 
Tissue inhibitor of metalloproteinases (TIMP) inhibits the actions of MMPs and ADAMTS. 
Previously studied cohorts were genotyped for the ADAMTS2 rs1054480, ADAMTS5 
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rs226794, ADAMTS14 rs4747096, ADAM12 rs3740199 and TIMP2 rs4789932 gene 
variants. Researchers found a significant association between the rs4789932 TIMP2 variant 
and Achilles tendinopathy. The balance between TIMPs and MMPs could be a contributing 
factor for Achilles tendinopathy development (El Khoury et al., 2013). An attempted 
replication of the study of MMP3 and TIMP2 gene variants in a British cohort showed that a 
gene variant in TIMP2 rs4789932 was associated with a reduced risk of Achilles tendon 
pathology in males (El Khoury, Ribbans, & Raleigh, 2016). The continued investigation of 
proteins involved in the tendon structure included research of fibrillin and elastin for their 
role in elasticity, strength and flexibility of tendons. The polymorphisms FBN2 rs331079 and 
ELN rs2071307 were studied in Australian and South African cohorts, and the GG genotype 
in rs331079 was overrepresented in the group with Achilles tendinopathy, indicating an 
association between fibrillin and the injury (El Khoury et al., 2015). Another study conducted 
on the same cohorts investigated the contribution of genes encoding growth factors that play 
an important role in tendon growth and homeostasis. TGFB1 and GDF5 (encoding for 
transforming growth factor-β1 and growth/differentiation factor-5, respectively) were 
selected as candidates as these proteins had been shown to increase mechanical strength 
after gene transfection in Achilles tendon in experimentally injured animals (Rickert et al., 
2005). This study showed a significant association of Achilles tendinopathy with GDF5 
rs143383. However, no association with TGFB1 rs1800469 was identified (Posthumus et 
al., 2010). 
A thorough analysis of polymorphisms in COL5A1 identified this gene as one of the most 
likely predisposing factors for Achilles tendinopathy. However, several studies, investigating 
polymorphisms in genes encoding for proteins interacting with type V collagen, showed that 
it is important consider possible connections and pathways, whose interactions may be 
disrupted and therefore alter collagen structure and its functionality and lead to the increased 
or decreased risk of Achilles tendinopathy.   
Candidate genes involved in processes such as tendon turnover and inflammation have also 
been considered as possible genetic risk factors for Achilles tendinopathy. The SNPs in 
cytokine genes, which have been shown to be upregulated in tendinopathy and 
mechanically loaded tendon, were also investigated. Interleukin-1β (IL-1β) induces 
inflammatory mediators that upregulate the expression of proteins involved in the 
degradation of the tendon extracellular matrix such as MMPs which target type V collagen. 
The IL-1β receptor antagonist (IL-1ra) is encoded by the IL1RN gene and its variable number 
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tandem repeat (VNTR) rs2234663 polymorphism has been previously associated with 
gastrointestinal diseases (Mansfield et al., 1994), osteoporotic fractures (Langdahl, Løkke, 
Carstens, Stenkjær, & Eriksen, 2000) and atherosclerosis (Olofsson et al., 2009). The 
genetic variants in IL1B (rs1143627 and rs16944) have been implicated to the increased 
expression of the  IL1B gene (Landvik et al., 2009), and interleukin-6 (IL-6) was found to be 
linked to the tenocyte apoptosis, which is typical for tendinopathy. Thus, IL-1β and IL-6 may 
also affect COL5A1 gene expression (September et al., 2011). A SNP in IL6 (rs1800795) 
was previously shown to alter the IL6 expression (Fishman et al., 1998), which may lead to 
the increased tenocyte apoptosis and therefore, potentially increase the risk of the 
development of Achilles tendinopathy. In total, the study investigated four polymorphisms in 
IL1B, IL1RN and IL6, although none of these polymorphisms were associated with the 
Achilles tendinopathy diagnosis in either of the South African and Australian population 
groups studied. However, inferred allele combinations constructed from previously studied 
COL5A1 polymorphisms and IL1B, IL6 and IL1RN VNTR polymorphisms were associated 
with an increased risk of Achilles tendinopathy in combined groups (September et al., 2011). 
This study concluded that genetic polymorphisms contributing to the changes in 
inflammatory pathways may be significant contributors to the risk of Achilles tendinopathy. 
Polymorphisms in genes, encoding caspases (CASP) and nitric oxide synthases (NOS), 
have also been investigated, as these molecules were involved in pathways accompanying 
the tendon cell apoptosis, and their expression was elevated in tendinopathy (Nell et al., 
2012). South African and Australian cohorts were genotyped for four polymorphisms: 
(CASP8 rs3834129, rs1045485, NOS3 rs1799983, and NOS2 rs2779249). A significant 
association between both CASP8 polymorphisms (rs3834129, rs1045485) and Achilles 
tendinopathy was found in both populations. The D/D genotype of rs3834129 was 
associated with tendinopathy, whilst the C allele of rs1045485 was associated with the 
absence of Achilles tendinopathy. NOS3 (rs1799983), and NOS2 (rs2779249) were not 
associated with Achilles tendinopathy. However, the data presented in this study showed 
that the control group in the Australian cohort was not in Hardy-Weinberg equilibrium (HWE), 
which refers to constant proportions of allele and genotype frequencies in a population, and 
therefore this association should be interpreted with caution. Deviations from HWE in the 
control group may indicate significant methodological flaws including selection bias, 
population stratification and genotyping errors (Namipashaki, Razaghi-Moghadam, & 
Ansari-Pour, 2015). Yet study was the first that investigated polymorphisms in caspase 
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pathways. However, recent genome-wide association study (GWAS) of almost 5,000 
patients with Achilles tendinopathy failed to identify any statistically significant 
polymorphisms as well as replicate findings of the previously described studies of 
polymorphisms located in CASP8, COL5A1, MMP3 and several other genes (Kim et al., 
2017). Possibly, the failure to identify statistically significant polymorphisms and to replicate 
results of the previous studies was due to different characteristics of cohorts, as Kim et al. 
used samples and data collected from the hospital patients, who were diagnosed with 
Achilles tendon bursitis, tendinopathy or rupture, and Kim et al. did not control for the 
patients’ physical activity levels. Additionally, studies used as a reference by Kim et al., 
utilised a candidate gene approach, and generally were underpowered and demonstrated 
weak statistical associations. 
A tumour necrosis factor receptor 1 gene TNFRSF1A, which signals inflammation and 
apoptosis in response to the tumour necrosis factor-alpha (TNFα), was investigated as a 
potential gene associated with Achilles tendinopathy (Gaida et al., 2012). TNFRSF1A 
rs4149577 polymorphism was previously associated with several musculoskeletal and 
inflammatory diseases. However, this study by Gaida et al. was the first to investigate this 
polymorphism in association with Achilles tendinopathy. Another polymorphism investigated 
in this study was rs1049253 in the caspase-3 gene CASP3, which was shown to influence 
CASP3 mRNA expression. Caspase-3 is involved in cellular apoptosis, including roles in 
chromatin condensation and DNA fragmentation (Porter & Jänicke, 1999). This study also 
investigated the influence of the copy number variant (CNV) spanning intron 11-intron 12 in 
CASP8. CNVs are segments of DNA greater than 1kb in size that can influence phenotypes 
by changing gene dosage and disruption of coding sequences in DNA. The results did not 
show any significant association between Achilles tendinopathy, the investigated 
polymorphisms and CNV. This was possibly due to the study limitations, such as a relatively 
small sample size and a possible additional degree of error due to the rounding of copy 
number data into discrete calls, which, therefore, may indicate that there was no association 
between these CNVs and Achilles tendinopathy (Rickaby, El Khoury, Ribbans, & Raleigh, 
2015) (Table 1.1). An expanded version of Table 1.1, which includes sample sizes and 




Table 1.1 Summary of genes and polymorphisms investigated in association with 
Achilles tendinopathy. 
Gene Polymorphisms Product References 






Tenascin-C  (Kim et al., 2017; Mokone et 
al., 2005; Saunders et al., 
2013) 




Pro-a1 (V) chain of 
the type V collagen 
(Abrahams et al., 2013; 
Brown et al., 2016; Hay et al., 
2013; Kim et al., 2017; 
Mokone et al., 2006; Raleigh, 
2009; September, 2009) 
COL27A1 rs946053 Type XXVII collagen (Saunders et al., 2013) 
MIR608 rs4919510 Micro-RNA 608 (Abrahams et al., 2013; 






metalloproteinase 3  
(El Khoury et al., 2016; 
Gibbon et al., 2016; Kim et 
al., 2017; Raleigh, 2009) 
COL12A1  rs240736 
rs970547 
Type XII collagen (September et al., 2008) 
COL14A1 rs4870723 
rs1563392 
Type XIV collagen (September et al., 2008) 
COL11A1 rs3753841 
rs1676486 
α1 chain of type XI 
collagen 
(Hay et al., 2013) 
COL11A2  rs1799907 α2 chain of type XI 
collagen 
(Hay et al., 2013) 
ADAMTS2 rs1054480 Tendon procollagen 
N-propeptidase 2 
(El Khoury et al., 2013) 
ADAMTS5  rs226794 Tendon procollagen 
N-propeptidase 5 
(El Khoury et al., 2013) 
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Table 1.1 Summary of genes and polymorphisms investigated in association with Achilles 
tendinopathy (continuation). 
Gene Polymorphisms Product References 
ADAMTS14 rs4747096 Homologue of 
ADAMTS2 
(El Khoury et al., 2013; 
Kim et al., 2017) 
ADAM12 rs3740199 Disintegrin and 
metalloproteinase 12 
(El Khoury et al., 2013) 
TIMP2 rs4789932 Tissue inhibitor of 
metalloproteinases 2 
(El Khoury et al., 2013; El 
Khoury et al., 2016; Kim et 
al., 2017) 
FBN2  rs331079 Fibrillin-2 (El Khoury et al., 2015; 
Kim et al., 2017) 
ELN rs2071307 Elastin (El Khoury et al., 2015) 
TGFB1 rs1800469 Transforming growth 
factor-β1 
(Posthumus et al., 2010) 
GDF5 rs143383 Growth/differentiation 
factor-5  
(Posthumus et al., 2010) 
IL1RN  rs2234663 IL-1β receptor 
antagonist 
(September et al., 2011) 
IL1B rs1143627 
rs16944 
Interleukin-1β (September et al., 2011) 
IL-6 rs1800795 Interleukin-6  (September et al., 2011) 
CASP8  rs3834129 
rs1045485 
CNV (intron 11, 12) 
Caspase 8 (Kim et al., 2017; Nell et 
al., 2012) 
NOS3 rs1799983 Nitric oxide synthase 3 (Nell et al., 2012) 
NOS2  rs2779249 Nitric oxide synthase 2 (Nell et al., 2012) 
TNFRSF1A rs4149577 Tumour necrosis factor 
receptor 1 
(Rickaby et al., 2015) 





While these studies indicate some links between polymorphisms in genes involved in 
apoptosis, inflammation and Achilles tendinopathy, the majority of these studies were unable 
to demonstrate that these genes are probable risk factors for Achilles tendinopathy. The 
processes of apoptosis and inflammation contribute to the pathology of Achilles 
tendinopathy, however, further investigation should be undertaken to clarify the role of 
genetic variation, which may impact these pathological processes.  
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1.5 Bone stress injuries  
1.5.1 Bone structure and pathology 
The skeleton is a metabolically active organ which changes and adapts under mechanical 
stimuli by remodelling bone structure (Karlsson & Rosengren, 2012). Bone is a connective 
tissue with cells embedded in a mineralised matrix composed of collagen, mainly collagen 
type I (30% of the matrix) and inorganic salts rich in calcium and phosphates (70% of the 
matrix). Bone tissue exists in two forms: compact and cancellous. The compact bone 
constitutes the surface of the bones and consists of collagen fibres arranged in layers with 
embedded osteocytes. Cancellous bone is a sponge type tissue, also known as trabeculae 
and is found in the interior of bones. Bone modelling is a process when osteoclasts form 
bone tissue by producing collagen matrix, which leads to an increase in bone mass. This 
process occurs during the growth period of the skeleton and defines bones shapes and 
sizes. Bone remodelling is a lifelong renewal process of the bone, which is responsible for 
bone maintenance and repair (Kiuru, Pihlajamäki, & Ahovuo, 2004). The bone tissue can be 
remodelled by osteoclasts, which resorb matrix to mineral content, and then osteoblasts 
deposit new bone matrix (Figure 1.5) (Sinnatamby, 2011). The ability of the bone to remodel 
is essential as it allows the bone to adapt to the mechanical loads and modulate its density. 
Bone requires the load to develop normally, and if the load is eliminated and osteoblastic 
function decreases, this may lead to low diffuse osteoporosis (Kiuru et al., 2004). However, 
under the increased load, osteoclastic and osteoblastic functions may become unbalanced. 
Therefore, when there is a gap in time between the high osteoclastic activity and the high 
osteoblastic activity, the bone is weakened during remodelling, predisposing it to 
microfractures (Bennell, Matheson, Meeuwisse, & Brukner, 1999; Mattila, Niva, Kiuru, & 




Figure 1.5 Bone remodelling process (adapted from (Encyclopaedia Britannica, 
2017)).  
 
A bone stress injury is an overuse injury attributed to the repetitive loading of the bone with 
vigorous weight-bearing activity, such as marching, running and jogging (Mattila et al., 
2007). Initially, this injury was recognised in soldiers, and the most prevalent diagnosis was 
a metatarsal stress fracture. Later, with the increase of athletic participation, bone stress 
injuries were also noted among civilians, particularly athletes (Flinn, 2002). Stress fractures 
occur under two circumstances. Fatigue fractures occur when the normal bone is exposed 
to repeated abnormal stress, while insufficiency fractures occur in the abnormal bone under 
normal stress (Mattila et al., 2007). Pathologically, bone stress injuries begin with stress 
reactions, which can develop into stress fractures and finally complete bone fractures 
(Figure 1.6) (Warden, Davis, & Fredericson, 2014). Typical symptoms can be characterised 
by local pain, which occurs during impact loading, and worsens if the loading continues and 
eventually can persist after the impact loading has finished (Pollock, 2011). The most 
common locations of the bone stress injuries are the tibial shaft and metatarsal bones, 
whereas pelvis, hip, thigh and knee are less common anatomic locations (Korpelainen, 
Orava, Karpakka, Siira, & Hulkko, 2001b; Mattila et al., 2007). In a systematic review of 
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running-related injuries, medial tibial stress syndrome (MTSS) was shown to be the most 
prevalent bone injury (9.5%) associated with running (Dias Lopes et al., 2012). A recent 
prospective cohort study of 933 novice runners also demonstrated that 15% of injured 
runners developed MTSS (Figure 1.7) (Nielsen, Ronnow, Rasmussen, & Lind, 2014). 
 
 
Figure 1.6 Pathophysiologic mechanisms of bone stress injury development (adapted 




Figure 1.7 A typical pain localization with medial tibial stress syndrome (adapted from 
(Walsh, 2017)). 
 
Magnetic resonance imaging (MRI) was shown to be the most accurate and reliable image 
assessment of bone stress injuries, including early stages of these types of injury (Beck et 
al., 2012). The management of bone stress injuries depends on their anatomic location and 
severity. Firstly, physical activity should be modified, considering the location of the injury. 
The damaged bone should be unloaded after the injury occurrence. Partial weight-bearing 
exercise can be introduced in the next several weeks, depending on injury severity. 
Secondly, the rehabilitation process should include muscle strengthening and a gradual 
return to usual physical activity (Flinn, 2002; Pollock, 2011). Prevention of bone stress injury 
occurrence is the priority of injury management. Bone strength can be maximised by 
analysing and correcting intrinsic factors and directed training to help to improve bone 
strength (Pollock, 2011). 
Due to the complexity of the interaction between factors contributing to the development of 
bone stress injuries, risk factors may be divided into factors modifying the load applied to a 
bone, and factors influencing bone density, and hence the ability of bone to resist the load. 
The first group of factors includes biomechanical traits, training habits and environmental 
conditions. The second group of factors includes sex, age, endocrine and hormonal status, 
chronic disorders, physical activity levels, diet and nutrition, therapeutic agents and genetic 
factors (Warden et al., 2014). 
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1.5.2 Factors modifying the load applied to the bone 
1.5.2.1 Anatomic and biomechanical characteristics 
Differences in leg length showed a consistent association with stress fractures both in 
military and civilian populations and can be considered as a key anatomic risk factor (Bennell 
et al., 1999). Abnormal movement patterns in runners can also increase the risk of bone 
stress injuries; for instance, static alignment may influence movement patterns and hence 
be implicated in bone stress injury development (Warden et al., 2014). Due to variations in 
anatomy, different anatomic and biomechanical characteristics are associated with bone 
stress injuries in males compared to females. For instance, increased external rotation hip 
range of motion is a risk factor of MTSS in men (Newman, Witchalls, Waddington, & Adams, 
2013), whereas narrow pelvis (<26cm) is associated with a greater risk of stress fractures 
among female marines (Winfield, Moore, Bracker, & Johnson, 1997). 
 
1.5.2.2 Running habits and training characteristics 
Bone adaptation time for increasing loads should be considered in the development of a 
training regimen. Repetitive mechanical load contributes to stress fracture development. 
The load applied to the bone is the result of the summation of external and internal forces, 
which are determined by training factors, physical fitness and anatomy. Several military 
studies reported a correlation between the levels of previous physical activity and rates of 
stress fractures during training (Bennell et al., 1999). For instance, poor physical 
conditioning measured in male Finnish conscripts was associated with an increased risk of 
stress fractures (Välimäki et al., 2005). Changes in the training regimen, such as rest 
periods, elimination of running and marching on concrete, reduction of high impact activity 
may reduce the risk of stress fractures (Bennell et al., 1999). Incrementing a training 
program too rapidly may be the central training factor, which leads to the microdamage 
accumulation and disruptions in bone turnover (Warden et al., 2014). In addition, a 
systematic review of risk factors of MTSS demonstrated that fewer years of running 
experience was associated with the development of the injury (Newman et al., 2013). 
However, the cut-off values for running experience and MTSS risk remained undetermined. 
Overall, the longer experience of training and physical activity appears to be protective 
against bone stress injuries (Warden et al., 2014). Training surface may contribute to the 
development of stress injuries. The ability to adapt leg stiffness to the surface makes this 
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risk factor very complex to study. Runners alter their leg stiffness when running on surfaces 
of different compliance in order to maintain a constant vertical excursion of their centre of 
mass. Therefore, changes in running surfaces might increase the risk of injuries as a runner 
must adapt their biomechanics to the new training conditions (Warden et al., 2014). 
Athletic footwear and orthotics aim to attenuate shock with ground contact and to control the 
motion of the foot and ankle. Indeed, the choice of appropriate training shoes is essential 
for injury prevention. However, the majority of the studies showed a limited effect of wearing 
insoles and orthotics in relation to stress fracture development. However, a systematic 
review of MTSS showed that orthotic use was associated with increased risk of the injury 
(Newman et al., 2013). Military studies demonstrated reduction of overuse injuries in the 
foot, but not in tibia when military boots were replaced by athletic shoes during training. 
Further studies showed that wearing semi-rigid orthotic devices decreased the incidence of 
femoral stress fractures, but not overall incidence. The inconsistency of results in these 
studies may be explained by the interaction between sports shoes/orthotic use, the anatomy 
of the foot and the site of stress fracture (Bennell et al., 1999).  
 
1.5.3 Factors affecting bone density 
1.5.3.1 Physical characteristics of recreational runners with bone stress injuries below the 
knee 
Incidence of bone stress injuries was significantly higher in female runners in several 
studies, and a systematic review of risk factors of MTSS reported that there was a 1.7-fold 
higher risk of developing MTSS for female runners than male runners in 9 analysed studies 
(Newman et al., 2013). Several studies of military populations showed a significantly 
increased incidence of bone stress injuries among female conscripts (Mattila et al., 2007; 
Protzman & Griffis, 1977). However, this association may be due to sex-related factors, such 
as hormones, menstrual cycle, bone density, diet and anatomic characteristics (Tuan, Wu, 
& Sennett, 2004). The term ‘female athlete triad’ was established in order to describe three 
major factors of bone stress injuries in female athletes: low bone mineral density (BMD), 
menstrual disturbances and nutritional issues. The underlying mechanism of these co-
factors is a negative energy balance, developing if energy expenditure is higher than energy 
intake (Korsten-Reck, 2011). A cohort study of 259 physically active female adolescents 
showed that a cumulative risk of bone stress injuries increases as the number of triad-related 
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factors accumulates (Barrack et al., 2014). However, in April 2014, the International Olympic 
Committee published a consensus statement and introduced a new, more comprehensive 
and broad term – Relative Energy Deficiency in Sport (RED-S). The previous term ‘female 
athlete triad’ was exclusive to women, and did not consider some negative outcomes of low 
energy availability (Mountjoy et al., 2015). Some indicated that energy deficiency may also 
occur in male athletes, and they also may have dietary disorders, hormonal disruption and 
impaired bone health (Bennell, Brukner, & Malcolm, 1996a). RED-S allows athletes and 
coaches to take into account numerous health consequences of energy deficiency and 
sports clinicians can apply this model to a range of athlete clinical presentations (Mountjoy 
et al., 2015). For instance, low BMI (<20kg/m2) is typical in case of RED-S; however, its 
association with the increased risk of bone stress injuries may also be explained by poor 
muscle strength, which could lead to injuries (Mattila et al., 2007). 
Bone density decreases with age, and therefore, the ability of bone to endure overloading 
is reduced with age. Bones with lower density are more likely to accumulate microdamage 
leading to the stress fractures in older age. On the other hand, children and adolescents 
may be at risk of stress fractures due to the immature condition of their bones. Hormonal 
status and training loads may be important co-factors of age as a risk factor (Bennell et al., 
1999). 
Body size and BMI were associated with the development of bone stress injuries in several 
studies. Increased BMI was associated with the development of MTSS (Newman et al., 
2013). A case-control study of tibial stress injury (TSI) showed that both men and women 
with TSI had significantly higher body fat and lower lean mass than uninjured matched 
controls (Beck, Rudolph, Matheson, Bergman, & Norling, 2015).  
 
1.5.3.2 Lifestyle habits 
Smoking and alcohol consumption may have an adverse effect on bone turnover by limiting 
calcium absorption (Pollock, 2011). Numerous studies demonstrated an inverse relationship 
between smoking and bone mineral density. A meta-analysis of smoking and stress fracture 
risk showed that smoking was associated with reduced bone mineral density in men and 
post-menopausal women. Even though both ‘having ever smoked’ and ‘current smoking’ 
contribute to the increased risk of stress fractures, current smoking had higher risk ratios of 
stress fractures than ever-smoking (Kanis et al., 2005). A prospective study of 3,758 female 
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US army recruits showed that the history of smoking and current smoking increase risk of 
stress fractures among young female recruits, moreover, the relative risk increased with 
more years of smoking and more packs of cigarettes per day (Lappe, Stegman, & Recker, 
2001).  
Long-term excessive alcohol consumption was associated with low bone mass in both males 
and females. The same study of the female conscripts also reported that alcohol 
consumption of 10 or more alcoholic drinks per week was a risk factor of stress fractures 
(Lappe et al., 2001). Unfortunately, it was hard to ascertain alcohol consumption as an 
independent risk factor because many participants who consume alcohol also smoked in 
this study.  
 
1.5.3.3 Diet and nutrition affecting bone health 
Eating disorders are common among athletes when individual low weight and lean body are 
a pre-condition for high performance. Anorexia athletica is an eating disorder, which along 
with anorexia nervosa may lead to disrupted endocrine status and following osteoporosis 
and proneness to bone stress injuries (Korsten-Reck, 2011).  
Calcium is an essential component of bone mineralisation, and vitamin D is an essential 
factor of calcium absorption. The vitamin D metabolite 1,25-dihydroxyvitamin D 
(1,25(OH)2D) is the most physiologically active metabolite. It acts through the vitamin D 
receptor directly, to increase intestinal calcium absorption and to enhance renal calcium 
reabsorption. It is also known to decrease parathyroid hormone secretion and enhance the 
differentiation of both osteoblast and osteoclast precursors. If dietary calcium is inadequate, 
vitamin D causes osteoclasts to mature and resorb calcium from the bone. One study 
demonstrated that lowered serum 1,25(OH)2D levels were a significant risk factor for stress 
fractures among a military population of Finnish conscripts (Ruohola et al., 2006). A 
prospective study of young female runners showed that women whose calcium daily intake 
was less than 800mg had a nearly 6 times higher incidence rate of bone stress injuries when 
compared to women who consumed more than 1,500 mg of calcium per day (Nieves et al., 
2010). Calcium and vitamin D supplementation was also demonstrated to be an efficient 
means of preventing bone stress injuries among female navy recruits (Lappe et al., 2008). 
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1.5.3.4 Hormonal status 
Female athletes have a higher prevalence of menstrual disturbances when compared to the 
general female population (Torstveit & Sundgot-Borgen, 2005). These disturbances include 
delayed menarche, anovulation, oligomenorrhoea and amenorrhoea. Higher incidence of 
bone stress injuries in female athletes may be explained by low oestrogen levels. Oestrogen 
deficiency accelerates bone remodelling and causes increased calcium excretion leading to 
decreased bone density. The combination of these circumstances may contribute to the 
development of bone stress injuries. Regarding post-menopausal women, falling oestrogen 
levels also lead to similar consequences and also predispose older women to stress 
fractures and osteoporosis (Pollock, 2011). Although many studies have investigated the 
effect of the oral contraceptive pill on the development of bone stress injuries, the obtained 
results were contradictory, and the oral contraceptive pill could not be suggested as an 
effective preventive therapy against bone stress injuries (Bennell et al., 1999). Interestingly, 
other hormones related to calcium metabolism failed to show any association with the 
incidence of bone stress injuries, possibly due to poor sampling and measurement 
procedures in the studies (Bennell et al., 1999). Hormonal status is an important contributor 
to bone health and should be considered as a risk factor of bone stress injuries.  
 
1.5.3.5 Medications affecting bone structure 
Glucocorticoids (a class of steroid hormones) induce osteoblast apoptosis and increase 
osteoclast activity, these two effects leading to disruptions in bone turnover and weakened 
bones (Rehman & Lane, 2003). Corticosteroids have an adverse effect on bone density, 
causing an imbalance between osteoclast and osteoblast activities. Corticosteroid use is a 
significant risk factor for osteoporosis, which is included in the clinical guidelines for the 
assessment of osteoporosis. A meta-analysis of corticosteroid use in seven prospectively 
studied cohorts showed that prior corticosteroid use increased the risk of stress fractures 
and should be considered as an independent factor for bone mineral density and the 
previous fragility fracture (Kanis et al., 2004).  
Patients with active epilepsy require regular medication, and therefore, in addition to the 
benefits of the treatment, they are exposed to the side effects of anti-epileptic drugs. The 
prevalence of bone disorders among patients chronically treated with anti-epileptic drugs 
was reported at 50% (Petty, O’Brien, & Wark, 2007). Multiple biochemical abnormalities take 
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place when patients take anti-epileptic drugs: reduced serum calcium, phosphate and 
vitamin D, increased concentration of the parathyroid hormone. Parathyroid hormone 
regulates calcium metabolism. When calcium concentration is decreased, the parathyroid 
hormone triggers bone breakdown and resorption (Pack, 2003). The mechanism of the anti-
epileptic drug’s impact on bone remains controversial, the most popular theory being that 
anti-epileptic drugs induce cytochrome p450 enzymes, which cause increased vitamin D 
degradation. However, some studies showed hypocalcaemia and low bone density in 
patients without vitamin D deficiency (Petty et al., 2007). 
Cancer therapies, including radiotherapy and chemotherapy, can directly or indirectly 
damage bone. Several chemotherapy agents may have a direct effect on bone metabolism. 
For instance, methotrexate reduces osteoblast production by inhibiting DNA synthesis and 
simultaneously increases osteoclast production. Overall, the main side effect of 
chemotherapy is decreased bone formation and subsequent bone mass loss. Likewise, 
chemotherapy, radiation causes significant bone loss (Michaud & Goodin, 2006). 
Bisphosphonates are stable pyrophosphate analogues which bind bone mineral. 
Bisphosphonates are prescribed to reverse bone loss and slow or stop the natural process 
that dissolves bone tissue, resulting in maintained or increased bone density and strength. 
These are prescribed for osteoporosis and in some cancer treatments (Armamento-Villareal 
et al., 2009; Michaud & Goodin, 2006). However, the detrimental effects of long-term 
bisphosphonate treatment were also found. The prolonged suppression of resorption by 
continuous use of bisphosphonates indirectly inhibits bone formation, which may lead to the 
decreased ability to repair micro-damage or rejuvenate old bone (Armamento-Villareal et 
al., 2009).  
 
1.5.3.6 Chronic disorders 
Several chronic disorders have been shown to be associated with an increased incidence 
of bone stress injuries, often due to an inherent occurrence of low bone density. 
Cerebral palsy is defined as a non-progressive disturbance of the developing foetal or infant 
brain that results in movement and posture disorders that cause activity limitations 
(Rosenbaum et al., 2007). Cerebral palsy is a common chronic motor disability, with 3.6 per 
1,000 children prevalence (Esen, Demirel, Güven, Değerliyurt, & Köse, 2011). Many children 
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and adults with cerebral palsy have diminished bone mineral density, which results in bone 
fractures and therefore impaired physical function and poor quality of life (Houlihan & 
Stevenson, 2009).  
Cystic fibrosis is an inherited, chronic, progressive and fatal disease, caused by mutations 
in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Cystic fibrosis 
affects the lungs, liver, pancreas and intestines (Li et al., 2014). Although this disease 
doesn’t affect bone directly, decreased bone mineral density is demonstrated in patients 
with cystic fibrosis. Robertson et al. reported 5.5% incidence of bone fractures among cystic 
fibrosis patients. Reduced bone density in cystic fibrosis patients is thought to be associated 
with nutritional deficiency and use of bisphosphonate medication (Robertson & Macdonald, 
2010).  
Rheumatoid arthritis is an autoimmune disease which causes irreversible joint damage and 
functional disability (Fechtenbaum, Nam, & Emery, 2014). Patients with rheumatoid arthritis 
have a greater risk of osteoporosis than the general population due to their impaired walking 
ability, chronic inflammation and glucocorticoid use. A prospective study of fracture 
incidence in rheumatoid arthritis patients reported a significantly higher risk of fractures than 
in previous retrospective studies, and the majority of occurred fractures caused a gait 
disturbance in patients (Nampei et al., 2008). 
 
1.5.3.7 Genetic markers associated with bone stress injuries 
Several signs of the existence of genetic variants have been mentioned in the literature: the 
presence of stress fractures in monozygotic twins (Singer, Ben-Yehuda, Ben-Ezra, & 
Zaltzman, 1990) and high recurrence rates of bone stress injuries in track-and-field athletes 
(Bennell et al., 1996b). There is minimal knowledge of the genetic contribution to the 
development of bone stress injuries and findings are usually based on studies of genetic 
markers of osteoporosis and exercise. Osteoporosis is a multifactorial disorder in which loss 
of bone strength leads to fragility fractures. A large genetic study of 2018 male patients with 
osteoporosis searched for polymorphisms in the genes that play an important role in bone 
structure and remodelling and could be associated with bone mineral density. This study 
found 11 polymorphisms in 10 genes that showed a strong association with vertebral bone 
mineral density (Zmuda et al., 2011). In addition to calcium and vitamin D supplementation 
and oestrogen levels, around 30 genetic markers, involving a vitamin D receptor gene 
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(VDR), bone morphogenetic protein (BMP2) genes showed association with the 
development of osteoporosis (Raisz, 2005; Styrkarsdottir et al., 2003).  
The Wnt signalling pathway has extensive functions and regulates processes related to cell 
growth, differentiation, function and cell death during embryonic development as well as 
adult life. This pathway plays an essential role in bone formation, and the decreased 
functioning of the Wnt pathway results in osteopenia or osteoporosis (Piters, Boudin, & Van 
Hul, 2008) Polymorphisms in genes encoding a protein involved in this pathway (LRP5) or 
a protein-antagonist of this pathway (SOST), were shown to be associated with significant 
increase or decrease of bone mineral density (Piters et al., 2008). 
The most extensively studied gene in relation to stress fractures is the vitamin D receptor 
(VDR) gene. The vitamin D receptor plays a vital role in calcium metabolism as it is located 
in various tissues, including intestine and bone, and mediates the effects of vitamin D 
(Kehoe & Montgomery, 2006). Several polymorphisms in VDR were found to be associated 
with either increased or decreased bone mineral density (Ferrari, Rizzoli, Slosman, & 
Bonjour, 1998; Kehoe & Montgomery, 2006). Another investigated genetic marker is a 
calcitonin receptor gene (CALCR). Calcitonin is a hormone involved in osteoclast activity. A 
case-control study of 203 uninjured soldiers and 182 soldiers with stress fractures showed 
that several SNPs in CALCR (rs12154667, rs1548456) and VDR (rs4328262) genes were 
associated with stress fractures (Yanovich et al., 2012).  
Genetic analysis of 518 DNA samples obtained from elite athletes with radiologically 
confirmed stress fractures showed that several polymorphisms in genes within the 
RANK/RANKL/OPG signalling pathway were associated with stress fracture susceptibility. 
The RANK/RANKL/OPG signalling pathway plays an important role in the regulation of bone 
remodelling and bone adaptation (Varley et al., 2015). Another candidate gene studied in 
the same elite athletes, and a cohort of conscripts is P2X7 that encodes a highly purinergic 
P2X7 receptor. This receptor is expressed by osteoblasts and osteoclasts and involved in 
cellular responses to stress. Identified significant SNPs (rs3751143 and rs1718119) have 
also been shown to be associated with bone phenotypes in other studies (Varley et al., 2016) 
(Table 1.2). An expanded version of Table 1.2 can be found in Appendix 2.
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Table 1.2 Summary of genes and polymorphisms investigated in association with 
bone stress injuries. 
Gene Polymorphisms Product References 
VDR rs4328262 Vitamin D receptor (Ferrari et al., 1998; 
Kehoe & Montgomery, 





Calcitonin receptor (Yanovich et al., 2012; 
Zmuda et al., 2011) 
BMP2 Not specified Bone morphogenetic protein 2 (Raisz, 2005; 
Styrkarsdottir et al., 2003) 
LRP5 Not specified Low-density lipoprotein 
receptor 5 
(Piters et al., 2008) 
SOST rs1877632 Sclerostin (Piters et al., 2008; 
Zmuda et al., 2011) 
RANK rs3018362 Receptor activator of nuclear 
factor-KB 
(Varley et al., 2015) 
RANKL rs1021188 Receptor activator of nuclear 
factor-KB ligand 
(Varley et al., 2015) 
P2X7 rs3751143 
rs1718119 





1.6 Genome-Wide Association Studies  
The development of high-density genetic methods has led to a shift towards a genome-wide 
association study (GWAS) approach based on the linkage disequilibrium (LD) principle 
(Hartl, Clark, & Clark, 1997), specifically, the non-random association of genetic variants at 
different genomic loci in a population. Loci are said to be in LD when the frequency of 
association of the different genetic variants is higher or lower than what would be expected 
if they were independent and associated randomly. This technology allows researchers to 
identify multiple genetic markers, from hundreds of thousands-to-millions, simultaneously 
across the whole genome and avoid a bias of preselection of potentially important genes as 
in the candidate gene approach. However, genome-wide association studies have several 
limitations. Specifically, GWAS require a large sample size to achieve adequate statistical 
power and provide statistically significant results. The sample size of GWAS depends on 
many factors: disease prevalence, disease allele frequency, LD, effect size and inheritance 
models (Hong & Park, 2012). As GWAS evaluate hundreds of thousands of SNPs, this leads 
to multiple comparisons and increases the risk of false-positive results. Therefore, the p-
value threshold must be adjusted, usually through the employment of a Bonferroni correction 
(standard p-value of 0.05 divided by the number of analysed SNPs (Abdi, 2007). However, 
with a large sample size, it may be difficult to control for homogeneity of the studied groups 
and consistent and precise diagnoses. Finally, the effect size of the association is important 
for the application of the findings in clinical practice. According to Klein et al., only 6.8% of 
GWAS reported Odds Ratio (OR) of more than 3.0 at a p-value less than 10-5 (Klein, 
Lohmann, & Ziegler, 2012).  
In relation to exercise and health, several consortiums have been established to collect data 
and samples in order to reach a sufficient sample size. The HERITAGE family study (HEalth, 
RIsk factors, exercise Training and GEnetics) was organised by five universities to 
investigate the role of genetic variants in cardiovascular, hormonal and metabolic responses 
to aerobic exercise training (Bouchard et al., 1995). In addition, the Athlome Project 
Consortium has been established in order to study genetic and phenotypic data of athletes 
in adaptation to exercise and on exercise-related injuries (Pitsiladis et al., 2016). This 
Consortium investigates data collected from cohorts of athletes across many countries such 
as the UK, Japan, Eastern European countries, East African countries, and continues to 
expand their collaborative efforts and grow numbers of participants in each of the project. A 
recent publication of the GWAS on Achilles tendinopathy and Anterior Cruciate Ligament 
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(ACL) injuries presented results from the Genetic Epidemiology Research on Adult health 
and ageing (GERA) cohort of over 100,000 people (Kim et al., 2017). These examples of 
collaborative efforts and large-scale studies, which aimed to identify genetic variants in 
association with exercise and exercise-related injuries indicate the validity and great 
potential of the GWAS approach in this field.  




1.7 Conclusion  
Physically active people, particularly athletes, are more likely to develop overuse injuries 
due to the biology of these types of injuries. The consequences of overuse injuries have a 
detrimental effect on the individual’s health, quality of life and sports performance. The main 
priority in managing lower limb injuries in tendon and bone is to prevent these injuries. 
Treatment is expensive and time-consuming and, according to the relatively high injury 
recurrence rates, not always efficient. In order to reduce injury incidence, contributing risk 
factors should be taken into account and corrected if possible. This literature review of 
overuse injuries demonstrates several gaps in the current knowledge base, particularly in 
regard to genetic risk factors. The reviewed risk factors of Achilles tendinopathy and bone 
stress injuries represent a complex interrelationship between intrinsic and extrinsic 
contributors for each type of injury. Contradictory outcomes between some studies and low 
repeatability of the results necessitate comprehensive investigations of the risk factors, their 
significance and interactions. Prospective studies have demonstrated reliability with respect 
to training and biomechanical risk factors, as they allow the collection of more precise data 
by following the participants of the studies. Although genetic markers can be studied 
retrospectively, the data on the genetics of injuries is limited to several case-control studies 
on relatively small cohorts. This thesis will explore the genetics of overuse injuries in a cohort 
of recreational runners to attempt to provide a better understanding of the genetic 
contribution to the development of overuse injuries and the biological processes and 





1.8 Project overview 
1.8.1 Purpose of the study 
The purpose of the study is to identify training and lifestyle-related characteristics of 
physically active people, genetic polymorphisms associated with Achilles tendinopathy and 
bone stress injuries, and to systemise and make these data available for the preventive 
strategy against running-related injuries. This study will use both epidemiological and GWAS 
approaches to investigate training and lifestyle-related factors associated with running-
related injuries and identify genetic polymorphisms associated with the incidence of Achilles 
tendinopathy and bone stress injuries in lower extremities. Due to the high popularity of 
running in Australia and a relatively high incidence of overuse injuries while running, 
recreational runners were selected as the study group. An online questionnaire approach 
was selected as a method to collect phenotypic data from Australian recreational runners, 
and to provide a platform for the selection of appropriate candidates for the GWAS. The 
main hypothesis of this project is that certain discovered genetic polymorphisms will be 
associated with either increased or decreased risk of Achilles tendinopathy and/or bone 
stress injuries. 
Specific objectives of the project: 
1. To collect and analyse health, lifestyle and training data from Australian recreational 
runners, and describe the training and lifestyle habits of the runners. 
2. To identify and report frequencies of the running-related injuries and investigate risk 
factors contributing to the risk of these injuries in recreational runners. 
3. To investigate which training and lifestyle habits may be risk factors of Achilles 
tendinopathy in recreational runners. 
4. To investigate which training and lifestyle habits may contribute to the risk of bone 
stress injuries in recreational runners. 
5. To collect and analyse DNA samples of the runners using a GWAS approach and 
investigate which genetic markers are associated with either increased or decreased 
risk of Achilles tendinopathy. Following imputation of additional genotypes will allow 
replication of previously identified associations from the studies which utilised a 
candidate gene approach.  
6. To collect and analyse DNA samples of the runners using a GWAS approach and 
investigate which genetic markers are associated with either increased or decreased 
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risk of bone stress injuries. Following imputation of additional genotypes will allow 
replication of previously identified associations from the studies which utilised a 
candidate gene approach. 
 
1.8.2 Significance of the study 
This study will be the largest cross-sectional study conducted of Australian recreational 
runners. Collected data will allow the analysis of training patterns and injury frequencies in 
a large number of physically active Australians. This knowledge may help to promote 
physical activity among less active groups of the population as well as contribute to running 
injury prevention programs. The use of GWAS as a discovery-based and unbiased approach 
will allow investigation of multiple genetic polymorphisms simultaneously. Findings of the 
genetic arm of the study may contribute to a better understanding of the molecular pathways 
and mechanisms underlying the development of running-related injuries.  
 
1.8.3 Sample size estimation and power calculations for GWAS 
The sample size is a crucial aspect of study design that researchers can control and change 
in order to reach the expected power of the study and the significance level of GWAS. As a 
GWAS analyses hundreds of thousands of genetic variants, they require a large sample size 
in order to reach estimated significance levels. Initially, statistical power calculations for the 
project were determined as the GWAS significance level of p<5x10-8 and a minimum 
threshold of the expected power at 80% (Cohen, 1988). Additional parameters required for 
power calculations were disease prevalence, minor allele frequency (MAF) and relative risk 
(RR). Thus, disease prevalence was set up at an average of 10% for each type of injury 
(Section 1.4.2 and Section 1.5.1). The MAFs of previously investigated polymorphisms, 
which were described in the literature review varied between 0.05 and 0.5 (Section 1.4.4 
and Section 1.5.3) and six values were included in the power calculations: 0.05, 0.1, 0.2, 
0.3, 0.4 and 0.5. Finally, three values of RR were employed in the power calculations: 1.3, 
1.5 and 2.  
In order to investigate the required sample size with variation in MAFs and RR, an online 
power calculator for GWAS (Power-Calculator, 2015; Skol, Scott, Abecasis, & Boehnke, 
2006) was utilised. The results of these calculations are displayed in Figure 1.8. If the RR is 
high (RR=2) and the MAF is high (MAF=0.5), then the sample size may be as small as 150 
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cases and 150 controls, whereas for interrogation of the SNPs with the lowest MAF of 0.05 
the sample size must include 1,000 cases and 1,000 controls. Therefore, when the RR is 
high, and the sample size is large, statistical analysis would permit an investigation of SNPs 
with low MAFs. When the RR is 1.5, then a sample size of 800 cases and 800 controls will 
be required to interrogate SNPs with MAFs of at least 0.3. Less common SNPs will require 
a sample size of over 1,200 cases and 1,200 controls. Finally, if the RR is 1.3, then even 
the most common SNPs with MAF of 0.5 will require a sample size of 20,000 cases and an 
equal number of controls. These calculations demonstrated that at least 800 cases and 800 
controls would be a sufficient sample size for investigation of the identified common SNPs 
at the RR of 1.5 and the required significance level.    
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Figure 1.8 Required sample size to reach power at 80% with combinations of ranged minor allele frequencies (MAFs) and 
relative risk (RR). 
Blue, green and red colour spectrums refer to 1.3, 1.5 and 2 values of relative risk, respectively. Each colour spectrum reflects the 
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Running is a popular recreational pastime. In Australia, the rate of participation in running 
increased from 4.3% of the population in 2005–06, to 7.4% in 2013–14 (Australian Bureau 
of Statistics, 2015). Recent data have indicated that current participation levels in athletics, 
including running, in the Australian population may be as high as 15.8% (Australian Sports 
Commission, 2016). Running provides a low-cost option for increasing physical activity, 
without the restrictions of specific equipment or costs of sports club membership. Furthering 
the understanding of the running habits and wider health characteristics of male and female 
recreational runners may assist in the development of sex-specific messaging to promote 
the health benefits of recreational running as a form of physical activity. 
This study aimed to recruit a large sample size of approximately 10,000 participants in order 
to conduct case-control studies on the obtained phenotypic and genetic data and identify 
training-related factors and genetic variants associated with two most common running-
related injuries – Achilles tendon injuries and bone stress injuries (Dias Lopes et al., 2012). 
The design of the study required gathering high volume data from Australian recreational 
runners across the country and subsequently, a remote collection of biological material from 
prospective participants for the genetic arm of the study.  
The purpose of the descriptive part of this study was firstly, to describe the health and 
lifestyle characteristics of Australian recreational runners and compare body mass index 
(BMI) to the general Australian population, and secondly, to examine the similarities and 
differences in training habits of male and female runners. It was hypothesised that 
recreational runners would display characteristics of a healthy lifestyle, including 
participation in physical activity, maintaining a healthy BMI and having low rates of chronic 






2.2.1 Online Questionnaire 
An online survey was developed utilising the SurveyGizmo Platform (Boulder, CO, USA), 
and comprised 185 questions with an expected average time of 30 minutes for completion. 
This survey contained questions covering a number of topics in the following order: physical 
characteristics, ethnic background, running habits, injury history (e.g. injured/uninjured in 
prior two years and details about injuries), history of chronic conditions, dietary habits (e.g. 
nutritional requirements and dietary supplements), and female health (for female 
participants e.g. menstrual cycle) (Appendix 5). The majority of the health, lifestyle and 
training-related questions were closed-ended and were either dichotomous or offered 
multiple choice answers. However, several questions were open-ended, which, for example, 
allowed respondents to provide diagnoses of injuries different from Achilles tendon injuries 
or bone stress injuries, dietary preferences, lost weight in kilograms. 
A test-retest reliability study demonstrated that this self-reported, retrospective 
questionnaire is able to provide stable and reliable data and meets the recruitment needs 
for the project (Domaschenz, Vlahovich, Keogh, Compton, & Hughes, 2015). This survey 
also enabled the selection of eligible participants and subsequent sample collection for the 
GWAS. Several selection criteria for a GWAS have been indicated based on the literature 
review and further discussed in chapters 4 and 5: 
• 18-50 years of age,  
• reported background of at least 75% of Caucasian European or Mediterranean  
• current non-smoker with at least five years after giving up,  
• have no history of chronic conditions that could affect the musculoskeletal system 
(osteoarthritis, osteoporosis, rheumatoid arthritis, chronic renal failure),  
• no history of chemotherapy. 
An essential requirement for eligibility was acceptance of the following survey items: ‘I give 
permission, if I am eligible, to be contacted in the future for related research’ and ‘I give 
permission, if I am eligible, to be contacted in the future to provide a saliva sample for genetic 
related analysis’. The study was approved by the Bond University Human Research Ethics 




2.2.2 Recruitment strategies 
An overview of the project on the AIS website and SurveyGizmo platform described its aim 
to recruit Australian recreational runners being age over 18 years and recreational running 
practice of more than 15 km per week. Hence participants who identified themselves as 
recreational runners, self-selected for inclusion into the study with consideration of these 
two inclusion criteria – minimal age of 18 years and minimal weekly running distance of 15 
km. 
In order to simplify an online search for the study and its promotion, it was given a short title, 
the ‘AIS Running Injury Study’. The study was actively promoted using websites of the 
involved research institutions, social media, running organisations and events (Appendices 
6 and 7). Some of the recruitment activities were free of charge, and while others were paid 
for (Table 2.1). Free strategies comprised partnerships with running clubs and organisations 
such as parkrun, the establishment of a study Facebook page, voluntary referrals by runners 
and medical professionals, and collaborations with sports-related businesses to provide 
respondents with online discount codes upon survey completion. Methods that incurred a 
cost comprised advertising on websites, including Facebook and running-related websites, 
and researchers’ attendance of ten running-related events, including a three-day CityFit 
Expo.  
The enrolment period spanned September 2014 until October 2016. All respondents 
provided informed consent to participate and provided personal data after accepting the 
conditions of the study on the first page of the online questionnaire (Appendix 5). The last 
question of the survey ‘How did you hear about this research?’ was included in the survey 
16 months after the commencement of the recruitment. This question aimed to identify the 




Table 2.1 Summary of recruitment strategies incorporated in the project with 
specified expenses. 
Strategy Methods and channels Outcomes (other 
than recruitment) 
Expenses 
Facebook Group page with regular 
posts 
Paid advertisements 
Posts in other pages 
Page followers & 
post sharing 



















Running events Flyers 
Emails to event participants 
Presence in race results 
emails 










CityFit Expo  Flyers 
Presence in Expo social 
media 











Parkrun Presence at events 
Newsletters 







Table 2.1. Summary of recruitment strategies incorporated in the project with specified 
expenses (continuation). 










Word of mouth 
Facebook posts 
 















personal trainers, running 
coaches 



















2.2.3 Statistical data analyses 
Statistical analyses were conducted in IBM SPSS Statistics version 24 (SPSS, Inc.). 
Participants’ BMI was calculated from the responses to weight (kg) and height (cm) and 
categorised as very underweight (<16 kg/m2), underweight (16-18.5 kg/m2), normal (18.5 to 
<25 kg/m2), overweight (25 to <30 kg/m2), moderately obese (30 to <35 kg/m2), severely 
obese (35 to <40 kg/m2) and very severely obese (≥40 kg/m2). 
All numerical variables were checked for normality using Kolmogorov-Smirnov and Q-Q 
plots, which indicated that the data were not normally distributed. Median, minimum and 
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maximum values and interquartile range (IQR) were calculated for physical characteristics 
(age, height, weight, BMI) and independently presented for the entire cohort and male and 
female subgroups. Mann-Whitney U test was performed to compare the distributions of 
these continuous variables between male and female subgroups and showed a significant 
difference (p<0.001) across all four variables. There were no missing data for these 
variables. Logarithmic transformation was attempted to correct skewness, however, the 
majority of the variables remained skewed after the transformation. Therefore, BMI and age 
were categorised, and subsequent analyses were performed using only categorical 
variables.   
Categorical variables describing running habits and health conditions were summarised 
using counts and percentages. Statistical comparisons of recruitment strategies and male 
and female subgroups for the descriptive analysis were implemented for all categorical 
variables using the chi-squared (χ2) test. This test was used to investigate whether 
distributions of categorical variables differ from one another. Not available (NA) data were 
presented for each categorical variable and comprised less than 0.5%. BMI data of 
recreational runners were compared to published health data from the general Australian 
population (18-74 years of age), which had been collected in the same way. 
Multiple logistic regression was performed to assess the effect of running experience on the 
reported clinically significant weight loss (≥5kg), after adjusting for sex, age, BMI, 
participation in other sports, smoking history and injury history. Whilst weekly running 
distance and race pace were both independently strongly associated (p<0.001) with 
reported weight loss in univariable analyses, they were not used as predictors in the model 
due to strong association with running experience and sex, respectively. To avoid 
multicollinearity, only predictors of interest that were not strongly associated with each other 
were selected in the model. Results of the multivariable analysis are presented as adjusted 
odds ratios with 95% confidence intervals and p-values. A Hosmer and Lemeshow test 
indicated that the model fit was acceptable (𝜒8
2=11.69, p=0.17). Statistical significance was 




2.3 Results – Recruitment of Australian recreational runners 
2.3.1 Implemented recruitment strategies 
During 25 months of recruitment, 9,069 participants started entering data into the survey, 
however, only 5,250 complete responses were received. Recruitment progress and related 
recruitment activities are displayed in Figure 2.1. From February 2016 until October 2017, 
regular paid Facebook advertisement were employed as part of the recruitment strategy. In 
addition, researcher’s attendance at multiple running events in Canberra, Sydney and 
Brisbane may be reflected by peaks on this recruitment graph. 
 
 
Figure 2.1 Response activity timeline and recruitment strategies implemented during 
25 months. 
 
A question about recruitment strategies was introduced to the survey only 16 months after 
the commencement of the project. Approximately a half (n=2,760) of completed responses 
contained data about the recruitment strategy, which led a respondent to the survey (Table 
2.2). Facebook was the most popular source referenced by over a third of the respondents. 
Running events and parkrun together helped to recruit a similar number of runners as a 
Facebook advertisement. Almost 500 runners referred other media resources. The 
remaining strategies, including referrals and the AIS website and social media accounts, 




Table 2.2 Summary of utilised recruitment strategies reported by participants. 
Recruitment strategy Participants 
n % 
Facebook 979 35.5% 
Running events 618 22.4% 
Parkrun 368 13.3% 
Other social media 324 11.7% 
Online media (articles and 
interviews) 
161 5.8% 
Referrals (personal and 
professional) 
144 5.2% 
AIS 133 4.8% 
Other  33 1.2% 
Total 2760 100.0% 
 
When participants’ characteristics were statistically compared by recruitment strategy, it was 
shown that age, sex and weekly running distance were associated with different recruitment 
methods (Table 2.3). Facebook recruitment showed a significant association with female 
participation, whereas online media appeared to recruit more male participants (p<0.001). 
There were significantly more runners aged 35-44 years recruited through Facebook than 
runners of other age groups. Older runners were more typically recruited through other 
social media resources and parkrun, whereas younger runners aged between 18 and 24 
were more likely to proceed to the survey through the AIS website (p<0.001). 
Participants who ran less than 20 km per week were more highly represented in the 
Facebook and parkrun categories. In contrast, those who run 40 km per week or more 
showed the least presence in the parkrun category. As the study was explicitly focused on 
the injury, this factor was also tested for association with recruitment methods. Over half of 
the participants had sustained an injury in the past two years, however, this rate was not 
significantly different between the different recruitment categories. No association was found 

























Sex* Male 38.6 50.9 67.7 51.1 48.9 54.9 50.4 36.4 
Female 61.4 49.1 32.3 48.9 51.1 45.1 49.6 63.6 
Age* 18-24 6.8 7.7 4.3 7.1 2.7 5.6 15.0 9.1 
25-34 22 17.6 26.1 25.9 14.4 16.7 25.6 15.2 
35-44 39.1 27.5 30.4 30.6 25.8 34 24.1 33.3 
45-54 22.8 25.3 27.3 25 32.3 29.2 24.1 21.2 
55-64 8.2 17.6 8.7 9.2 17.9 13.9 9 9.1 
≥ 65 1.1 4.3 3.1 2.1 6.7 0.7 2.3 12.1 
Weekly running 
distance* 
< 20 km 29.9 32.4 34.8 38.7 43.0 31.9 42.9 43.8 
20-40 km  46.9 42.6 44.1 42.8 42.8 44.4 40.6 34.4 
> 40 km 23.2 25 21.1 18.5 14.2 23.6 16.5 21.9 
Injured in the past 
two years 
Yes 59.1 53.4 54.7 52.6 55.7 62.5 54.9 48.5 
No 40.9 46.6 45.3 47.4 44.3 37.5 45.1 51.5 
Eligible for genetic 
study 
Yes 35.2 30.6 33.5 29.9 26.9 30.6 30.8 20.6 
No 64.8 69.4 66.5 70.1 73.1 69.4 69.2 79.4 
* - statistically significant difference between categories (p<0.001).
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Whilst an online survey platform and described recruitment strategies were utilised in an 
effort to recruit recreational runners across all states and territories of Australia, the analysis 
of runners’ location by state showed that the most commonly reported residential states 
were three largest states of Australia: New South Wales (NSW) - 25.2%, Queensland (QLD) 
– 19.7% and Victoria (VIC) – 17.2%. However, the fourth most reported location was the 
Australian Capital Territory (ACT) – 11.6%, which is the second smallest state or territory in 
Australia. The least common states and territories where residents completed the survey 
were Western Australia (WA) – 6.5%, South Australia (SA) – 3.8%, Tasmania (TAS) – 2.5%, 
and Northern Territory (NT) – 0.5%. However, 13.1% did not provide their residential state 
or territory (Figure 2.2).  
 
 
Figure 2.2 Distribution of the respondents by their residential state/territory.  
NA – Not Available 
 
In addition, when numbers of respondents from each state were recalculated as per 100,000 
people, the ACT had the highest rate of participants per 100,000 territory residents – 142 
per 100,000. This number was approximately seven times higher than values in the three 
largest states of Australia – NSW (n=16), VIC (n=14) and QLD (n=20) (Table 2.4). Although 
Tasmania had the second-highest rate of respondents per 100,000 residents (n=24), this 

















NSW QLD VIC ACT WA SA TAS NT NA
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and SA, had lower than other states scores with only 319 and 188 runners representing 
these states in the study, respectively. The least represented territory was NT with just 23 
completed surveys.  
Table 2.4 Distribution of respondents by state and rates of participant numbers by 
100,000 residents in each state.  
Population data sourced from (Population Australia, 2018). 
State Population  Number of 
runners 
Number 
per 100,000  
ACT 401,137 571 142 
TAS 519,166 125 24 
QLD 4,900,000 974 20 
NSW 7,700,000 1244 16 
VIC 6,150,000 848 14 
WA 2,640,000 319 12 
SA 1,710,000 188 11 




2.4 Results - A profile of health, lifestyle & training habits of 4720 Australian recreational 
runners 
Data from 5,250 respondents who described themselves as recreational runners were 
collected over the 25 months of recruitment. After duplicate (n = 272), nonsense (n = 4) and 
incomplete (n = 35) responses were removed, and 4,939 responses remained. As a weekly 
running distance of greater than 15 km was stated as an inclusion criterion for participation 
in the survey, data from 219 runners who reported less than this distance were removed, 
resulting in 4,720 responses included in the analysis. All respondents were 18 years of age 
or over. The study cohort was 54.1% female and 45.9% male (Table 2.5).  
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Table 2.5 Physical characteristics of the Australian recreational running cohort. 
 
Characteristics 
All runners (N=4720) Male runners (N=2165) Female runners (N=2555) 
Median (range) IQR Median (range) IQR Median (range) IQR 
Age (years) 40 (18 – 80) 33 – 47 42 (18 – 80) 34 – 49 39 (18 – 77) 32 – 46 
Weight (kg) 68 (40 – 135) 60 – 77 76 (45 – 135) 70 – 83 61 (40 – 110) 56 – 68 








2.4.1 Running habits  
The training characteristics of respondents are described in Table 2.6. The most common 
weekly running distance was 20–40 km (45.8%) among the entire cohort, with very similar 
rates in male and female runners. However, males were more likely than females to run 
distances more than 40 km per week (𝜒1
2=77.6, p<0.001), whereas females were more likely 
than males to run 15–20 km per week (𝜒1
2=65.5, p<0.001). The most common category of 
respondents was of those with over ten years of running experience (37.8%), with 
significantly more males than females within this experienced group (𝜒1
2=71.3, p<0.001). 
The majority of respondents stated that they typically ran between two and five sessions per 
week. It was, however observed that males were significantly more likely to run six or more 
times per week than females (𝜒1
2=33.3, p<0.001). The typical race pace of a male runner 
was reported as 4–5 min/km, whereas female runners reported 5–6 min/km. The majority of 
respondents participated in other sports in addition to running. Significantly more female 
than male runners reported participation in sports other than running (𝜒1
2=63.8, p<0.001). 
Over half of recreational runners reported injuries that occurred while running in the past two 




Table 2.6 Training characteristics of the Australian recreational running cohort. 
Training characteristics All runners  
(N=4720) 
Male runners  
(N=2165) 
Female runners  
(N=2555) 
























Running experience**   ≤2 years 942 20.0 364 16.8 578 22.6 
3-5 years 1267 26.8 542 25.0 725 28.4 
6-9 years 722 15.1 297 13.7 425 16.6 
10+ years 1783 37.8 958 44.2 825 32.3 
NA 6 0.1 4 0.2 2 0.1 
Run sessions per week** 1 15 0.3 10 0.5 5 0.2 
2 or 3 2041 43.2 869 40.1 1172 45.9 
4 or 5 2226 47.5 1027 47.4 1199 46.9 
6+ 422 8.9 250 11.5 172 6.7 
NA 16 0.3 9 0.4 7 0.3 
NA – Not Available; * - statistically significant difference between males and females (p<0.05), **- statistically significant difference 
between males and females (p<0.001). 
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Table 2.6 Training characteristics of the Australian recreational running cohort (continuation).  
Training characteristics All runners  
(N=4720) 
Male runners  
(N=2165) 
Female runners  
(N=2555) 
n % n % n % 
Race pace** <4 min/km 403 8.5 329 15.2 74 2.9 
4-5 min/km 1591 33.7 1022 47.2 569 22.3 
5-6 min/km 1819 38.5 633 29.2 1186 46.4 
6-7 min/km 706 15.0 141 6.5 565 22.1 
>7 min km 189 4.0 34 1.6 155 6.1 
NA 12 0.3 6 0.3 6 0.2 
Participation in other 
sports** 
Yes 3590 76.1 1530 70.7 2060 80.6 
No 1113 23.6 629 29.1 484 18.9 
NA 17 0.4 6 0.2 11 0.5 
Reported injuries 
occurred while running in 















NA – Not Available; * - statistically significant difference between males and females (p<0.05), **- statistically significant difference 





2.4.2 Smoking habits 
Smoking was uncommon among surveyed runners, with 0.6% reporting that they were 
current smokers and a further 25.8% of runners reporting that they had smoked at any time 
in their life. The reported smoking experience was not significantly associated with sex 
(24.7% versus 26.7%; 𝜒1
2=2.1, p=0.1). The analysis of self-reported rates of alcohol 
consumption rates has been excluded from this study due to its unreliability, supported by 
other studies of self-reported alcohol use (Ekholm, Strandberg-Larsen, & Grønbæk, 2011; 
Proude, Britt, Valenti, & Conigrave, 2006). 
 
2.4.3 Chronic conditions 
The survey included questions about 18 lifetime diagnoses of chronic conditions (Table 2.7). 
The most common reported diagnosis was depression (15.3%) with significantly higher 
reported depression rates among females than males (𝜒1
2=55.7, p<0.001). The second most 
common diagnosis was respiratory conditions (11.7%), which was significantly higher in 
females than males (𝜒1
2=9.0, p=0.002). Although anaemia was the third most common 
diagnosis (10%), this was mainly reported by females (𝜒1
2=315.8, p<0.001). A lifetime 
diagnosis of hypertension was reported by 290 runners (6.1%). Hypertension was the third 
most common diagnosis for males, accounting for 7.8%, with a significantly lower reported 
rate in females – 4.8% (𝜒1
2=18.1, p<0.001).    
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n  % n % n % 
Depression** 724 15.3 240 11.1 484 18.9 
Respiratory 
conditions** 
554 11.7 221 10.2 333 13.0 
Anaemia** 472 10.0 34 1.6 438 17.1 
Hypertension** 290 6.1 168 7.8 122 4.8 
Skin disease* 277 5.9 111 5.1 166 6.5 
Cancer 238 5.0 108 5.0 130 5.1 
Insomnia** 193 4.1 54 2.5 139 5.4 
Osteoarthritis 184 3.9 74 3.4 110 4.3 
Gastrointestinal 
disease** 
186 3.9 56 2.6 130 5.1 
Cardiac conditions 179 3.8 94 4.3 85 3.3 
Thyroid disease** 180 3.8 30 1.4 150 5.9 
Neurological 
conditions 
88 1.9 37 1.7 51 2.0 
Diabetes 68 1.4 30 1.4 38 1.5 
Rheumatoid arthritis 54 1.1 19 0.9 35 1.4 
Osteoporosis* 53 1.1 14 0.6 39 1.5 
Chronic renal failure 11 0.2 7 0.3 4 0.2 
Cerebral palsy 8 0.2 5 0.2 3 0.1 
Cystic fibrosis 7 0.1 5 0.2 2 0.1 
* - statistically significant difference between males and females (p<0.05), ** - statistically 
significant difference between males and females (p<0.001)  
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2.4.4 Body mass index and weight loss    
Respondents were grouped by their BMI in accordance with the World Health Organisation 
guidelines (Table 2.8) (World Health Organization, 2000). The majority of runners were in 
the normal weight category with a BMI between 18.5 kg/m2 and 25 kg/m2 (72.9%). Of the 
remainder, 2.6% of runners were underweight (16 to 18.5 kg/m2), 21.8% were overweight 
(25 to <30 kg/m2) and 2.7% were obese (≥30 kg/m2). There were no participants in the 
cohort that were classified as severely underweight (<16 kg/m2). When levels of obesity 
were categorised, 127 runners were divided into 3 subgroups: moderate level of obesity 
(n=111), severe (n=14) and very severe (n=2), accounting for approximately 2.35%, 0.30% 
and 0.04%, respectively, of the entire sample. Due to these low numbers in severe and very 
severe categories, it was decided to keep a general ‘obese’ group for analysis. Significantly 
more women than men were in the underweight and normal weight categories (𝜒1
2=50.6, 
p<0.001; 𝜒1
2=66.8, p<0.001, respectively), whereas significantly more men than women 
were overweight (𝜒1
2=136.3, p<0.001). Nevertheless, the proportions of obese male and 
female runners were almost equal. The BMI distribution data of surveyed runners were 
compared to BMI data in the Australian population collected in the 2014-15 National Health 
Survey published by the Australian Bureau of Statistics (Figure 2.3) (Australian Bureau of 
Statistics, 2016a).  
 
Table 2.8 Frequencies of the body mass index categories. 
 









n % n %  n % 
Underweight (<18.5 kg/m2)* 121 2.6 17 0.8 104 4.1 
Normal (18.5 to <25 kg/m2)* 3443 72.9 1455 67.2 1988 77.8 
Overweight (25 to <30 kg/m2)* 1029 21.8 637 29.4 392 15.3 
Obese (≥30 kg/m2) 127 2.7 56 2.6 71 2.8 





Figure 2.3 Comparison of BMI group percentages between Australian surveyed a) 
male and b) female runners and Australian population surveyed by the Australian 





Recreational runners were asked whether they had gained or lost a clinically significant 
amount of weight (≥5kg) in the past two years. Clinically significant weight loss over the last 
two years was reported by 27% of all respondents. Multiple logistic regression analysis 
(Table 2.9) showed that clinically significant weight loss was more likely to be reported by 
younger runners, and overweight and obese runners. Runners with two or fewer years of 
running experience were three times more likely to report clinically significant weight loss in 
the past two years than runners with over ten years of running experience. However, sex, 
participation in other sports, and history of injuries in the past two years did not have a 
statistically significant association with clinically significant weight loss. Interestingly, 
smoking experience (smoking at any time in life) was associated with reported clinically 
significant weight loss. The logistic regression results indicate that commencing a running 
program may lead to a clinically significant weight loss irrespective of sex, participation in 
other sports and injury in the previous two years.   
73 
 
Table 2.9 Multiple logistic regression analysis results with adjusted odds ratio (OR) 
estimates for the effects of runner characteristics on clinically significant weight loss 
(≥5kg). 
Variable OR1 95% CI p-value 
Sex        
Female2 1.00   
 
Male 1.04 0.90, 1.19 0.62 
Age group     
 
> 55 years2  1.00   
 
35-55 years  1.91 1.43, 2.54 <0.001 
< 35 years  2.20 1.62, 2.96 <0.001 
BMI group     
 
Normal2 1.00   
 
Underweight  0.69 0.42, 1.13 0.14 
Overweight  1.96 1.68, 2.29 <0.001 
Obese 2.51 1.76, 3.58 <0.001 
Running experience     
 
≥ 10 years2 1.00   
 
6-9 years  1.22 0.98, 1.52  0.07 
3-5 years  1.63 1.36, 1.94 <0.001 
≤ 2 years  3.15 2.63, 3.78 <0.001 
Participation in other sports      
 
No2 1.00   
 
Yes 0.99 0.85, 1.16  0.92 
Injury occurrence     
 
No2 1.00   
 
Yes 1.02 0.89, 1.69  0.77 
Smoking history     
 
No2 1.00   
 
Yes 1.34 1.15, 1.56 <0.001 




2.5 Discussion  
2.5.1 Discussion of the recruitment strategies and participants’ residential distribution 
The development of secure online platforms for data collection, the ubiquitous presence of 
the Internet and the multiplicity of access devices allow researchers to collect health data 
for multiple research purposes. The online survey utilised for this project was completed by 
over 5,000 Australian recreational runners who were half of the initially targeted number of 
10,000 runners. The number of adult runners in Australia in 2015-2016 was estimated at 
over 2.8 million (Australian Sports Commission, 2016), hence there was no shortage of 
potential participants. The analyses of the recruitment strategies employed, their efficiency 
and their impact on population representativeness identified some associations between 
participants’ characteristics and recruitment strategies. Thus, Facebook and online media 
had an effect on participants’ sex distribution. Despite the absence of sex-related differences 
in social media or Facebook usage or behaviour (Sensis, 2016), Facebook was more likely 
to recruit women to the survey than men. The female recruitment rate through Facebook 
(61.39%) aligned with previous studies, which also used Facebook (60% on average) as 
summarised in a recent systematic review (Thornton et al., 2016). The opposite was true for 
online media, however, the leading online media channel used was a specific blog with a 
predominantly male readership.  
Although Facebook continues to be the most popular social media platform in Australia for 
all ages (Sensis, 2016), this platform preferentially recruited participants in the 35-44 age 
bracket. This bias may be a result of the advertisement campaign being targeted exclusively 
to runners aged 30-50 during the first 3 months of the 9-month long campaign, although it 
was later extended to ages 18-50 for a further 6 months. The runners recruited from parkrun, 
a network of free, weekly, timed 5 km runs in outdoor spaces, were predominantly in the 55-
64 age category. This age group was also mainly recruited by other social media, particularly 
our email campaign, which spread information through media such as members’ newsletters 
of parkrun and running clubs. Interestingly, the youngest age group, 18-24 years, were more 
likely to be recruited directly through the AIS. Possibly, since the AIS provides programs and 
facilities for developing and elite athletes, younger survey respondents who were initially 
attracted to the AIS website were young athletes. Respondents who reported running less 
than 20 km per week were over-represented and those who run over 40 km per week were 
under-represented in the parkrun group, which aligns with the observation that parkrun 
attracts people with the lower running ability (Stevinson & Hickson, 2013).  
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Additional analysis of the residential location of the respondents demonstrated recruitment 
bias towards Eastern shore states and territories - QLD, NSW, ACT and VIC. The highest 
rate of respondents per 100,000 people was identified in the ACT. This highest rate could 
be explained by the fact that the research group responsible for the recruitment was based 
in the ACT and therefore had access to more recruitment opportunities at the local running 
events. In addition, the AIS is a renowned institution in the ACT, which could also help to 
draw more interest to the project from the local physically active community. Running and 
media events in the remaining three states were attended by the research group for 
promotion purposes multiple times. This attendance may have boosted recruitment in these 
particular states, whereas more remote states and territories were reached only through 
online social media resources and emails.  
Overall, the data suggest that the combined use of traditional, online and physical 
recruitment strategies resulted in a diverse sample. However, the recruitment bias towards 
older age among physically active people suggests that people aged under 35 are 
particularly hard to reach and may require the employment of more specific recruitment 
strategies. Additionally, offline recruitment contributes to the bias of the geographical 
distribution of the recruited participants. This suggests that if research requires a particular 
distribution of participants across the country, online and offline strategies should be 
implemented evenly across all states and territories.    
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2.5.2 Discussion of physical characteristics, training and lifestyle habits of 4,720 Australian 
recreational runners   
This study described one of the largest cohorts of Australian recreational runners, analysing 
the medical and lifestyle characteristics of the participants and sex differences in training 
habits. In this study, we demonstrated that a large proportion of recreational runners avoided 
the majority of modifiable risk factors that contribute to the burden of disease. In the 
Australian population, the five strongest contributors to the burden of disease in 2011 were 
tobacco use (9%), high body mass (5.5%), alcohol use (5%), physical inactivity (5%) and 
hypertension (5%) (Australian Institute of Health and Welfare, 2016a). Data from the 
‘Australian Nutrition and Physical Activity Survey’ showed that both sufficient physical 
activity level and reduced sitting time were important factors for the prevention of 
cardiovascular disease and metabolic syndrome (Engelen et al., 2016). This study 
demonstrated that Australian recreational runners typically have a BMI in the normal range, 
are meeting physical activity guidelines through recreational running and participation in 
other sports and have low levels of smoking. This cohort runs on average 20–40 km in 
greater than two sessions per week, and 76.1% of respondents play additional sport, 
indicating that recreational runners are likely to be meeting the recommended ‘WHO 
Physical Activity Guidelines’ (World Health Organisation, 2010). Considering that 80% of 
surveyed recreational runners have been running for at least three years, we can speculate 
that they have managed to sustain a habit of regular physical activity at the recommended 
level for at least three years.  
Australian recreational runners self-reported a lower BMI than the general population. 
Additionally, a weight loss of greater than five kilograms in the past two years was reported 
by approximately 40% of runners with less than two years of experience. Physical activity is 
a critical component in the multidisciplinary approach of effective weight loss programs, and 
is especially important when preventing continued weight gain or maintaining lower weight 
(Söderlund, Fischer, & Johansson, 2009). Indeed, endurance running has been shown to 
be beneficial to physically inactive adults leading to body mass and body fat reduction, with 
a systematic review concluding that one year of running training was effective in reducing 
body mass by 3.3 kg (Hespanhol Junior, Pillay, van Mechelen, & Verhagen, 2015). Several 
systematic reviews have shown that aerobic exercise, such as running, significantly 
contributes to weight loss, with strong evidence that this type of activity is effective in 
reducing visceral fat (Ismail, Keating, Baker, & Johnson, 2012; Thorogood et al., 2011). 
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Additionally, there is a dose-response relationship between aerobic exercise and visceral 
fat reduction in obese participants, indicating that an activity such as recreational running 
could be effective in improving health via a reduction of visceral fat (Ohkawara, Tanaka, 
Miyachi, Ishikawa-Takata, & Tabata, 2007). A systematic review indicated that risks of all-
cause mortality and cardiovascular mortality were lower in people with high BMI and good 
aerobic fitness than in people with normal BMI and poor fitness. However, aerobically fit 
people with high BMI were still at a greater risk of type 2 diabetes mellitus and cardiovascular 
disease (Fogelholm, 2010). In an Australian population, it has been shown that walking is 
the most common type of physical activity recommended to patients by their doctor (Porter, 
Eccleston, & Vilshanskaya, 2002; Robertson, Jepson, Shepherd, & McInnes, 2011). Our 
results, taken together with previous findings, indicate that recreational running could be 
promoted by general practitioners as an effective mechanism for building aerobic fitness 
and maintaining healthy body weight.  
Only one-quarter of recreational runners surveyed reported smoking at any time during their 
life, and 0.6% were current smokers. These rates were substantially lower than those 
reported by the Australian Bureau of Statistics, which showed that 14.5% of adult Australians 
were daily smokers, 1.5% smoked less often than daily, and about one third (31.4%) were 
ex-smokers (Australian Bureau of Statistics, 2016a). A systematic review of co-occurrence 
of smoking and physical activity showed negative association in 20 studies on adults in 
several European countries, Japan and Australia and 13 studies with nonsignificant, mixed 
or positive association, indicating possible complex relationships between smoking and 
physical activity due to race, income level and other factors (Kaczynski, Manske, Mannell, 
& Grewal, 2008). Hence, the very small proportion of runners currently smoking could reflect 
their overall healthy lifestyle as well as the positive effects of individual exercise bouts in 
reducing cravings for smoking. 
Depression was the most common life-time diagnosis reported by recreational runners 
(15.3%). Affective disorders which comprise all levels and severity of depressive disorders 
and bipolar disorder, accounted for 15% of life-time prevalence in the Australian population 
(Slade, Teesson, & Burgess, 2009). This study population contained a slightly higher 
proportion of females (54.1%) compared to the general Australian population (50.4%) 
(Australian Institute of Health and Welfare, 2018). As female recreational runners were more 
likely to report depression, this finding was similar to results of other studies (Kruijshaar et 
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al., 2005; Nolen-Hoeksema, 2001). Overall, the depression rate in the Australian 
recreational running population is largely the same as in the general population. 
Hypertension is a significant risk factor for chronic diseases including stroke, coronary heart 
disease, heart failure and chronic kidney disease and is identified as the leading global risk 
factor for mortality (World Health Organization, 2009). Based on measured data from the 
Australian Institute of Health and Welfare, 32% of Australians aged 18 and over have 
hypertension (Australian Institute of Health and Welfare, 2017). However, only 6.1% of 
Australian recreational runners surveyed self-reported that they had been diagnosed with 
hypertension. The reduced levels suggest that recreational running is associated with lower 
rates of hypertension as a risk factor for burden of disease. These findings are supported 
by the previous reports of approximately 50% reduction in the risk of hypertension in long-
distance runners (Williams, 1997), and a meta-analysis of 72 studies of effect of aerobic 
endurance exercise (running, cycling, swimming) on blood pressure, demonstrated that this 
type of physical activity reduces blood pressure, and the reduction was more pronounced in 
hypertensives than non-hypertensives (Cornelissen & Fagard, 2005). 
Running, as a form of physical activity, has consistently been shown to provide a range of 
health benefits, including reducing the overall risk of cardiovascular disease and all-cause 
mortality (Chakravarty, Hubert, Lingala, & Fries, 2008; Lee et al., 2014; Oja et al., 2016; 
Schnohr, O’Keefe, Marott, Lange, & Jensen, 2015). More importantly, the clustering of 
various healthy behaviours has been shown to be inversely related to the risk of all-cause 
mortality, with four or more healthy behaviours reducing mortality risk by 66% (Loef & 
Walach, 2012). Here we demonstrated that a large proportion of Australian recreational 
runners displayed healthy behaviours including meeting physical activity guidelines, 
avoidance of overweight or obesity and reduced smoking.  
We suggest that recreational running could be promoted as a low-cost option for adhering 
to physical activity guidelines. Marketing of recreational running through mass participation 
events, for example, parkrun has been considered as a public health intervention (Stevinson 
& Hickson, 2013; Stevinson, Wiltshire, & Hickson, 2015). However, there is a risk of 
sustaining an injury during participation in recreational running, with 58.3% of participants in 
the ‘AIS Running Injury Study’ reporting a running injury over the preceding two years. A 
recent study of 1,145 parkrun participants in the United Kingdom reported a 49.8% injury 
rate over 12 months (Linton & Valentin, 2018). This potential injury risk must be considered 
when advising participation in recreational running. Additionally, the commencement of a 
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running program for individuals with musculoskeletal injuries of the lower body should be 
supervised by a qualified medical practitioner. The current study demonstrated that there 
are differences in male and female training characteristics to consider when aiming to 
encourage people to begin a running program. We show here that female runners were 
more likely to report shorter weekly distances while running a similar number of sessions as 
male runners. This study did not investigate the motivations for participation in recreational 
running, however several studies have demonstrated that the motivations of males and 
females, in relation to participation in physical activity, differ in a number of ways 
(Lauderdale, Yli-Piipari, Irwin, & Layne, 2015; Louw, Van Biljon, & Mugandani, 2012; Stults-
Kolehmainen, Ciccolo, Bartholomew, Seifert, & Portman, 2013). An Australian study 
demonstrated that, while both males and females are motivated by general health and 
maintenance of fitness, women often cite weight loss/appearance and mental health as 
motivating factors for increasing their physical activity levels while men participate for social 
reasons and enjoyment (Australian Sports Commission, 2016). Both motivational factors 
and running habits should be considered when marketing recreational running for health 
benefits or encouraging participation.  
While the self-report nature of data collection could introduce bias and error, the survey tool 
has been shown to be reliable and questions did not require respondents to recall long-term 
details of running habits or injuries (Domaschenz et al., 2015). The term of recall for injuries 
and running habits was limited to the two years preceding survey response, as it has been 
shown that retrospective data beyond this point is not reliable (Gabbe, Finch, Bennell, & 
Wajswelner, 2003; Kolt & Kirkby, 1999). A further study limitation may have been sampling 
bias with a higher proportion of female runners and middle-aged runners in the studied 
cohort in comparison with demographic data of physically active Australian adults 
(Australian Bureau of Statistics, 2015). Lastly, the absence of data from non-runners or 
those who may be interested in taking up recreational running precludes extrapolation of 
findings to non-runners. 
Recreational running is associated with benefits across a range of measurable health 
outcomes. A high proportion of the Australian recreational runners who participated in this 
study had a body mass index within the healthy weight range, seemed to be meeting the 
WHO Physical Activity Guidelines each week for many years and were non-smokers. 
Additionally, our results indicate that taking up running is associated with weight loss and 
weight remains stable if individuals persist with running. Male and female runners reported 
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different running characteristics, and these should be considered when promoting 
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Running is one of the most popular recreational physical activities in the Australian 
population (Australian Sports Commission, 2016). Running is a low cost and an easily 
implemented activity with proven health benefits involving improvements in aerobic fitness 
and cardiovascular function (Oja et al., 2015). However, running is a sport with relatively 
high rates of injuries, varying between 19% and 79% (van Gent et al., 2007). Running-
related injuries may be of acute or overuse nature, and the latter comprises 80%, mainly 
affecting Achilles tendon, knee and foot (Walther et al., 2005). According to a systematic 
review of running-related injuries, three most common injuries were: medial tibial stress 
syndrome (13.6—20%), Achilles tendinopathy (9.1—10.9%) and plantar fasciitis (4.5—10%) 
(Dias Lopes et al., 2012). The development of running-related injuries is affected by a 
number of modifiable and non-modifiable factors, of which interrelationship is highly 
complex.  
Among physical characteristics, factors such as age, sex, BMI were extensively studied on 
multiple running cohorts. However, all these factors showed inconsistent results across 
many studies, confirming the complexity of the risk of injuries, and challenges of research 
design to study risks factors (van der Worp et al., 2015; van Gent et al., 2007; Van Mechelen, 
1992). Training habits of runners are modifiable factors, which may either increase or 
decrease the risk of running-related injuries. Thus, a weekly running distance of more than 
64 km was reported a risk factor of injuries in two studies (Macera et al., 1989; Walter et al., 
1989). Additionally, high-frequency running sessions was identified as a risk factor in one 
study (Walter et al., 1989), whereas a later study showed that one running session per week 
may increase risk of injuries in female runners (Taunton et al., 2003). Stretching was another 
risk factor of running injuries investigated in several studies but showed ambiguous results 
(Hreljac, 2005; Shrier, 1999). Wearing orthotics and a certain type of running shoes is 
important for the running biomechanics, and their correct choice may assist in injury 
prevention (McKenzie et al., 1985; Nigg et al., 1999). One of the main identified factors was 
a previous injury occurred in the past 12 months, however, this association could be 
explained by incomplete recovery from the original injury (Saragiotto et al., 2014; Walter et 
al., 1989).  
Risk factors of different types of running-relates injuries are diverse and require more 
specific research. This study was focused on the two most common running-related injuries: 
an Achilles tendon injury and a bone stress injury. According to the literature review in 
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Chapter 1, male sex, older age and training overload were the main risk factors of Achilles 
tendon injuries, however, these factors may be interdependent, as males would typically 
report higher training load than females (Dias Lopes et al., 2012; Hirschmüller et al., 2012; 
Magnan et al., 2014; Taunton et al., 2002). The main previously identified risk factors of 
bone stress injuries were female sex, older age, increased BMI, training regimen, running 
surfaces and wearing orthotics (Beck et al., 2015; Bennell et al., 1999; Newman et al., 2013; 
Warden et al., 2014). However, these factors also interact and may cumulatively contribute 
to the development of bone stress injuries. Overall, the multifactorial nature of running-
related injuries makes their research challenging and requires careful and comprehensive 
data analyses to identify important risk factors. 
This part of the study aimed to identify the most common reported running-related injuries 
and their frequencies, and investigate risk factors of running-related injuries, particularly 
Achilles tendon injuries and bone stress injuries, reported by Australian recreational runners 




3.2.1 Selection criteria for running-related injury study 
Recruitment efforts described in Chapter 2 resulted in a dataset of 4,720 unique responses 
from Australian recreational runners. All included participants were at least 18 years of age 
and reported running a minimum of 15 km per week. In the survey, runners were asked 
whether they acquired any injuries which affected their running routine in two years prior to 
the survey completion. Injured runners could describe a maximum of four injuries that 
occurred in the past two years. The questionnaire comprised questions specific to Achilles 
tendon injuries and bone stress injuries in the lower leg. All other types of injuries were 
reported via open-ended questions and then were classified by either a formal injury 
diagnosis, for example ‘plantar fasciitis’ or ‘iliotibial band syndrome’ (if a participant specified 
whether this injury was diagnosed by a health professional or clearly detailed the diagnosis), 
or their anatomic location, if provided description of the injury was not precise. Additional 
questions about how the reported injuries occurred allowed the exclusion of not running-
related injuries and the analysis of only injuries which occurred while running. Therefore, 
only uninjured runners and runners who reported running-related injuries were included in 
the Running Injury (RI) cohort and the subsequent statistical analysis. The survey contained 
questions specifically about Achilles tendon injuries and bone stress injuries, as they were 
the injuries of interest in the project. Hence, besides a larger cohort of uninjured runners and 
runners with any type of running-related injury, two additional cohorts were formed: AT injury 
cohort, which comprised Achilles tendon injury cases and all uninjured runners, and BS 
injury cohort, which comprised bone stress injury cases and all uninjured runners.  
3.2.2 Statistical data analyses 
Categorical variables which describe physical and training characteristics of recreational 
runners were statistically compared using chi-squared χ2 test in each of three created 
cohorts (RI, AT, BS). The results were summarised and described in the tables in Section 
3.3. A multiple logistic regression method was selected to identify which factors are 
independently predictive of the outcome – an injury, in the presence of the other factors. 
Firstly, simple logistic regression using an injury as the outcome was conducted to identify 
univariate predictors with a significance level of p≤0.1 to include in the subsequent multiple 
logistic regression. This significance threshold of p≤0.1 was selected in order to identify 
variables that were not independently statistically significant but at the presence of other 
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variables in the multiple logistic regression model. Thus, these variables were included in 
the logistic regression analysis and underwent a number of iterations. During each iteration, 
the least significant variable was excluded from the model until the final logistic regression 
model included only statistically significant variables. Hosmer-Lemeshow test was used to 
assess the quality of the models with p>0.05, indicating an acceptable model fit. Logistics 
regression models with significant variables were summarised in the tables for each of three 
investigated cohorts.  
 
3.3 Results 
3.3.1 Frequencies of reported running-related injuries  
After the selection of the injuries, which occurred while running, 436 runners with injuries 
irrelevant to running were excluded, and a Running Injury (RI) cohort (N=4,284) was formed 
and comprised 1,969 (46%) uninjured runners and 2,315 (54%) runners, who reported 
various running-related injuries occurred in the past two years. The RI cohort was used to 
identify and classify running-related injuries and report frequencies of the injuries in the 
whole cohort and male and female runners separately. Injured runners were able to report 
between one and four running-related injuries that may belong to different groups, as well 
as recurrent injuries, and occurred in the past two years. Among 2,315 injured runners, 
1,360 (58.7%) reported only one injury, 749 (32.4%) reported two injuries, 162 (7%) runners 
reported three injuries, and 44 (1.9%) runners reported four injuries, resulting in 3,520 
reported injuries in total. Among these 3,250 injuries, 279 (7.9%) were either traumatic or 
unidentified running injuries; that is, the injury was reported, but no details were provided 
about the type or location of the injury. The remaining 3,241 injuries were classified 
depending on the affected anatomic part of the leg: an Achilles tendon injury, a bone stress 
injury (below knee), iliotibial band (ITB) syndrome, plantar fasciitis, hip and glute injuries, an 
upper leg injury (including quad tear and femur stress injury), a hamstring injury, a knee 
injury (including patella injury, meniscus injury, anterior cruciate ligament (ACL) tear), a 
lower leg injury (posterior tendon injury and unspecified tendinopathies, a calf injury 
(including muscle strain), an ankle injury (including ligament sprain), foot and toe (including 
unspecified tendinopathies, bursitis). Two most common of all 3,520 reported injuries were 
an Achilles tendon injury and a bone stress injury (16% and 15.7%, respectively). A calf 
injury, a knee injury and ITB syndrome were 12.3%, 10% and 7.3% of all reported injuries, 
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respectively. Plantar fasciitis, a hamstring injury, an ankle injury, hip and gluteal injuries were 
of similar frequencies just above 5% (5.5%, 5.3%, 5.2% and 5.1%, respectively). Foot and 
toe injuries comprised only 4.2%. Upper leg injuries and lower leg injuries were 1.6% and 
3.9%, respectively (Figure 3.1). Overall, 62.8% of all reported injuries affected the lower leg, 
17.3% affected knee area (knee injury and ITB syndrome), 12% of injuries affected upper 
leg, including hip and glute, and 7.9% of injuries were unspecified. 
 
 
Figure 3.1 Frequencies of reported running-related injuries.  
*ITB syndrome – iliotibial band syndrome. 
 
Runners also reported the number of weeks they interrupted running practice after each 
injury. However, these data were provided only for 3,484 injuries out of 3,520, resulting in 
1% (n=36) missing data. Only 7.4% of injuries prevented runners from training for one week. 
Over half of the reported injuries led to two to four weeks off running (56.8%), 11.6% of the 
injuries interrupted running practice for five or six weeks, whereas the remaining 23.2% of 
the injuries led to a period of longer than six weeks to return to running (Table 3.1).  
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Table 3.1 Frequencies of reported weeks off running due to an injury. 
Number of weeks 
off running 
Injuries (N=3520) 
n %  
1 261 7.4 
2 812 23.1 
3 604 17.2 
4 582 16.5 
5 142 4.0 
6 265 7.5 
6+ 818 23.2 
NA 36 1.0 
NA – Not Available 
 
3.3.2 Physical characteristics and training factors associated with running-related injuries 
In order to investigate the risk factors associated with running-related injuries, physical 
characteristics and training habits of 2,315 injured and 1,969 uninjured runners in the RI 
cohort were statistically compared (Table 3.2 and Table 3.3, respectively). Injured and 
uninjured subgroups statistically differed by the proportions of male and female runners 
(χ21=6.59, p=0.01). All runners were categorised into three age groups: 18-34 years, 35-50 
years and over 50 years of age. Injured and uninjured subgroups were significantly different 
by age group distribution (χ22=7.52, p=0.02), with fewer runners aged over 50 years in the 
injured group (16.5%) versus the uninjured group (19.7%). Comparison of injured and 
uninjured runners by BMI groups (normal, underweight, overweight and obese) showed no 
statistical difference (χ23=4.83, p=0.19). When injured and uninjured runners were compared 
by their training habits, there was no significant difference between these subgroups by 
weekly running distance (χ22=0.57, p=0.75) and reported race pace (χ24=8.89, p=0.06). 
However, the injured subgroup statistically differed from the uninjured subgroup by years of 
running experience (χ24=43.02, p<0.001), number of running sessions per week (χ22=11.71, 
p=0.003) and preferred running terrain (χ26=19.28, p=0.004). In addition, injured runners 
were more likely to report incorporation of stretching in their training routine than uninjured 
runners (65.7% versus 58.6%, χ21=23.09, p<0.001), as well as wearing orthotics while 
running (24.4% versus 13.8%, χ21=77.18, p<0.001), and participation in sports other than 
running (76.4% versus 73.5%, χ21=4.46, p=0.04). In summary, frequencies of eight variables 




Table 3.2 Physical characteristics of uninjured and injured runners. 

















Age groups* 18-34 years  600 30.5 722 31.2 
35-50 years 982 49.9 1212 52.4 




Normal 1465 74.4 1701 73.5 
Underweight 57 2.9 53 2.3 
Overweight 405 20.6 492 21.3 
Obese 42 2.1 69 3 





Table 3.3 Training characteristics of uninjured and injured runners. 




n % n % 
Weekly running 
distance  
15-20 km 559 28.4 678 29.3 
20-40 km 925 47 1063 45.9 
40+ km 485 24.6 574 24.8 
Race pace <4 min/km 163 8.3 213 9.2 
4-5 min/km 640 32.5 830 35.9 
5-6 min/km 781 39.7 872 37.7 
6-7 min/km 306 15.5 312 13.5 
>7 min km 74 3.8 82 3.5 
NA 5 0.3 6 0.3 
Running 
experience**   
≤ 1 year 252 12.8 163 7.1 
2 years 197 10.0 242 10.5 
3-5 years 505 25.6 652 28.2 
6-9 years 280 14.2 384 16.6 
10+ years 732 37.2 871 37.6 
NA 3 0.2 3 0.1 
Run sessions 
per week* 
1 to 3 852 43.3 999 43.1 
4 or 5 897 45.6 1128 48.7 
6+ 211 10.7 182 7.9 
NA 9 0.5 6 0.3 
Running terrain* Bitumen 883 44.8 1060 45.8 
Cement 628 31.9 680 29.4 
Hard dirt/gravel 342 17.4 442 19.1 
Grass 42 2.1 64 2.8 
Treadmill 53 2.7 50 2.2 
Synthetic 6 0.3 16 0.7 
Sand 14 0.7 3 0.1 




Yes 1153 58.6 1521 65.7 
No 811 41.2 789 34.1 
NA 5 0.3 5 0.2 
Wearing 
orthotics** 
Yes 271 13.8 566 24.4 
No 1689 85.8 1740 75.2 
NA 9 0.5 9 0.4 
Participation in 
other sports* 
Yes 1448 73.5 1768 76.4 
No 513 26.1 539 23.3 
NA 8 0.4 8 0.3 
NA – Not Available; * - statistically significant difference between uninjured and injured 
runners (p<0.05), ** - statistically significant difference between uninjured and injured 
runners (p<0.001).  
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3.3.3 Logistic regression model of the factors associated with running-related injuries 
In order to investigate which of the factors are independently associated with running-related 
injuries in the presence of other factors, a logistic regression model was built. Firstly, simple 
logistic regression analysis identified variables of p≤0.1: sex (p=0.01), age group (p=0.02), 
years of running experience (p<0.001), number of running sessions per week (p=0.003), 
running terrain (p=0.009), stretching (p<0.001), wearing orthotics (p<0.001), and 
participation in other than running sports (p=0.035). After exclusion of non-significant 
variables from the logistic regression model, six variables remained (Table 3.4). In this 
model, male sex was associated with 29% increased chance of reporting running-related 
injuries, runners aged over 50 years were 26% less likely to report running-related injuries 
than runners aged under 35 years. Runners with one year or less of running experience 
were also 45% less likely to report injuries when compared with runners with ten and more 
years of running experience. However, this could be explained by the survey design, which 
requested injury history of the past two years, which was longer than running experience of 
these runners. Runners, who reported running one to three sessions and four to five 
sessions per week, were more likely to report injuries than runners who reported running at 
least six times per week (34% and 43%, respectively). Additionally, stretching in relation to 
a running session was associated with a 38% higher chance of reporting running-related 





Table 3.4 Logistic regression model of factors associated with running-related 
injuries. 
Variable OR (95% CI) p-value 
Sex (0=Female, 1=Male) 1.29 (1.13 to 1.46)  <0.001 
Age group  
  
<35 years (reference category) 1.00 
 
35-50 years  1.00 (0.87 to 1.16)  0.97 
>50 years  0.74 (0.62 to 0.9) 0.002 
Years of running experience 
  
≤1 year  0.55 (0.44 to 0.69) <0.001 
2 years  1.03 (0.83 to 1.29) 0.77 
3-5 years  1.07 (0.92 to 1.26) 0.39 
6-9 years  1.15 (0.95 to 1.39) 0.14 
≥10 years (reference category) 1.00   
Number of running sessions per week 
  
1-3 sessions  1.34 (1.07 to 1.68) 0.01 
4-5 sessions  1.43 (1.14 to 1.79) 0.002 
≥6 sessions (reference category) 1.00   
Stretching in relation to a running session 
(0=No, 1=Yes) 
1.38 (1.13 to 1.46) <0.001 
Wearing orthotics (0=No, 1=Yes) 1.29 (1.13 to 1.46)  <0.001 
OR – odds ratio; CI – confidence interval; Hosmer-Lemeshow test χ2=7.51, p=0.48. 
 
3.3.4 Factors associated with Achilles tendon injuries 
One of the most commonly reported injuries was an Achilles tendon injury reported by 508 
recreational runners. The AT injury cohort comprised these 508 runners who reported at 
least one Achilles tendon injury that had occurred in the past two years, and 1,969 uninjured 
runners. Statistical comparisons of uninjured runners and runners with Achilles tendon 
injuries identified several significant factors among physical characteristics and training 
habits (Table 3.5; Table 3.6). Almost two-thirds of runners with Achilles tendon injuries were 
males. Thus, uninjured runners significantly differed from runners with Achilles tendon 
injuries by the proportions of male and female runners (χ22=59.69, p<0.001). Uninjured 
runners also significantly differed from the injured runners by the age group distribution 
(χ22=19.01, p<0.001). However, there was no statistical difference in the distribution of BMI 
categories between uninjured and injured runners (χ23=4.58, p=0.21). Injured runners did 
not differ from uninjured runners by two training characteristics: reported weekly running 
distance (χ22=3.65, p=0.16) and a number of running sessions per week (χ22=2.66, p=0.26). 
However, injured runners were significantly different from uninjured runners by frequencies 
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of runners with different running experience (χ24=38.6, p<0.001), race pace (χ24=26.03, 
p<0.001) and preferred running terrain (χ26=12.64, p=0.049). Compared subgroups were 
also statistically different by incorporation of stretching into running practice and wearing 
orthotics with higher rates of positive responses in the injured subgroup (χ21=7.89, p=0.005, 
χ21=26.42, p<0.001). However, the rate of participation in other sports was similar for both 
subgroups (χ21=0.17, p=0.68).  
 
Table 3.5 Physical characteristics of uninjured runners and runners with Achilles 
tendon injuries. 






n % n % 
Sex** Male 866 44 321 63.2 
Female 1103 56 187 36.8 
Age groups** 18-34 years  600 30.5 105 20.7 
35-50 years 982 49.9 291 57.3 
>50 years 387 19.7 112 22 
Body mass index (BMI) 
groups 
Normal 1465 74.4 361 71.1 
Underweight 57 2.9 11 2.2 
Overweight 405 20.6 121 23.8 
Obese 42 2.1 15 3 
AT – Achilles tendon; ** - statistically significant difference between uninjured and injured 





Table 3.6 Training characteristics of uninjured runners and runners reported Achilles 
tendon injuries. 
Training characteristics Uninjured runners 
(N=1969) 
AT Injured runners 
(N=508) 
n % n % 
Weekly running 
distance  
15-20 km 559 28.4 124 24.4 
20-40 km 925 47 245 48.2 
40+ km 485 24.6 139 27.4 
Run sessions per 
week 
1 or 3 sessions 852 43.3 215 42.3 
4 or 5 sessions 897 45.6 248 48.8 
6+ sessions 211 10.7 44 8.7 
NA 9 0.5 9 0.5 
Running 
experience**   
≤ 1 year 252 12.8 26 5.1 
2 years 197 10 36 7.1 
3-5 years 505 25.6 120 23.6 
6-9 years 280 14.2 82 16.1 
10+ years 732 37.2 244 48 
NA 3 0.2 0 0 
Race pace** 
<4 min/km 163 8.3 66 13 
4-5 min/km 640 32.5 202 39.8 
5-6 min/km 781 39.7 166 32.7 
6-7 min/km 306 15.5 60 11.8 
>7 min km 74 3.8 14 2.8 
NA 5 0.3 0 0 
Running terrain* 
Bitumen 883 44.8 234 46.1 
Cement 628 31.9 139 27.4 
Hard dirt/gravel 342 17.4 108 21.3 
Grass 42 2.1 17 3.3 
Treadmill 53 2.7 8 1.6 
Synthetic 6 0.3 1 0.2 
Sand 14 0.7 1 0.2 
NA 1 0.1 0 0 
Stretching in relation 
to a running session* 
Yes 1153 58.6 333 65.6 
No 811 41.2 175 34.4 
NA 5 0.3 0 0 
Wearing orthotics** 
Yes 271 13.8 117 23 
No 1689 85.8 388 76.4 
NA 9 0.5 3 0.6 
Participation in other 
sports 
Yes 1448 73.5 376 74 
No 513 26.1 127 25 
NA 8 0.4 5 1 
AT – Achilles tendon, NA – Not Available, * - statistically significant difference between 
uninjured and injured runners (p<0.05), ** - statistically significant difference between 
uninjured and injured runners (p<0.001).  
95 
 
3.3.5  Logistic regression model of the factors associated with Achilles tendon injuries 
Simple logistic regression analysis identified seven significant variables (p≤0.1): sex 
(p<0.001), age group (p<0.001), years of running experience (p<0.001), race pace 
(p<0.001), running terrain (p=0.056), stretching (p=0.005) and wearing orthotics (p<0.001). 
These variables were included in the multiple logistic regression analysis to identify those 
variables, which would be statistically significant, and statistically associated with an injury 
status, at the presence of other variables. As a result, the developed logistic regression 
model comprised six variables as the variable, which described preferred running terrain, 
was non-significant when grouped with other factors (Table 3.7). Male runners were twice 
more likely to report Achilles tendon injuries than female runners. Runners aged between 
35 and 50 years were 70% more likely to report Achilles tendon injuries in comparison to 
younger runners aged less than 35 years. Similarly, older runners aged over 50 years were 
46% more likely to report Achilles tendon injuries comparing to the reference group of young 
runners. Runners with one year or less of running experience were 59% less likely to report 
running-related injuries than runners with ten and more years of running practice. The most 
commonly reported race pace of 5-6 min/km was selected as a reference category for this 
variable. Runners who reported their typical race pace faster than 4 min/km were 1.5 times 
more likely to report Achilles tendon injuries. Runners who incorporated stretching in their 
running routine were 41% more likely to report Achilles tendon injuries. Finally, runners who 




Table 3.7 Logistic regression model of independent factors associated with the risk 
of Achilles tendon injuries. 
Variable OR (95% CI) p-value 
Sex (0=Female, 1=Male) 2.01 (1.6 to 2.52)  <0.001 
Age group    
<35 years (reference category) 1.00  
35-50 years  1.7 (1.31 to 2.21)  <0.001 
>50 years  1.46 (1.05 to 2.04) 0.03 
Years of running experience   
≤1 year  0.41 (0.26 to 0.64) <0.001 
2 years  0.72 (0.48 to 1.07) 0.1 
3-5 years  0.88 (0.68 to 1.15) 0.36 
6-9 years  1.06 (0.79 to 1.43) 0.7 
≥10 years (reference category) 1.00   
Race pace    
<4 min/km  1.51 (1.04 to 2.2) 0.03 
4-5 min/km  1.2 (0.93 to 1.54) 0.16 
5-6 min/km (reference category) 1.00  
6-7 min/km  1.06 (0.76 to 1.49) 0.72 
> 7 min/km  1.09 (0.59 to 2.04) 0.78 
Stretching in relation to a running session 
(0=No, 1=Yes) 1.41 (1.15 to 1.75) 0.001 
Wearing orthotics (0=No, 1=Yes) 1.93 (1.5 to 2.5)  <0.001 





3.3.6 Factors associated with bone stress injuries 
Recreational runners who reported at least one case of a bone stress injury occurred in the 
past two years (n=475) were merged with uninjured runners (n=1969) into the BS injury 
cohort (N=2,444). The injured and uninjured subgroups were statistically compared across 
physical and training characteristics (Table 3.8; Table 3.9). Rates of male and female 
runners in the injured and uninjured subgroups were similar (χ21=0.82, p=0.29). The 
compared subgroups were statistically different by the age group (χ22=34.61, p<0.001) and 
BMI group distributions (χ22=10.2, p=0.02). Although the subgroups were similar in the 
reported numbers of running sessions per week (χ22=1.54, p=0.46), they statistically differed 
across the remaining training characteristics. Thus, there were significantly more runners 
running over 40 km per week in the injured subgroup than in the uninjured subgroup (30.9 
versus 24.6%, χ22=10.11, p=0.006). The subgroups also significantly differed by years of 
running experience (χ24=26.03, p<0.001), race pace (χ24=13.59, p=0.009) and preferred 
running terrain (χ26=22.78, p=0.001). Additionally, it was more typical for injured runners 
than uninjured runners to report the incorporation of stretching into running practice (67.6% 
versus 58.6%, χ21=12.98, p<0.001) and wearing orthotics (29.5% versus 13.8%, χ21=68.32, 
p<0.001). However, the subgroups had very similar rates of the reported participation in 
other sports (χ21=0.12, p=0.73).  
 
Table 3.8 Physical characteristics of uninjured runners and runners with bone stress 
injuries. 
Physical characteristics Uninjured 
runners (N=1969) 
BS Injured runners 
(N=475) 
n % n % 
Sex 
Male 866 44 198 41.7 
Female 1103 56 277 58.3 
Age groups** 
18-34 years  600 30.5 193 40.6 
35-50 years 982 49.9 237 49.9 
>50 years 387 19.7 45 9.5 
Body mass index 
(BMI) groups* 
Normal 1465 74.4 354 74.5 
Underweight 57 2.9 17 3.6 
Overweight 405 20.6 83 17.5 
Obese 42 2.1 21 4.4 
BS – bone stress; * - statistically significant difference between uninjured and injured runners 





Table 3.9 Training characteristics of uninjured runners and runners with bone stress 
injuries. 




n % n % 
Run sessions per 
week 
1 or 3 sessions 852 43.3 193 40.9 
4 or 5 sessions 897 45.6 231 48.9 
6+ sessions 211 10.7 48 10.2 
NA 9 0.5 9 0.5 
Weekly running 
distance* 
15-20 km 559 28.4 109 22.9 
20-40 km 925 47 219 46.1 
40+ km 485 24.6 147 30.9 
Running 
experience**   
≤ 1 year 252 12.8 29 6.1 
2 years 197 10 55 11.6 
3-5 years 505 25.6 146 30.7 
6-9 years 280 14.2 88 18.5 
10+ years 732 37.2 157 33.1 
NA 3 0.2 0 0 
Race pace* 
<4 min/km 163 8.3 54 11.4 
4-5 min/km 640 32.5 179 37.8 
5-6 min/km 781 39.7 173 36.5 
6-7 min/km 306 15.5 53 11.2 
>7 min km 74 3.8 15 3.2 
NA 5 0.3 0 0 
Running terrain* 
Bitumen 883 44.8 211 44.4 
Cement 628 31.9 133 28 
Hard dirt/gravel 342 17.4 94 19.8 
Grass 42 2.1 23 4.8 
Treadmill 53 2.7 9 1.9 
Synthetic 6 0.3 5 1.1 
Sand 14 0.7 0 0 
NA 1 0.1 0 0 
Stretching in 
relation to a running 
session** 
Yes 1153 58.6 321 67.6 
No 811 41.2 153 32.2 
NA 5 0.3 1 0.2 
Wearing orthotics** 
Yes 271 13.8 140 29.5 
No 1689 85.8 331 69.7 
NA 9 0.5 4 0.8 
Participation in 
other sports 
Yes 1448 73.5 353 74.3 
No 513 26.1 120 25.3 
NA 8 0.4 2 0.4 
BS – bone stress, NA – Not Available, * - statistically significant difference between uninjured 
and injured runners (p<0.05), ** - statistically significant difference between uninjured and 
injured runners (p<0.001).  
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3.3.7 Logistic regression model of the factors associated with bone stress injuries 
To identify factors associated with bone stress injuries in the presence of other factors, 
simple logistic regression was performed for each variable. Eight statistically significant 
variables were included in the logistic regression model: age group (p<0.001), BMI group 
(p=0.02), years of running experience (p<0.001), running km per week (p=0.007), race pace 
(p=0.009), running terrain (p=0.006), stretching (p<0.001) and wearing orthotics (p<0.001). 
The final model comprised seven factors as the variable ‘race pace’ became non-significant 
at the presence of other variables (Table 3.10). The age group of under 35 years was a 
reference category, and runners aged between 35 and 50 years and aged over 50 years 
were 25% and 65% less likely to report bone stress injuries, respectively. BMI was a 
significant factor for bone stress injuries – obese runners were 2.8 times more likely to report 
injuries than runners with normal BMI. However, underweight and overweight categories 
were not significantly different from the normal BMI category. In relation to the running 
experience, the group of runners with ten and more years of running experience was the 
reference category. Inexperienced runners, with one year or less of running, were 43% less 
likely to report bone stress injuries, whereas runners with 2-5 years and 6-9 years of running 
experience were 36% and 38% more likely to report this type of injuries. A longer weekly 
running distance was associated with an increased risk of bone stress injuries. Thus, 
runners who reported that they would run over 40 km per week had a 1.6 times higher risk 
when compared to the reference category of 15 to 20 km per week. Regarding the preferred 
running terrain, bitumen was the most common reported terrain and thus was selected as a 
reference category. Only one out of six terrains were associated with twice as higher chance 
of reporting bone stress injuries compared to the ‘grass’ reference running terrain. 
Additionally, stretching in relation to running and wearing orthotics were associated with 1.4 




Table 3.10 Logistic regression model of independent factors associated with risk of 
bone stress injuries. 
Variable OR (95% CI) p-value 
Age group    
<35 years (reference category) 1.00  
35-50 years  0.75 (0.6 to 0.95) 0.02 
>50 years  0.35 (0.24 to 0.5) <0.001 
BMI group   
Normal (reference category) 1.00  
Underweight  1.03 (0.56 to 1.89) 0.92 
Overweight  1 (0.75 to 1.31) 0.97 
Obese  2.79 (1.55 to 5.05) 0.001 
Years of running experience   
≤1 year  0.57 (0.37 to 0.89) 0.01 
2 years  1.35 (0.94 to 1.95) 0.11 
3-5 years  1.36 (1.04 to 1.78) 0.03 
6-9 years  1.38 (1.01 to 1.89) 0.045 
≥10 years (reference category) 1.00   
Running km per week   
15-20 km (reference category) 1.00  
20-40 km  1.26 (0.96 to 1.64) 0.09 
>40 km  1.6 (1.18 to 2.16) 0.002 
Running terrain   
Bitumen (reference category) 1.00  
Cement  0.87 (0.68 to 1.12) 0.29 
Grass  2 (1.14 to 3.53) 0.02 
Hard dirt/gravel  1.06 (0.8 to 1.41) 0.69 
Sand  0.00 1.00 
Synthetic  2.08 (0.59 to 7.3) 0.25 
Treadmill  0.68 (0.32 to 1.45) 0.32 
Stretching in relation to a running session 
(0=No, 1=Yes) 1.44 (1.15 to 1.8) 0.001 
Wearing orthotics (0=No, 1=Yes) 2.73 (2.13 to 3.5)  <0.001 
OR – odds ratio; CI – confidence interval; Hosmer-Lemeshow test χ2=9.14, p=0.33. 





3.4.1 Discussion: reported running-related injuries 
This study was the first to collect and report injury data from approximately 5,000 Australian 
recreational runners. One of the objectives of the project was to report frequencies of the 
running-related injuries in Australian runners. In this study, 54% of runners reported running-
related injuries occurred in the past two years. Similarly, a recent cross-sectional study of 
1,145 novice and recreational runners recruited through parkrun reported a 49.8% injury 
rate (Linton & Valentin, 2018). A prospective cohort study followed 191 recreational runners 
over a 12-week period and registered 60 (31%) injured runners (Hespanhol Junior, Costa, 
& Lopes, 2013). Another prospective two-year study of 300 runners reported that 66% of 
the participants sustained at least one injury (Messier et al., 2018). A systematic review of 
17 studies reported the incidence of running-related injuries varying between 19.4% and 
79.3% with a follow-up period ranging between one day and 18 months (van Gent et al., 
2007). Whilst the reporting period in this project’ questionnaire was longer than in studies 
included in this systematic review, the injury rate of 54% was similar to the average rate 
reported in the systematic review. However, differences in the population characteristics, 
injury definitions and study designs were present. Our study survey was designed to not 
only collect epidemiological and injury data from recreational runners but to identify runners 
eligible for the genetic arm of the study. Therefore, the survey design and included questions 
also differed from other running injury studies, yet met our recruitment needs and was 
demonstrated to be a reliable questionnaire (Domaschenz et al., 2015).   
The two most common reported injuries in this study were an Achilles tendon injury and a 
bone stress injury. Each type of injury was of approximately 16% of all reported running-
related injuries. According to a systematic review, the same injuries were reported as the 
most common running-related musculoskeletal injuries, however, their rates were around 
10% for Achilles tendon injuries and 13-20% for bone stress injuries (Dias Lopes et al., 
2012). Importantly, the criteria of this systematic review required a specific definition of the 
injury, but not an injured anatomic part of the leg. Reported types of different injuries were 
classified and grouped by specific diagnoses and anatomic locations of these injuries. Van 
Gent et al. showed that the most common location of running-related injuries was the knee 
(van Gent et al., 2007). However, in this study, knee injuries were the fourth most common 
reported injuries.  
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The variability in recovery time was similar to a reported range of recovery time by Nielsen 
et al. The reported number of weeks off running after an injury occurred, showed that only 
7.4% of runners returned to running after a one-week break, whereas about 30% of injuries 
required at least six weeks of recovery time. In comparison, a study of novice runners 
showed that the median recovery time among 254 runners was 71 days (10 weeks), varying 
between 9 and 617 days (Nielsen et al., 2014).  
Overall, our study demonstrated high heterogeneity of sustained running-related injuries, as 
well as variability in the recovery time. It is important to acknowledge that the two most 
reported injuries were also injuries of interest for the subsequent genetic analyses – Achilles 
tendon injuries and bone stress injuries. Although the description of the study available for 
public and promotion material included information about the scope of study and its focus 
on genetic predisposition to tendon and bone injuries, the recruitment process was not 
biased towards the search of runners with these two types of injuries. The study aimed to 
collect an extensive amount of injury data in Australian physically active community of 
recreational runners both injured and uninjured and was promoted as such.  
 
3.4.2 Discussion: risk factors associated with running-related injuries, and specifically 
Achilles tendon injuries and bone stress injuries 
Recreational running has multiple health benefits as it is easily accessible. However, a risk 
of running-related injuries affects the health of runners and regularity of their physical 
activity. Therefore, prevention of running-related injuries is an important issue for the public 
and medical system. Throughout decades of research into risk factors contributing to 
running-related injuries, the findings have been relatively heterogeneous due to variation in 
data collection and analyses. Several factors were summarised in a meta-analysis as 
important contributors to the risk of injuries: longer weekly running distance for male runners, 
history of the previous injury in the past 12 months (Saragiotto et al., 2014). Additionally, an 
increase in training distance per week was protective for knee injuries (van Gent et al., 
2007). Our study analysed the largest cohort of Australian recreational runners and 
attempted to contribute to the knowledge of risk factors of running-related injuries identified 
in the studied cohort. 
Statistical analysis of data from 4,284 recreational runners demonstrated that there were 
significantly more male runners in the injured subgroup. The following regression analysis 
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showed that male sex was associated with a higher chance of reporting running-related 
injuries. Sex was assessed as a potential factor in multiple studies, however, the majority of 
the studies, which investigated overall injury risk, did not find any associations with sex 
(Macera et al., 1989; van Gent et al., 2007; Walter et al., 1989). However, one study found 
an association between male sex and higher rates of running-related injuries among 
younger runners aged under 40 years (McKean, Manson, & Stanish, 2006). Additionally, 
Linton et al. reported that among recreational runners recruited via parkrun men were 1.45 
times more likely to report running-related injuries than women (Linton & Valentin, 2018). In 
addition to overall injury risk associated with male sex, our study demonstrated that male 
runners were more likely to report Achilles tendon injuries. These findings corresponded 
with the higher rates of Achilles tendinopathy in male runners in the study of 2002 running 
injuries (Taunton et al., 2002). Although men are more likely to report Achilles tendon injuries 
than women, previously described sex differences in training loads and patterns (Section 
2.4.1), including running longer weekly distances and more frequently, may explain these 
differences and therefore, complicate the evaluation of sex as an independent factor. 
Interestingly, previous literature reviews demonstrated that bone stress injuries were more 
typical for female runners (Mattila et al., 2007; Newman et al., 2013). However, in our study, 
the frequencies of bone stress injuries did not differ between male and female runners. 
Similarly, to Achilles tendon injuries, sex should not be considered as an independent factor, 
being possibly associated with training factors and other sex-related factors. 
Age was a factor associated with overall injury risk, as well as for both Achilles tendon 
injuries and bone stress injuries. Regression analysis showed that runners aged over 50 
years were less likely to report running-related injuries than runners under 35 years of age. 
Previously, older age was demonstrated as a contradictory factor, which may increase risk 
of injuries, yet with limited evidence (van der Worp et al., 2015; van Gent et al., 2007). 
Potentially, our study’s results could be explained by the speculation that injuries at an older 
age would make runners reconsider their training routine and stop running. Interestingly, 
different age groups were associated with reporting of Achilles tendon injuries and bone 
stress injuries. Thus, age groups of 35 to 50 years and over 50 years were associated with 
1.7 and 1.5 increased risk of Achilles tendon injuries, respectively. These results were 
consistent with the literature review reporting that people aged between 30 and 55 had the 
highest rates of Achilles tendinopathy, which could be explained by molecular changes in 
the tendon, as ageing processes start in the body (Cook, Khan, & Purdam, 2002). 
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Conversely, the same age groups were associated with decreased risk of bone stress 
injuries in the BS injury cohort. Although bone density decreases with age, and reduced 
bone density potentially increases the risk of injuries in older age, younger runners may also 
be at risk of bone stress injuries due to unfinished maturation of bone and its susceptibility 
to injuries at that time. This could explain why runners aged under 35 years were more likely 
to report bone stress injuries than runners older than 35 years.               
In this study, BMI was not a significant factor for running-related injuries and Achilles tendon 
injuries, however, was a contributing factor to the risk of bone stress injuries. Obese runners 
were 2.8 times more likely to report bone stress injuries when compared to runners with 
normal BMI. It is important to acknowledge that the BS injury cohort comprised only 63 
obese runners, and one-third of these runners (n=21) reported bone stress injuries. Several 
previous studies also demonstrated that increased BMI was associated with the risk of bone 
stress injuries, such as medial tibial stress syndrome and tibial stress injuries (Beck et al., 
2015; Newman et al., 2013). 
The performed logistic regression analyses demonstrated that runners with only one year 
or less of running experience were less likely to report running-related injuries overall, as 
well as bone stress injuries and Achilles tendon injuries, when compared to runners with 
more than ten years of running practice (a reference group). However, in the survey, the 
respondents were asked about injuries that occurred only in the past two years. Therefore, 
the reported lower rates of sustained injuries among inexperienced runners could be 
explained by a shorter period of running practice. Interestingly, uninjured and injured 
subgroups comprised of similar proportions of runners with two years of running experience, 
and their injury rates did not differ significantly from runners with over ten years of running 
experience. Interestingly, runners with 3-5 and 6-9 years of running experience were more 
likely to report bone stress injuries than the reference group. Similar observations were 
reported in a systematic review of risk factors of MTSS: fewer years of running experience 
were associated with the development of MTSS (Newman et al., 2013). Potentially, running 
experience could be one of the markers of muscular and bone adaptation to the load, in 
conjunction with running volume, frequencies of training sessions, and running terrain. 
Therefore, correct preconditioning of runners and adaptation to load may reduce injury risk 
making this factor modifiable through training adjustments.   
Two other factors characterising training characteristics were also associated with a higher 
chance of reporting bone stress injuries, but not other types of injuries: longer weekly 
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running distance and running on grass. Thus, runners who would run 20-40 km per week 
and over 40 km per week were 26% and 60% more likely to report bone stress injuries than 
runners with 15-20 km of weekly running distance, respectively. Longer distance may be a 
parameter of either high training load or gradual increase of the load. Both may contribute 
to the accumulation of microdamage in the bone and subsequent development of bone 
stress injuries (Warden et al., 2014). Preferred running terrain may also influence bone 
loading. Originally harder surfaces such as bitumen and cement were hypothesised to 
increase the load to bone comparing to more compliant surfaces such as grass and sand. 
However, no studies have identified a clear association between running terrain and the risk 
of bone stress injuries. Interestingly, the risk of bone stress injuries was associated with the 
recent change in terrain, as this change requires adaptation to different ground reaction 
forces and therefore, may increase the risk of microdamage in the bone (Warden et al., 
2014). Therefore, we did not find any literature to support our finding of the running terrain 
‘grass’ as a potential risk factor. However, it should be taken into consideration that only 65 
runners reported ‘grass’ as their preferred running terrain, and one-third of those runners 
reported bone stress injuries. 
The number of running sessions per week was a significant factor for development of 
running-related injuries. Runners who reported running 1-3 and 4-5 times per week were 
more likely to report running-related injuries than runners who would run at least six times 
per week. According to a systematic review, some of the previous studies reported an 
increased risk of injuries associated with the increase in the number of running sessions per 
week, whereas other studies did not find this association (van Gent et al., 2007). Although 
our results may differ from the previous findings, may be considered in the following 
research.     
Race pace of less than 4 minutes per kilometre was associated with 1.5 higher chance of 
Achilles tendon injuries. However, this variable was not associated with either risk of all 
running-related injuries or bone stress injuries. McCrory et al. reported that runners with 
Achilles tendinopathy would train at a higher pace, prior to the injury, comparing to uninjured 
runners (McCrory et al., 1999). Another study demonstrated that runners competing at 
shorter distances of 1,500-3,000 metres were more likely to develop Achilles tendinopathy 
than runners competing at the 10 km race. Additionally, Achilles tendinopathy was the most 
common injury among elite runners in this study, as they would train at faster paces than 
recreational runners (Knobloch et al., 2008). Our findings support these observations and 
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suggest that faster race pace may be an important contributor to the risk of Achilles tendon 
injuries.   
Two remaining factors associated with a higher chance of reporting both types of injuries 
and overall running-related injuries were stretching and wearing orthotics. Stretching was 
often considered as a part of injury prevention program as muscle stiffness, and restricted 
range of motion were factors for musculoskeletal injuries in runners (Van Mechelen, Hlobil, 
Kemper, Voorn, & de Jongh, 1993). However, a systematic review of the impact of stretching 
on sports injury risk concluded that included studies failed to demonstrate any protective 
effect of stretching, both in cohort studies and randomised controlled trials (Thacker, 
Gilchrist, Stroup, & Kimsey Jr, 2004). Moreover, this study suggested that not only may not 
prevent sports injuries but also might compromise sports performance as stretching may 
decrease joint stability, decrease muscle and tendon ability to absorb energy and change 
body position leading to overloading of tissues. Although the results of our study showed an 
association between the development of injuries and stretching, we were unable to derive 
any conclusions about their link as our study lacked details about the timeline of injuries and 
introduction of the stretching into running practice. Orthotics influence the biomechanics of 
the foot and usually are used for improving running and for additional cushioning (McKenzie 
et al., 1985). Therefore, correctly prescribed orthotics may assist in injury prevention as well 
as recovery from injuries. However, an inaccurate choice of orthotics may increase risk of 
injury. The results of our study showed that injured runners would wear orthotics significantly 
more often than uninjured runners, yet our data were missing the time link between the injury 
occurrence and the introduction of orthotics. Similarly, to stretching, we were unable to 
conclude on the role of orthotics in the injury risk, and therefore these two factors require 
additional data collection with more detailed questions.  
In summary, our study identified factors associated with the development of running-related 
injuries and two most common overuse injuries – Achilles tendon injuries and bone stress 
injuries. These findings may contribute to the injury prevention programs, optimisation of 
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4.1 Introduction  
An Achilles tendon injury is one of the most common lower leg injuries amongst runners. A 
systematic review of running-related injuries reported that a typical rate of Achilles tendon 
injuries was 9.1-10.9% (Dias Lopes et al., 2012). Multiple risk factors have been associated 
with Achilles tendon injuries. Risk factors are divided into modifiable and non-modifiable; 
with modifiable risk factors comprising of training, lifestyle factors and medications, which 
may affect tendons, and non-modifiable comprising of physical and anatomic characteristics 
and genetic variants associated with the development of Achilles tendon injuries. 
Although training characteristics such as running distances and the number of years of 
running did not show consistent associations with the development of Achilles tendon 
injuries (Lorimer & Hume, 2014), running on soft terrains such as sand has been shown to 
increase the risk of Achilles tendon injuries, whereas running on asphalt was a protective 
factor against this type of injury (Knobloch et al., 2008). Lifestyle habits such as smoking 
cigarettes and alcohol consumption are also considered potential risk factors to developing 
Achilles tendon injuries, yet show contradictory results or very moderate associations with 
the development of the injuries, and could alternatively be explained by training-related 
factors (Owens et al., 2013). Several studies have shown a significant effect of 
fluoroquinolone antibiotics on the increased risk of Achilles tendon injuries, in particular, 
tendon ruptures, with a reported three-fold increase in a Danish cohort and 4.1-fold increase 
in an Italian cohort (Corrao et al., 2006; Sode et al., 2007). Moreover, with additional 
exposure to corticosteroids risk of tendon rupture increased to 10-fold in the same Italian 
population (Corrao et al., 2006).  
It is more typical for men to report Achilles tendon injuries, yet this difference could be 
explained by differences in training loads between sexes (Magnan et al., 2014). A systematic 
review regarding the pathogenesis of Achilles tendinopathy showed that age was a 
significant factor affecting the tendon matrix (Magnan et al., 2014). With the highest rate of 
Achilles tendinopathy observed amongst individuals aged between 30 and 55 (Cook et al., 
2002). A cohort study of long-distance runners also showed a significant association of older 
age and risk of Achilles tendinopathy (Hirschmüller et al., 2012). Specific anatomic 
characteristics, such as malalignment and hyperpronation, were shown to be associated 
with increased risk of Achilles tendinopathy (Järvinen et al., 2005). At the same time, 
correction with orthotics of foot anatomy may prevent the risk of Achilles tendon injuries 
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(Peters et al., 2015). Stretching may also contribute to the Achilles tendon injury, although 
the evidence of this is currently inconclusive (Peters et al., 2015). 
The majority of genetic studies investigating the risk of Achilles tendinopathy have employed 
a candidate gene approach, targeting genes which encode different types of collagen and 
other molecules responsible for the regulation of extracellular matrix homeostasis. The most 
investigated gene was COL5A1, with several genetic variants in this gene being associated 
with the development of Achilles tendon injuries across three Caucasian populations: 
Australian, South-African and British (Brown et al., 2016; Mokone et al., 2006; September, 
2009). Genetic variation in the TNC gene, a regulator of cell-matrix interaction in tendon 
tissue, was associated with decreased risk of Achilles tendinopathy (Mokone et al., 2005). 
Further investigation of proteins involved in the tendon structure has also targeted fibrillin 
and elastin, due to their role in tendon elasticity, strength and flexibility. However, only a 
single association between a variant in the FBN2 gene and injury has been shown in 
Australian and South-African cohorts (El Khoury et al., 2015). Metalloproteinase 3 (MMP3) 
is a key regulator of extracellular matrix homeostasis, and three investigated polymorphisms 
in the MMP3 gene were significantly associated with decreased risk of Achilles tendinopathy 
(Raleigh, 2009). Tissue inhibitors of metalloproteinases (TIMP) have also been considered 
as potential contributors to the genetic risk of Achilles tendinopathy. Genetic variation in the 
TIMP2 gene was significantly associated with reduced risk of Achilles tendinopathy in two 
studies, which concluded that the balance between metalloproteinase and TIMPs function 
may be important for the development of Achilles tendinopathy (El Khoury et al., 2013; El 
Khoury et al., 2016). Since several growth factors play an important role in tendon growth 
and homeostasis, one study investigated the role of polymorphisms in the genes TGFB1 
and GDF5, which encode transforming growth factor-β1 and growth/differentiation factor-5, 
respectively. This study found a significant association of one polymorphism located in 
GDF5 but did not find any association between TGFB1 and Achilles tendinopathy 
(Posthumus et al., 2010). Caspases are involved in the pathways accompanying tendon cell 
apoptosis, and their expression was elevated in tendinopathy cases. A genetic 
polymorphism located in the CASP8 gene has been associated with the risk of Achilles 
tendinopathy in Australian and South-African populations (Nell et al., 2012). Although a 
number of reviewed genes were associated with development of Achilles tendon injuries, 
multiple other genes with relevant roles in tendon structure (COL11A1, COL12A1, 
COL14A1, COL27A1) and tendon homeostasis (NOS2, NOS3, CASP3) did not show any 
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association with the condition (Hay et al., 2013; Nell et al., 2012; Rickaby et al., 2015; 
September et al., 2008).  
Since Achilles tendinopathy is a multifactorial condition, and the contribution of each 
polymorphism is relatively small, it is important to acknowledge the importance of the 
sufficient samples size and unbiased approach when candidate genes are investigated. 
Unfortunately, the majority of these studies incorporated a candidate gene approach and 
used relatively small cohort size, with approximately 150 cases and 350 controls in the 
largest studied cohorts, which could lead to biased results and hence require replication 
analysis, which could prove their findings.  
With the development of high-density molecular methods, it is now possible to investigate 
thousands-to-millions of genetic variants at one time, at relatively low cost. GWAS is one 
such approach and based upon the principle of linkage disequilibrium (LD) at the population 
level. As a GWAS enables the genotyping of thousands-to-millions of genetic markers, 
simultaneously across the whole genome, it avoids the bias of preselection of potentially 
important genes as observed in the candidate gene approach (Hartl et al., 1997; Visscher, 
Brown, McCarthy, & Yang, 2012). This unbiased genome-wide approach has been used in 
the search for single-nucleotide polymorphisms (SNPs) associated with many complex 
diseases (Donnelly, 2011). Within the first five years of its introduction, GWAS identified 
many new associated genes in relation to a number of autoimmune diseases such as 
ankylosing spondylitis, rheumatoid arthritis and type 1 diabetes, as well as metabolic 
diseases such as type 2 diabetes and obesity (Visscher et al., 2012). However, one of the 
critical considerations in GWAS is that since each polymorphism may contribute a small 
effect on the studied trait, it is essential to have a large sample size to provide statistically 
reliable results.  
To date, only a single GWAS has investigated genetic variants associated with Achilles 
tendon injuries (Kim et al., 2017). This study used genomic data of a cohort, which 
comprised of over 100,000 hospital patients, including over 5,000 patients with Achilles 
tendon injuries. Whilst no statistically significant SNPs were identified, four SNPs reached a 
suggestive significance level (1 x 10-6). Two of these four SNPs (rs57104447, rs60713544) 
were located in the intragenic regions on chromosomes 1 and 4, respectively. The other two 
identified SNPs (rs1937810, rs57224706) were located in the MMP7 and SMARCD1 genes, 
respectively. In addition, previously identified SNPs from candidate gene studies were 
unable to be replicated in this cohort (Kim et al., 2017). The genetic contribution to the 
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Achilles tendon injury predisposition is still unclear and requires further investigation, 
therefore this part of the project aimed to identify novel polymorphisms associated with 
Achilles tendon injuries in recreational runners. Also, results from this cohort of recreational 
runners were assessed for SNPs previously associated with Achilles tendinopathy 





Participants for the genomic study were a subset of 1,165 (23.6%) recreational runners 
derived from 4,720 respondents (described in Chapter 2) who met the following eligibility 
criteria:  
• 18-50 years of age,  
• reported background of at least 75% of Caucasian European or Mediterranean  
• current non-smoker with at least five years after giving up,  
• have no history of chronic conditions that could affect the musculoskeletal system 
(osteoarthritis, osteoporosis, rheumatoid arthritis, chronic renal failure),  
• no history of chemotherapy. 
With the application of these criteria, only runners who reported injuries, which were more 
likely to be running-related, but not affected by ageing, chronic conditions, smoking and 
chemotherapy. In addition, those runners who reported Achilles tendon injuries and bone 
stress injuries were included in the genetic study if they did not have a fracture or surgery 
preceding the injury, and in case of only an Achilles tendon injury did not report corticosteroid 
injections and the use of quinolone antibiotics in the past six months.  
 
4.2.2 Sample collection 
Eligible participants were contacted via email to confirm their agreement to provide a saliva 
sample. In these emails, eligible participants also received two documents: ‘Participant 
information sheet’ and ‘The ethics of genetic research’, aiming to provide an understanding 
of the project, and the possible benefits and risks of participating in genetic research 
(Appendices 8 and 9). Saliva as a source of genomic DNA was chosen due to the non-
invasive, simple collection method and the ability to transport these samples at room 
temperature through the mail. Oragene DNA (OG-500) collection kits (DNA_Genotek, 2015) 
were selected for the sample collection due to simple instructions to provide a saliva sample, 
long-term sample storage at room temperature and expected high median DNA yield 
(110ng/2mL of saliva). Participants were mailed the collection kit, all associated paperwork, 
and a reply-paid envelope and were asked to return the sample and consent forms via the 
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mail (Appendix 10). Samples were received at Bond University and registered in BCSNP 
system (BC, 2015). Saliva samples were stored at room temperature until processing. 
4.2.3 DNA Extraction  
DNA extractions were conducted in the Molecular Biology research laboratory at the Faculty 
of Health Sciences and Medicine, Bond University. DNA was extracted from saliva samples 
according to standard protocols with minor modifications (DNA_Genotek, 2015). 
Specifically, 1mL of Oragene saliva samples were incubated at 50oC overnight to maximise 
DNA yield and inactivate nucleases. Following incubation, 40µL (1/25th volume) of PrepIT-
2LP lysis solution was added to the saliva samples and mixed by vortexing. Then samples 
were incubated on ice for 10 minutes, then centrifuged at 4,500 rpm for 10 minutes. The 
supernatant (~1mL) was transferred to a new tube with 1.2 mL (1.2x volume) of 100% 
ethanol added to precipitate the DNA. Samples were re-centrifuged to pellet the DNA 
precipitate and supernatant was discarded. The DNA pellet was washed with 70% ethanol 
(1mL), centrifuged as before, the supernatant removed, and the DNA pellet allowed to dry 
to remove ethanol traces. The DNA pellet was rehydrated with 200µL of ddH2O and 
incubated at 50°C for one hour to ensure complete resuspension. To assess concentration 
and quality of the samples, DNA samples were analysed using UV spectrophotometry 
(NanoDrop) and fluorometry (Qubit 3). Extracted DNA was stored at -20°C prior to 
subsequent analysis. 
 
4.2.4 Genotyping and Quality Control 
All samples were genotyped using Infinium CoreExome-24 BeadChips (Illumina, 2015). This 
microarray contains ~550,000 genetic markers, made up of exonic variants, splice variants, 
stop altering variants, ancestry informative markers and MHC tag SNPs (Illumina, 2015). All 
arrays were processed according to standard protocols and workflows on the Illumina iScan 
platform at the Australian Translational Genomics Centre, Queensland University of 
Technology/Translational Research Institute. Samples were processed in three batches 
across the two-year project timeline. Sample quality was assessed using Illumina Genome 
Studio v. 2011.1, and final data were released as .map and .ped files. Files were imported 
into the BCSNP database (BC, 2015) and analysed. Quality Control (QC) analysis was 
conducted using BC Platforms software (BC, 2015), with QC thresholds set to exclude 
individuals with >5% failed genotypes. In addition, an X chromosome inbreeding estimate 
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was applied to identify sex non-concordance of genotyped samples. Samples displaying 
heterozygosity rates outside the range of three standard deviations of the mean were also 
excluded. Identity by state (IBS) was used to identify cryptic relatedness and individuals 
excluded that were >10% related. Finally, Principal Component Analysis (PCA) was 
performed to assess the population stratification of our participants. SNP genotypes from 51 
populations from the Human Genome Diversity Project (HGDP) were used as our population 
reference (Cavalli-Sforza, 2005). HGDP genotype data and sample descriptions are freely 
available from: http://hagsc.org/hgdp/files.html.  Thresholds for PCA analysis were set up at 
six standard deviations from the mean. Markers with >7.5% genotypes missing, out of 
Hardy-Weinberg Equilibrium (p<0.0001) and a minor allele frequency (MAF) <0.01 were 
excluded. 
 
4.2.5 Statistical Analyses 
After the QC steps, samples were assigned to one of two case groups (an Achilles tendon 
injury or a bone stress injury) or an uninjured control group. Genotyped AT genomic and BS 
genomic cohorts were statistically compared to the previously described AT injury cohort 
and BS injury cohort, respectively, using a χ2 test. GWAS data were tested using logistic 
regression with an additive genetic model implemented in PLINK (Purcell et al., 2007). 
Genome-wide significance and suggestive levels of p<5x10-8 and p<1x10-5, respectively, 
were chosen initially, according to standard guidelines. Manhattan plots were generated 
using HaploView software (Barrett, Fry, Maller, & Daly, 2004), PCA plots and QQ-plots were 
generated in R-software (R Development Core Team, 2008). Power calculations were 
performed using the Genetic Power Calculator (Purcell, Cherny, & Sham, 2003). 
 
4.2.6 Imputation 
SHAPEIT2 was used for pre-phasing of the data and Sanger Imputation Service platform 
was used for imputation based on Haplotype Reference Consortium as a reference dataset  
(Delaneau, Zagury, & Marchini, 2013; Haplotype Reference Consortium, 2016; Sanger 
Institute, 2017). The outcome .vcf files containing imputed genotypes were then filtered to 
exclude imputed SNPs with an INFO score of <0.6 (Danecek et al., 2011). Filtered files were 
transformed into PLINK format (.bed, .bim, .fam) prior to data analysis. Case-control 
116 
 
analyses were implemented using PLINK, with the outcome association files split by 
chromosome and plots generated for each chromosome in Haploview (Barrett et al., 2004). 
The LocusZoom online service was used to visualise genotyped and imputed significant 
SNPs (Pruim et al., 2010).  
 
4.2.7 Replication Analysis 
Using the imputed dataset, p-values of identified significant SNPs in this study were 
compared to the p-values of the same SNPs acquired from publicly available data from 
GWAS of Achilles tendon injuries by Kim et al. (Kim et al., 2017). Previously identified by 
candidate gene approach studies SNPs, described in Table 1.1 in Chapter 1, were further 
investigated using imputed data to attempt replication of those results in the current study 




4.3 Results  
4.3.1 Phenotypic characteristics of the participants 
4.3.1.1 Definition of investigated cohorts 
Initial recruitment for the project resulted in 4,720 unique responses from recreational 
runners who reported running at least 15 km per week. However, in order to investigate 
training-related risk factors of running-related injuries, particularly Achilles tendon injuries 
and bone stress injuries, these responses were filtered by the circumstances the injuries 
occurred. Only runners who reported injuries that occurred while running (as opposed to 
injuries which occurred during other activities) were included in the study. Firstly, runners 
who reported injuries that occurred while not running were excluded (n=436), resulting in a 
cohort of 4,284 runners, corresponding to 2,315 (54%) injured and 1,969 (46%) uninjured 
runners. Secondly, individuals who reported specifically Achilles tendon injuries and bone 
stress injuries were grouped separately, resulting in 508 Achilles tendon injury cases and 
475 bone stress injury cases. Finally, each case group was merged with the uninjured 
runners (n=1,969) for the subsequent case-control analyses. This resulted in two cohorts: 
the Achilles tendon (AT) injury cohort and the bone stress (BS) injury cohort. With the AT 
cohort comprising of 2,477 runners (508 Achilles tendon injury cases and 1,969 uninjured 
controls) and the BS injury cohort comprising of 2,444 runners (475 bones stress injury 
cases and 1,969 uninjured controls).  
Selection criteria for the genetic arm of the study applied to 4,720 participants, identified 
1,651 recreational runners (35%) eligible for genetic analysis. These study participants were 
contacted for recruitment into the genomic study, of which 1,165 (70.6%) provided signed 
consent and a saliva sample (Figure 4.1). In order to assess whether responsiveness to 
participate was biased by sex, age or both, a χ2 test was performed. As shown in Table 4.1, 
response rates from both males and females were very similar. However, participant age 
was associated with willingness to participate in the study, as younger age was associated 
with a lower rate of response to the invitation email (p<0.001). Considering relatively low 
rates of young runners in the cohort, this association predicted higher proportions of middle-






Table 4.1 Summary of response rates to the invitation email by sex and age group 
categories. 
Categories Eligible and replied with contact 
details 
Yes (%) No (%) 
Sex 
Male 78.4 21.6 
Female 81.4 18.6 
Age group* 
18-24 65 34.9 
25-34 77.3 22.7 
35-44 82.8 17.2 
45-50 82.6 17.4 
*- statistically significant difference between ‘Yes’ and ‘No’ responses (p<0.001).  
 
Of the 1,165 collected saliva samples, 1,099 passed quality control analysis and were 
grouped as uninjured or with a specific type of injury. This resulted in two genomic cohorts: 
AT genomic cohort of 938 runners (171 Achilles tendon injury cases and 767 uninjured 
controls) and BS genomic cohort of 941 runners (174 bone stress injury cases and 767 
uninjured controls). These two cohorts were used for subsequent comparison to the AT and 
BS injury cohorts, as described earlier (Chapter 3). The remainder of this chapter is focused 
on the AT injury and genomic cohorts, while the BS cohorts are further discussed in Chapter 
5. 
 
4.3.1.2 Statistical comparison of AT genomic cohort and AT injury cohort 
The physical characteristics and reported ethnic background of the participants included in 
the AT genomic cohort are displayed in Table 4.2, with the physical characteristics of AT 
injury cohort are previously presented in Table 3.5. 
Within the AT genomic cohort, 18.2% were injured cases. This rate was very similar to the 
rate of 20.5% of injured runners in the AT injury cohort (χ21=2.217, p=0.09). Whilst the AT 
genomic cohort had significantly higher proportion of females than the AT injury cohort 
(56.4% versus 52.1% χ21=4.95, p=0.015), the frequencies of males and females did not 
significantly differ when injured and uninjured groups of the cohorts were compared to each 
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other (χ21=2.259, p=0.08, χ21=2.346, p=0.08, respectively). In regard to BMI group 
distribution, the AT genomic cohort had a significantly higher rate of runners with a BMI 
within a normal range relative to AT injury cohort (78.3% versus 73.7, χ21=7.45, p=0.004). 
Hence, when injured and uninjured groups of AT genomic cohort were compared to injured 
and uninjured groups from the AT injury cohort, frequencies of normal BMI groups also 
differed statistically (80.7% versus 71.1%, χ21=6.1, p=0.008, 77.7% versus 74.4%, χ21=3.23, 
p=0.044).   
A participant age between 18 and 50 years old was a key selection criterion for inclusion in 
the genomic study. However, one-fifth (20.2%) of the AT injury cohort were older than 50 
years of age. In order to compare the age groups between the two AT cohorts, older 
recreational runners were removed from the AT injury cohort, and the remaining runners 
categorised by the following age groups: 18-24, 25-34, 35-44 and 45-50. The same grouping 
was also applied to the AT genomic cohort. The distribution of age groups differed 
significantly between the AT injury and AT genomic cohorts (χ23=12.26, p=0.007). However, 
the frequencies of age groups did not differ significantly between injured groups (χ23=1.62, 
p=0.65). Only the uninjured AT genomic cohort group differed significantly from the 
uninjured group in the AT injury cohort by age group distribution (χ23=12.23, p=0.007). This 
was due to the uninjured group from AT genomic cohort having significantly less young (18-
24 years old) runners than the AT injury cohort (4.9% versus 7.9%). This could be explained 
by the previously described unwillingness of younger respondents to get involved in the 
genetic arm of the study.  
Reported ethnicity was a selection criterion for the genetic analysis. Runners reported the 
ethnic background of their four grandparents, which allowed for the identification of eligible 
participants with at least 75% of Caucasian European or Mediterranean background. Of the 
2,477 runners included in the AT injury cohort, 83.7% were reportedly 100% Caucasian 
European and 1.4% were of 100% Mediterranean ancestry. Among runners included in the 
AT genomic cohort and those who passed GWAS population stratification analysis, the 
majority (94.8%) were reportedly 100% Caucasian European, and only 5.2% of participants 
reported either various proportions of Caucasian European, Mediterranean and other 
backgrounds, or 100% Mediterranean background.   
The AT genomic cohort was compared to the AT injury cohort across training characteristics, 
these compared cohorts did not differ by years of running experience (χ24=7.66, p=0.105), 
number of running sessions per week (χ23=1.28, p=0.74), running terrain preferences 
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(χ24=2.81, p=0.59), stretching in relation to a running session (χ21=0.103, p=0.75), wearing 
orthotics (χ21=0.001, p=0.97) and participation in other sports besides running (χ21=2.28, 
p=0.13). However, a significant difference in the rates of reported race pace (χ24=21.89, 
p<0.001) was observed. Thus, the injured group from the AT genomic cohort had a 
significantly higher rate of the <4 min/km race pace than the injured group from the AT injury 
cohort (20.5% versus 9.2%, χ24=27.5, p<0.001). The same significantly higher rates of faster 
race paces were observed in the uninjured group from the AT genomic cohort comparing to 
the uninjured group from the AT injury cohort (χ24=13.34, p=0.01). In summary, AT genomic 
cohort differed from AT injury cohort by frequencies of males and females, frequencies of 
runners with normal BMI, frequencies of runners aged between 18-24 years old, and 
reported race pace. 
 
4.3.1.3 Statistical comparison of injured and uninjured runners within the AT genomic 
cohort 
The AT genomic cohort consisted of 410 (43.7%) males and 528 (56.3%) females. Within 
the AT genomic cohort, a higher proportion of males (n=97, 23.7%) reported Achilles tendon 
injuries compared to females (n=74, 14%). Injured and uninjured groups within the AT 
genomic cohort were statistically different by the proportions of males and females 
(χ21=14.396, p<0.001). These groups also statistically differed by frequencies of age groups 
with significantly more runners aged 45-50 in the injured group than in the uninjured group 
(χ23=8.895, p=0.031). Additionally, the median age of cases was 41 years, in comparison to 
39 years of age for the median age of uninjured controls. This could be explained by 
generally higher rates of injured than uninjured runners aged 45-50 in the AT injury cohort 
(21.9% versus 15.4%). The majority of runners, in both studied groups, those with Achilles 
tendon injuries and uninjured, were in the normal BMI range.   
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Table 4.2 Physical characteristics of runners with Achilles tendon injuries and 
uninjured runners in the AT genomic cohort. 




n % n % 
Sex** 
Male 97 56.7 313 40.8 
Female 74 43.3 454 59.2 
Age group* 
18-24 years 5 2.9 38 4.9 
25-34 years 37 21.6 204 26.6 
35-44 years 78 45.6 371 48.4 
45-50 years 51 29.8 154 20.1 
Body Mass 
Index  
Underweight (<18.5 kg/m2) 2 1.2 16 2.1 
Normal (18.5 to <25 kg/m2) 138 80.7 596 77.7 
Overweight (25 to <30 kg/m2) 26 15.2 141 18.4 




100% CE 161 94.2% 728 94.9% 
75% CE + 25% MT/Other 7 4.1% 14 1.8% 
50% CE + 50% MT/Other 1 0.6% 19 2.5% 
100% MT 2 1.2% 5 0.7% 
75% MT + 25% Other 0 0% 1 0.1% 
ATI – Achilles tendon injury, CE – Caucasian European, MT – Mediterranean, * - statistically 
significant difference between injured and uninjured groups within the AT genomic cohort 
(p<0.05), **- statistically significant difference between injured and uninjured groups within 
the AT genomic cohort (p<0.001). 
 
Training characteristics of the different sub-groups in the AT genomic cohort are displayed 
in Table 4.3. Only three parameters were statistically different: 1) years of running 
experience (χ23=29.325, p<0.001), 2) race pace (χ25=16.014, p=0.007) and 3) wearing 
orthotics (χ22=8.244, p=0.016). Almost half (47.4%) of the participants included in the case 
group reported more than 10 years of running experience, whereas only 35.5% of uninjured 
controls had over 10 years of running practice. At the same time, runners with Achilles 
tendon injury history were more likely to run at a race pace of less than 4 min/km compared 
to uninjured runners (20.5% versus 10.7%). It was also more typical for the runners with 
Achilles tendon injuries than uninjured runners to wear orthotics (22.8% versus 14.1%).  
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In summary, injured and uninjured groups within the AT genomic cohort differed by 
frequencies of males and females, frequencies of the age groups, running experience, race 
pace and wearing orthotics.   
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Table 4.3 Training characteristics of runners with Achilles tendon injuries and 
uninjured runners in the AT genomic cohort. 




n % n % 
Weekly running 
distance 
15-20 36 21.1 205 26.7 
20-40 83 48.5 362 47.2 
40+ 52 30.4 200 26.1 
Running 
experience** 
≤ 1 year 6 3.5 99 12.9 
2 years 9 5.3 73 9.5 
3-5 years 30 17.5 196 25.5 
6-9 years 45 26.3 127 16.5 
10+ years 81 47.4 272 35.5 
Running sessions 
per week 
1 session  0 0.0 2 0.3 
2 or 3 sessions 75 43.9 327 42.6 
4 or 5 sessions 83 48.5 358 46.7 
6+ sessions 13 7.6 74 9.6 
N/A 0 0.0 6 0.8 
Race pace* 
<4 min/km 35 20.5 82 10.7 
4-5 min/km 67 39.2 278 36.2 
5-6 min/km 51 29.8 291 37.9 
6-7 min/km 15 8.8 95 12.4 
>7 min/km 3 1.8 18 2.3 
N/A 0 0.0 3 0.4 
Running terrain 
Bitumen 79 46.2 322 42.0 
Cement 42 24.6 256 33.4 
Grass 3 1.8 16 2.1 
Hard dirt/gravel 43 25.1 146 19.0 
Treadmill 4 2.3 20 2.6 
Sand 0 0.0 4 0.5 





Table 4.3. Training characteristics of runners with Achilles tendon injuries and 
uninjured runners in the AT genomic cohort (continuation). 




n % n % 
Participation in 
other sports 
Yes 132 77.2 583 76.0 
No 37 21.6 182 23.7 
N/A 0 0.0 2 0.3 
Stretching in 
association with a 
running session 
Yes 110 64.3 447 58.3 
No 61 35.7 318 41.5 
N/A 0 0.0 2 0.3 
Wearing orthotics* 
Yes 39 22.8 108 14.1 
No 132 77.2 658 85.8 
N/A 0 0.0 1 0.1 
* - statistically significant difference between injured and uninjured groups within the AT 
genomic cohort (p<0.05), **- statistically significant difference between injured and uninjured 
groups within the AT genomic cohort (p<0.001). 
 
4.3.1.4 Discussion of phenotypic characteristics of investigated cohorts 
Here we present data showing that both the AT injury cohort and AT genomic cohort 
comprised more females than males. However, the rate of the Achilles tendon injury was 
higher in male runners than in female runners in both cohorts. Higher prevalence of female 
participants in the cohorts could be explained due to the use of social media as the key 
recruitment strategy (Manzanero, Kozlovskaia, Vlahovich, & Hughes, 2018), as well as the 
conclusions from a systematic review showing that women were more likely to participate in 
survey research if promoted through social media (Thornton et al., 2016). Previously it has 
been shown that Achilles tendon injuries are more typical for males (Maffulli, Wong, & 
Almekinders, 2003). An analysis of running-related injuries in 2,002 runners identified a 
significantly higher rate of Achilles tendinopathy in male runners compared to female 
runners (Taunton et al., 2002). Taunton et al. (2002) also identified that being aged under 
34 years is a protective factor against Achilles tendinopathy for male runners. Another study 
showed that older age is a risk factor of Achilles tendinopathy (Hirschmüller et al., 2012). 
Therefore, the findings in our cohorts that the majority of injured runners were aged between 
35 and 50 years in both AT genomic and AT injury cohorts supports previous findings. 
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However, the higher rate of middle age runners participated in the genetic analysis also 
could be explained by the finding that younger runners were more likely to reject the 
invitation to the genetic arm of the study (Manzanero et al., 2018). However, this recruitment 
bias affected only the uninjured group of the AT genomic cohort. Interestingly, this avoidance 
of participation in the genetic research by younger people was identified in other health-
related studies, which required the collection of DNA samples (McQuillan & Porter, 2011; 
Mezuk, Eaton, & Zandi, 2008).  
 
4.3.2 Sample and genotype data quality control 
Of the 4,720 responses, 1,651 (35%) recreational runners were eligible for the genetic arm 
of the study, being either uninjured or reporting an Achilles tendon injury or a bone stress 
injury, or both. These eligible runners were contacted via email with a request to provide a 
saliva sample. Of those contacted, 1,315 (79.6% eligible individuals) runners agreed to 
provide a saliva sample. A final total of 1,165 runners (88.6% return rate) submitted saliva 
samples for genetic analysis (Figure 4.1). In addition, 35 participants were recontacted to 
provide a second saliva sample due to low DNA yields. 
Quality control steps were performed on all participants. Firstly, 18 samples (1.6%) were 
excluded due to genotyping call rates of <95% or sex non-concordance. Additional sample 
QC steps identified 48 (4.1%) samples that were outside of the calculated thresholds for 
missingness (n=17), heterozygosity (n=4), relatedness (n=17) and population stratification 
analysis for ethnicity (n=10). As shown in Figure 4.2, the majority of the participants were 
within thresholds, matching the reported ethnic background of at least 75% of being 
Caucasian European or Mediterranean. There were ten outliers who had another dominating 
ethnic background. Three runners were allocated to Druze (Arabic) ethnic group, one runner 
was close to Burusho (Pakistani) ethnic group, and the remaining six were outside ethnicity 
thresholds towards Asian ethnic groups.  
Following sample QC, 1,099 participants passed and were included in the case-control 
analysis. Of these participants, 171 (15.6%) had a previous Achilles tendon injury (AT 
genomic cohort), 174 (15.8%) had a previous bone stress injury (BS genomic cohort), 13 
individuals were included in both groups as they reported both types of injuries, and 767 
(69.8%) uninjured controls (Figure 4.1).  
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A total of 535,190 genetic variants were initially genotyped in the case-control analysis, QC 
filtering, however, removed 251,626 variants due to a MAF threshold of <1%, a further 2,145 
variants were removed due to missing genotyped data and 251 variants failed Hardy-
Weinberg exact test. Following QC filtering a total of 281,168 genotyped genetic variants 
remained for association analysis. 
 
Figure 4.1 A flow chart of sample collection and subsequent filtering for case-control 
analysis.  
* - a group comprised 13 samples with both types of injuries. 
4720 unique 
online responses
1651 eligible for 
genetic analysis
336 did not reply 
to email
1315 agreed to 
provide a saliva 
sample





66 samples did 
not pass QC














Figure 4.2 Population stratification plot.  
PCA1 on the x-axis and PCA2 on the y-axis refer to the most variable components, which 
are commonly used to identify outliers in the population stratification analysis. Black dots 
identify the recreational runners used in this study, colour-coded shapes in the legend 
identify various ethnic groups. Red lines identify thresholds which were calculated by adding 
or subtracting of 6 standard deviations from the mean. The majority of the samples were 
located in the area of European ethnic groups and within defined thresholds. 10 samples 




4.3.3 Power calculations for the collected samples 
As presented in Section 4.3.1 the final numbers of participants included in the GWAS case-
control analyses were: 171 AT cases, 174 BS cases and 767 uninjured controls. These 
participant numbers were used to calculate the actual study power compared to our targeted 
recruitment and study design presented in Section 1.8.3. Using a disease prevalence level 
of 10%, the expected significance threshold was recalculated as only 281,000 SNPs 
remained after the genetic data quality control and the new employed threshold was 
determined to be p<2x10-7. These calculations demonstrated that with the study’s sample 
size, SNP variants with a MAF of between 0.3 and 0.5 could be investigated if their RR was 
estimated within a range 1.8-2.0 (Figure 4.12). Less common SNPs with MAFs 0.2 and 0.1 
could reach 80% power only if their RR were as high as 2.2 and 2.7, respectively. 
These calculations demonstrated that the collected sample size was not sufficient enough 
to propose strong associations between identified SNPs and AT or BS injuries and 
discussion of any putative SNPs is predominantly explorative in nature. Thus, a MAF 
threshold of 0.1 was selected to explore genotyped SNPs. 
 
 
Figure 4.3 Expected relative risks of the genetic variants for 170 cases and 770 
controls. 



















MAF=0.5 MAF=0.4 MAF=0.3 MAF=0.2 MAF=0.1
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4.3.4 Genetic polymorphisms associated with Achilles tendon injuries 
Logistic regression was used to calculate p-values for case-control analysis of AT genomic 
cohort. Following data QC, the p-values for 281,168 genetic variants were included in the 
analysis. A QQ plot of observed and theoretical p-values demonstrated that these values 
mainly overlapped, and none of the genotyped SNPs reached statistical significance 
(p<5x10-8) (Figure 4.4). A Manhattan plot (Figure 4.5) shows the distribution of estimated p-
values across 22 chromosomes and identified only one SNP close to suggesting a 
significance level of p<1x10-5 on chromosome 1. It was therefore decided to investigate the 
top 20 most significant SNPs, and a lower threshold of p<1x10-3.9 was employed. However, 
this significant decrease in p-value threshold dramatically increases the chance of type I 
errors. It was estimated that at this decreased p-value, 35 out of 281,168 SNPs may be 
false-positive associations. However, the subsequent imputation of SNPs and visualisation 
of the top-20 SNPs in LocusZoom software allowed us to investigate each SNP and discuss 
the likelihood of detecting potential false-positive signals.  
 
Figure 4.4 QQ plot for the Achilles tendon injury of observed and expected p-values, 
-log-transformed.  
The plot shows observed p-values plotted on the y-axis (black dots) and theoretical p-values 
plotted on the x-axis (red line). The black dots align closely with the red line indicating that 





Figure 4.5 Manhattan plot of p-values calculated for the Achilles tendon injury case-control analysis, -log-transformed.  
Y-axis shows –log10 p-value for association with an Achilles tendon injury. The red line indicates the suggestive significance threshold of 
p<1x10-5, the blue line indicates the threshold of p<1x10-3.9, which outlines the top 20 significant SNPs. Chromosome colour-coded legend 
is located along the x-axis. SNPs that were in the top 20 by their significance levels and located in genes, not in intragenic or uncharacterised 
regions are indicated on the plot. 
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The top 20 most significant SNPs are described in Table 4.4. The majority of these variants 
are located in genes; however, four SNPs were located in intragenic regions and were not 
in close proximity to any genes. In addition, there were four pairs of SNPs in high LD (r2>0.6), 
two of these pairs were located in separate regions of chromosome 1, the third pair on 
chromosome 2, and the fourth pair on chromosome 6. The remaining eight SNPs appeared 
as single signals across eight different chromosomes. The most statistically significant SNP 
was rs10910383 and is located in the solute carrier family 35, member F3 (SLC35F3) gene 
(p=3.68x10-6, OR=2.17) on chromosome 1. This was supported by another SNP 
(rs4333882) located in the same gene (p=3.69x10-5, OR=1.83). Another pair of SNPs 
(rs6663957 and rs520226) were located in the CUB and Sushi multiple domains 2 (CSMD2) 
gene, also on chromosome 1. Chromosome 2 contained four variants, two of which 
(rs17763853, rs6745529) were located close to each other in the transcription factor 7 like 
1 (TCF7L1) gene. The last pair of observed SNPs (rs9346970, rs750811) are located in the 




Table 4.4 Top-20 most significant genotyped SNPs, ordered by chromosomes and base-pair location. 
SNP Chr BP MAF Gene A1 OR SE p-value 
rs6663957 1 34437596 0.17 CSMD2 A 2.95 0.27 7.63E-05 
rs520226 1 34456109 0.26 CSMD2 A 2.94 0.27 5.89E-05 
rs10910383 1 234352349 0.33 SLC35F3 A 2.17 0.17 3.68E-06 
rs4333882 1 234352899 0.46 SLC35F3 G 1.83 0.15 3.69E-05 
rs17763853 2 85480715 0.25 TCF7L1 G 0.58 0.13 5.95E-05 
rs6745529 2 85503139 0.25 TCF7L1 A 0.61 0.12 8.52E-05 
rs16839837 2 208371011 0.11 Intragenic A 2.27 0.2 5.40E-05 
rs3815849 2 218713469 0.01 TNS1 A 4.86 0.4 9.03E-05 
rs1860623 4 58081590 0.37 Intragenic A 1.67 0.12 2.46E-05 
rs381637 5 134124658 0.43 DDX46 A 1.69 0.13 6.52E-05 
rs61753604 6 57246878 0.03 PRIM2 G 2.89 0.27 7.42E-05 
rs9346970 6 164109051 0.23 LOC107986666 C 0.37 0.22 6.00E-06 
rs750811 6 164111361 0.42 LOC107986666 A 0.5 0.18 6.82E-05 
rs1476517 7 111497826 0.29 DOCK4 A 1.7 0.13 4.23E-05 
rs815847 9 84222618 0.5 TLE1 G 1.65 0.13 6.47E-05 
rs1188017 11 63824364 0.09 MACROD1 A 1.77 0.15 1.13E-04 
rs1796002 12 78923183 0.42 Intragenic A 1.74 0.14 6.18E-05 
rs2242641 14 80286244 0.22 NRXN3 A 1.65 0.13 6.16E-05 
rs1110495 16 51914974 0.24 Intragenic A 1.75 0.14 3.97E-05 
rs6047404 20 21352236 0.28 XRN2 A 0.57 0.15 1.13E-04 
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4.3.5 Imputation of additional SNPs and visualisation of GWAS results 
Quality control of imputed genotypes resulted in 23,669,623 genetic variants available for 
case-control and replication analyses. Case-control analysis criteria for imputed data were 
the same as for genotyped data, resulting in the calculation of p-values for 7,438,753 genetic 
variants. The imputed data was used to generate more detailed plots around the previously 
identified 20 most significant SNPs (Table 4.4). As shown in Table 4.4, three genes were 
supported by two SNPs each, specifically SLC35F3 (rs10910383 and rs4333882), CSMD2 
(rs6663957 and rs520226) and TCF7L1 (rs6745529 and rs17763853). Imputation of SNPs 
around these loci showed they were in strong LD with other SNPs located in the same genes 
(Figure 4.6A-C). Thus, despite the determined low p-value threshold, these results were less 
likely to be false-positive discoveries and were included in the following discussion. The 
rs9346970 and rs750811 SNPs (LOC107986666) were also shown to be in high LD with 
other local SNPs. This gene encodes for a non-coding RNA of uncharacterised function. It 
is therefore difficult to explain any possible link between this genomic region and 
susceptibility to Achilles tendon injuries (Figure 4.6D).  
 LocusZoom plots of the SNPs that appeared as single signals on chromosomes 7, 9, 11 
and 14 (rs1476517, rs815847, rs1188017, rs2242641, respectively) showed consistent LD 
patterns of the supporting SNPs, located in the same genes as genotyped SNPs (Figure 
4.7A-D). Interestingly, rs1188017 was located in a region with a high density of genes, and 
supporting SNPs were also located in MACRO domain containing 1 (MACROD1) gene. The 
MAF of rs1188017 was 0.9, which was lower than defined threshold of 10%, however, it was 
decided to include the MACROD1 gene in the following discussion, as MAF was close to 
10%, and the function of this gene, as it is involved in regulation of transcriptional activity of 
nuclear factor κB (NF-κB) (Wu et al., 2011). Therefore, four genes: MACROD1, dedicator of 
cytokinesis 4 (DOCK4), transducing-like enhancer of split 1 (TLE1) and neurexin 3 (NRXN3) 
were also considered as potentially important genes in the development of Achilles tendon 
injuries. 
Plots of two SNPs (rs3815849, rs61753604) showed no LD patterns, and the plots of the 
other two SNPs (rs381637, rs6047404) had LD patterns scattered across surrounding 
genetic regions (Figure 4.8A-D). The former two SNPs (rs3815849, rs61753604) are located 
in tensin 1 (TNS1) and DNA primase subunit 2 (PRIM2) genes, respectively. As both of 
these SNPs also had low MAF (<10%), these two variants were excluded from the 
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subsequent investigation. The latter two SNPs (rs381637, rs6047404) were located in the 
DEAD-box helicase 46 (DDX46) and 5'-3' exoribonuclease 2 (XRN2) genes, respectively. 
These two genes were included in the subsequent discussion of identified SNPs. 
The last four plotted SNPs were located in intragenic regions, and LocusZoom plots did not 
show any SNPs in high LD, which would be located in genes in the surrounding regions 




Figure 4.6 Locus Zoom plots for identified significant SNPs from the paired signals.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 1 in SLC35F3 gene; B) signals on 




Figure 4.7 Locus Zoom plots for identified significant SNPs from chromosomes 7, 9, 11 and 14.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 7 in DOCK4 gene; B) signals on chromosome 




Figure 4.8 Locus Zoom plots for identified significant SNPs from chromosomes 2, 6, 5 and 20.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 2 in TNS1 gene; B) signals on chromosome 




Figure 4.9 Locus Zoom plots for identified significant SNPs from chromosomes 2, 4, 12 and 16. 
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 2 in the intragenic region; B) signals on 




4.3.6 Replication analysis 
Imputation of additional SNPs allowed us to attempt replication analysis of the top four 
significant SNPs previously identified in the GWAS by Kim et al.; identify frequencies of 
genotyped top 20 SNPs in the publicly available data from Kim et al. GWAS; identify p-
values of SNPs investigated in the previously described studies, which used a candidate 
gene approach. 
 
4.3.6.1  Replication analysis of top four significant SNPs using data from GWAS by Kim et 
al. 
None of the four SNPs (rs57104447, rs60713544, rs1937810, rs57224706) that reached 
suggestive significance levels in the GWAS by Kim et al., were identified in our cohort using 
the imputed dataset. 
 
4.3.6.2  Replication of top-20 SNPs using data from GWAS by Kim et al. 
The attempted replication analysis of the 20 most significant SNPs was performed using the 
publicly available Kim et al. data (National Heart, 2017). However, data on two SNPs 
(rs61753604, rs1796002) were not available in the accessed data. As shown in Table 4.5, 
none of the top 20 most significant SNPs identified in our cohort were at the suggested 




Table 4.5 Summary of p-values identified for top 20 genotyped SNPs in the dataset 
from Kim et al. 
SNP Chr Gene OR p-value 
rs6663957 1 CSMD2 1.04 0.4412 
rs520226 1 CSMD2 1.04 0.3765 
rs10910383 1 SLC35F3 0.1 0.7260 
rs4333882 1 SLC35F3 0.1 0.7073 
rs17763853 2 TCF7L1 1.0 0.8652 
rs6745529 2 TCF7L1 1.0 0.9927 
rs16839837 2 Intragenic 1.0 0.1772 
rs3815849 2 TNS1 0.92 0.4624 
rs1860623 4 Intragenic 0.98 0.4086 
rs381637 5 DDX46 0.97 0.8092 
rs61753604 6 PRIM2 n.d. n.d. 
rs9346970 6 LOC107986666 1.03 0.3618 
rs750811 6 LOC107986666 1.03 0.2029 
rs1476517 7 DOCK4 1.02 0.4466 
rs815847 9 TLE1 0.98 0.2549 
rs1188017 11 MACROD1 0.95 0.3574 
rs1796002 12 Intragenic n.d. n.d. 
rs2242641 14 NRXN3 1.02 0.4091 
rs1110495 16 N/A 0.95 0.0215 
rs6047404 20 XRN2 1.01 0.8361 





4.3.6.3 Replication analysis of SNPs identified in the studies using a candidate gene 
approach 
Previous studies investigating candidate genes have found several SNPs significantly 
associated with Achilles tendon injuries. These SNPs were included in replication analysis 
and imputed data were used to identify all p-values. A summary of p-values for 33 SNPs 
located in 25 genes investigated in relation to Achilles tendon injuries is presented in Table 
4.6. None of these 33 SNPs were associated with Achilles tendon injuries in our cohort, 
hence there was no strong evidence of replication of previously reported significant 
associations. While the rs12722 variant in the COL5A1 gene did reach putative significance 
(p=0.0194), this result should be interpreted with caution due to its low p-value and risk of 
type I error. Caution should also be taken as these data have been obtained through 
imputation, and require further confirmation by direct genotyping for more conclusive 
evidence of association. LocusZoom plots for rs12722 (COL5A1), rs2104772 (TNC), 
rs1045485 (CASP8), rs650108 (MMP3), rs4789932 (TIMP2), rs143383 (GDF5) are 
displayed in the Figures 4.10 A-D and 4.11 A-B, respectively. The statistical significance 
levels reached by these SNPs were low. Additionally, the significance levels of SNPs shown 
to be in LD pattern with replicated SNPs were also low. These plots confirmed the absence 
of any significant SNPs in the genetic regions containing genes reported to be significant by 
studies that used a candidate gene approach. This outcome, therefore, confirms the results 
of Kim et al. GWAS, which also was unable to replicate the association of these SNPs (Kim 





Table 4.6 Summary of candidate SNPs and their significance levels identified using 
imputed data. 
SNP Chr BP MAF Gene A1 OR SE p-value 
rs3753841 1 103379918 0.5 COL11A1 G 0.88 0.13 0.3176 
rs1676486 1 103354138 0.22 COL11A1 A 0.99 0.15 0.9278 
rs1045485 2 202149589 0.05 CASP8  C 0.85 0.18 0.3485 
rs1143627 2 113594387 0.47 IL1B G 1.07 0.13 0.6006 
rs1049253 4 185548951 0.08 CASP3 G 0.99 0.15 0.9261 
rs1054480 5 178540975 0.26 ADAMTS2 A 1.0 0.13 0.9816 
rs331079 5 127770805 0.11 FBN2  C 0.89 0.2 0.5584 
rs1799907 6 33152835 0.32 COL11A2  T 1.11 0.13 0.4123 
rs240736 6 75848181 0.27 COL12A1 G 1.09 0.13 0.5080 
rs970547 6 75797302 0.29 COL12A1 C 1.11 0.15 0.4823 
rs2071307 7 73470714 0.22 ELN A 1.05 0.12 0.7193 
rs1800795 7 22766645 0.14 IL-6 C 1.02 0.12 0.8493 
rs1799983 7 150696111 0.18 NOS3 T 1.1 0.13 0.4692 
rs4870723 8 121228679 0.41 COL14A1 C 0.89 0.12 0.3229 
rs1563392 8 121353692 0.48 COL14A1 T 1.0 0.12 0.9702 
rs946053 9 117049891 0.24 COL27A1 T 0.97 0.12 0.7891 
rs12722 9 137734416 0.35 COL5A1 C 1.32 0.12 0.0194 
rs1134170  9 137735274 0.39 COL5A1 A 1.15 0.18 0.2768 
rs13321 9 117792583 0.33 TNC C 0.98 0.13 0.8503 
rs2104772 9 117808785 0.48 TNC A 1.16 0.12 0.2249 
rs1330363 9 117813990 0.42 TNC C 0.99 0.12 0.9057 
rs3740199 10 128019025 0.48 ADAM12 C 1.09 0.12 0.5000 
rs679620 11 102713620 0.35 MMP3 C 1.04 0.12 0.7580 
rs591058 11 102711338 0.36 MMP3 C 1.05 0.12 0.6840 
rs650108 11 102708787 0.44 MMP3 A 0.88 0.14 0.3578 
rs4149577 12 6447522 0.4 TNFRSF1A G 0.97 0.12 0.7865 
rs2779249 17 26128581 0.27 NOS2  A 1.0 0.13 0.9922 
rs4789932 17 76924275 0.44 TIMP2 A 1.13 0.12 0.3194 
rs1800469 19 41860296 0.37 TGFB1 A 1.03 0.13 0.8189 
rs143383 20 34025983 0.45 GDF5 G 1.13 0.13 0.3389 
rs226794 21 28302355 0.19 ADAMTS5 A 0.83 0.2 0.3599 
SNP – single nucleotide polymorphism, Chr – chromosome, BP – base pairs, MAF – minor 





Figure 4.10 Locus Zoom plots for imputed SNPs included in replication analysis from chromosomes 9, 2 and 11. 
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 9 in COL5A1 gene; B) signals on 




Figure 4.11 Locus Zoom plots for imputed SNPs included in replication analysis from chromosomes 17 and 20.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs are 
coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of each plot. 
Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the horizontal blue 
lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 17 in TIMP2 gene; B) signals on chromosome 




4.4.1 Genetic case-control analysis  
Achilles tendinopathy is a multifactorial condition and one of the most common 
running-related injuries (Dias Lopes et al., 2012). Although training load plays a major 
role in the development of the pathology, it is modulated by other intrinsic factors such 
as sex, age, anatomy and genetic predisposition (Cook & Purdam, 2009). Previously 
investigated genetic polymorphisms located in genes encoding certain types of 
collagen and proteins involved in extracellular matrix metabolism showed significant 
association with the development of Achilles tendinopathy (Collins, 2010). However, 
these small numbers of genetic polymorphisms were analysed in small, limited cohorts 
with an average of 150 cases. Thus, development of large-scale approaches for 
genetic analysis, such as GWAS allowed screening of the whole genome and a search 
for genetic variants associated with multifactorial conditions such as Achilles 
tendinopathy. This GWA approach is unbiased and is more likely to identify the 
strongest associations between genetic polymorphisms and injury risk than previously 
utilised the candidate gene approach. 
The current GWAS was conducted on 938 samples, comprising of 171 Achilles tendon 
injury cases and 767 uninjured controls. All included individuals were physically active, 
running at least 15 km per week. However, case-control analysis of the genetic data 
did not identify any statistically significant polymorphisms at the expected for GWAS 
of p<5x10-8, this was not unexpected, given the lower than expected recruitment and 
power analysis. Therefore, it was decided to explore the 20 most significant genetic 
variants, which corresponded to above p<5x10-3.9 threshold. Whilst this exploratory 
approach increases the likelihood of type I errors, the additional imputation of SNPs 
and visualisation of the results allowed us to critically assess each signal and identify 
the most probable SNPs for investigation. Furthermore, the corresponding protein 
function was also considered to support the putative association with Achilles tendon 
injury development. Among these 20 SNPs, there were four paired SNPs located in 
CSMD2, SLC35F3, TCF7L1 and LOC107986666. After plotting genetic regions 
surrounding these genes, the function and the potential role of these genes in the 
development of the Achilles tendon injury were further explored. After revision of the 
remaining single SNPs and their plots, a further six genes were also considered as 
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potential contributors to the development of the Achilles tendon injury, specifically 
DOCK4, DDX46, TLE1, MACROD1, NRXN3 and XRN2.  
Transcription factor 7 like 1 (TCF7L1) is a gene the product of which is a member of T 
cell factor/lymphoid enhancer factor (Tcf/lef) family, activated by β-catenin and thus 
mediates the Wnt signalling pathway (Figure 4.12). This pathway is highly conserved 
and targets multiple genes, including MMPs (Clevers, 2006). MMPs regulate 
extracellular matrix homeostasis and have been previously implicated in Achilles 
tendinopathy, with MMP3 polymorphisms previously shown to be associated with 
Achilles tendinopathy (Raleigh, 2009). Bioinformatic analysis of an upstream region of 
the MMP3 gene showed a presence of a Tcf/lef binding site, also typical for many 
other MMPs (Clark, Swingler, Sampieri, & Edwards, 2008). This finding requires 
further research into whether a genetic variation of the TCF7L1 gene may affect the 
regulation of expression of MMP3 through the Tcf/lef transcription complex. 
Additionally, the Wnt pathway regulates the development of cartilage and skeletal 
system. Genetic studies showed that alterations in the expression of molecules 
involved in the Wnt/β-catenin pathway were associated with osteoarthritis and 
therefore may be a therapeutic target (Usami, Gunawardena, Iwamoto, & Enomoto-





Figure 4.12 A schematic illustration of the canonical Wnt pathway.  
Panel (A), in the absence of Wnt ligand, a destruction complex consisting of AXIN, 
APC, GSK3-β and CK1 resides in the cytosol. β-catenin is phosphorylated by CK1 and 
GSK3-β and targeted for degradation by the proteasomal machinery; Panel (B), with 
Wnt stimulation, some components of protein complex dislocate from the cytosol to 
the plasma membrane. The destruction complex falls apart, and β-catenin is stabilised. 
Dvl is also recruited to the membrane and binds to Fz and Axin, which is bound to 
phosphorylated LRP5/6. Stabilised β-catenin is translocated to the nucleus where it 
associates to LEF/TCF transcription factors, displacing co-repressor TLE and 
recruiting additional co-activators to Wnt target genes. Adapted from Pecina-Slaus et 
al. (Pećina-Šlaus, Kafka, & Lechpammer, 2016). 
 
Dedicator of cytokinesis 4 (DOCK4) is a gene located at chromosome 7q31.1. The 
encoded protein DOCK4 activates GTPase Rac1, which in turn is responsible for 
nuclear translocation of β-catenin and Tcf activation, and therefore regulates the Wnt 
signalling pathway (Wu et al., 2008). It has previously been shown that DOCK4 
enhances β-catenin stability and Tcf activation, therefore regulating the Wnt/β-catenin 
signalling pathway (Upadhyay et al., 2008). This function of DOCK4 may potentially 
affect the expression of MMPs and other target genes of the Wnt pathway, which may 
be involved in molecular processes of extracellular matrix homeostasis in the tendon. 
However, polymorphisms in DOCK4 and its expression were predominantly 
148 
 
investigated in relation to tumorigenesis, particularly ovarian cancer and 
myelodysplastic syndromes (Kuo et al., 2009; Sundaravel et al., 2015). 
Transducin-like enhancer of split 1 (TLE1) is a gene encoding a transcriptional co-
repressor and is bound to the Tcf/lef complex, which can block transcription of the Wnt 
target genes. When the Wnt pathway is activated, β-catenin directly displaces TLE 
repressor from the Tcf/lef complex and thus activates transcription of the target genes 
(Daniels & Weis, 2005). Since TLE1 is involved in regulation of expression of various 
genes, it was investigated in relation to neuron differentiation, its expression was 
shown in macrophages and used as a diagnostic immunochemical marker for synovial 
sarcomas (Bakrin, Hussain, & Tuan, 2016; Buscarlet et al., 2009; De Paoli et al., 
2016). However, TLE1 has not been studied in association with connective tissue. 
CUB and Sushi multiple domains 2 (CSMD2) is a gene encoding protein with a Sushi 
multiple domain feature, which characterises it as a regulator of the complement 
cascade – a signalling pathway of the innate immune system. This protein, therefore, 
helps to clear pathogens or tag them for subsequent destruction by other cells. 
Polymorphisms in this gene were investigated in relation to schizophrenia, as this gene 
is expressed in brain tissue. A study identified eight SNPs located in CSMD2, which 
were in a strong association with schizophrenia (Håvik et al., 2011). However, none of 
these eight SNPs matched either of two CSMD2 SNPs identified in this study. In 
addition, expression of CSMD2 is shown to be decreased in cancer tissue of patients 
with colorectal cancer, as well as expression of other two genes of CSMD family 
(CSMD1 and CSMD3) (Zhang & Song, 2014). This finding suggested that CSMD 
genes play a tumour suppressing role and may be used as predicting markers of 
colorectal cancer. In the current study, two polymorphisms in CSMD2 were associated 
with an increased risk of Achilles tendon injury. The role of inflammation in tendon 
pathology is complex, and although inflammatory cells are observed in pathological 
tendons, as well as an increase of inflammatory cytokines, this inflammatory response 
is not a primary event in the development of pathology. It was shown that tenocytes 
express cytokines in response to cyclic load (Cook, Rio, Purdam, & Docking, 2016). 
Potentially, two SNPs of the CSMD2 gene were among the top 20 signals because its 
product is involved in the immune response and regulation of complement cascade, 
which triggers expression of cytokines.  
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Solute carrier family 35, member F3 (SLC35F3) is a gene which encodes solute 
transporter catalyses thiamine (vitamin B-1) transport and was investigated in relation 
to hypertension. Two SLC35F3 SNPs were significantly associated with hypertension 
in a GWAS (Zhang et al., 2014). However, these significant SNPs differed from those 
identified in the current study. Thiamine deficiency causes a spectrum of phenotypes, 
including cardiovascular and neurological manifestations of beriberi. In a rat model, it 
was shown that thiamine repletion corrected glucose oxidation, elevated blood 
pressure and decreased expression of angiotensin-converting enzyme (ACE), 
angiotensin (AGT) and angiotensin II receptor (AGTR1) (Tanaka et al., 2007). 
Previously it was shown that joint functioning of ACE, AGT and angiotensin II receptor 
induces increased synthesis of protein of extracellular matrix and increased levels of 
connective tissue growth factor and TGFB1 in skeletal muscles (Cabello-Verrugio et 
al., 2011; Morales et al., 2012). Inhibition of ACE decreased fibrosis of skeletal 
muscles in dystrophic mice (Morales et al., 2013). Extracellular matrix disorganisation 
is characteristic for pathological tendons (Cook & Purdam, 2009). Although ACE 
functions were not investigated in relation to tendon pathology, we could speculate 
that the investigated gene SLC35F3 may distantly affect ACE functioning and 
therefore metabolism of the extracellular matrix. 
MACRO domain containing 1 (MACROD1) gene is located at the chromosome 
11q13.1. The encoded protein contains a highly conserved macro domain and is also 
known as LRP16. It was shown that the transcriptional activity of the nuclear factor κB 
(NF-κB) is regulated through the interaction between LRP16 and UXT (an α-class 
prefoldin protein) (Wu et al., 2011). NF-κB plays a role in multiple processes such as 
inflammation, cell survival and immunity and therefore its activity was associated with 
multiple human diseases that affect processes: arthritis, diabetes, cancer, 
inflammatory bowel disease (Baldwin Jr, 2001). Additionally, LRP16 has a specific 
function as a coactivator of both estrogen receptor α and androgen receptor, 
interestingly, at the same time, it is their target. This explains why LRP16 was 
extensively studied in hormone-dependent types of cancer (Wu et al., 2011). NF-κB is 
a mediator of cytokine expression (Kulms & Schwarz, 2006), which are elevated in the 
pathological tendon, but the development of inflammation is not necessarily a key 
driver event in tendinopathy (Cook et al., 2016). Therefore, NF-κB function and 
regulation may play a role in the inflammatory process, which may accompany 
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tendinopathy. However, the direct involvement of NF-κB has not currently been 
investigated in association with tendon pathology in detail. 
DEAD-box helicase 46 (DDX46) encodes a protein which belongs to a family of RNA 
helicases, which contain a highly conserved helicase domain. These proteins are 
responsible for mRNA splicing and ribosome and spliceosome assembly (Hirabayashi, 
Hozumi, Higashijima, & Kikuchi, 2013). DDX46 pre-mRNA splicing is required during 
the development of the digestive system and the brain (Hozumi et al., 2012). DDX46 
was also involved in the development of several tumours, such as oesophageal 
squamous cell carcinoma and osteosarcoma (Jiang, Zhang, Li, & Wang, 2017). 
However, the DDX46 gene’s function has not been investigated in tendon cells or in 
relation to any tendon pathology. 
5'-3' exoribonuclease 2 (XRN2) is a gene located at chromosome 20p11.22 and 
encodes for a 5'-3' exonuclease involved in transcription termination (Rother et al., 
2016). XRN2 forms a complex with NF-κB-repressing factor (NKRF) and DEAH-box 
RNA helicase (DHX15) to degrade excised ribosomal pre-rRNA spacer fragments 
(Memet, Doebele, Sloan, & Bohnsack, 2017). Due to its function of transcription 
terminator, XRN2 was identified as an important factor for the maintenance of genomic 
stability and cell survival (Morales et al., 2016). Although XRN2 is involved in crucial 
for living cell processes, it has never been investigated in association with tendon 
pathology.  
Neurexin 3 (NRXN3) is a protein-coding gene located on chromosome 14q24.3-q31.1. 
This gene is the largest of three neurexin genes with the most extensive possible 
alternative splicing, resulting in 1,764 transcript variants and leads to a high diversity 
of the proteins. These proteins function in the nervous system as receptors and cell 
adhesion molecules (Rowen et al., 2002). Polymorphisms in NRXN3 have been 
studied extensively in association with various neurodevelopmental conditions (autism 
spectrum disorder), addictive behaviours and borderline behaviour disorder 
(Panagopoulos et al., 2013; Stoltenberg, Lehmann, Christ, Hersrud, & Davies, 2011; 
Vaags et al., 2012). The function of this gene has not been investigated in relation to 
tendon pathogenesis.  
Overall, the analysis of the potential role of genes with top signal SNPs in tendon 
pathology identified three genes involved in the same pathway – the Wnt signalling 
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pathway. This pathway activates multiple transcriptional programs, which are essential 
in stem cell activation, cell proliferation and differentiation. The Wnt pathway has been 
investigated in association with various tissues, hemopoietic system and cancer 
(Clevers, 2006). The Wnt pathway also targets MMPs, which are involved in the 
homeostasis of the extracellular matrix in the tendon. Although genetic variations of 
MMPs have been investigated previously, regulatory mechanisms of their expression 
derived through the Wnt pathway have not been studied in relation to tendon 
pathology. Based on the findings of this study, future research of the Wnt pathway in 
the tendon may assist to a better understanding of the tendon pathogenesis. 
 
4.4.2 Replication analysis of GWAS results 
Complex traits, such as overuse injuries may have a very complicated interrelationship 
of genetic and other extrinsic factors. Therefore, replication of results is of high 
importance when such complex traits are investigated. At the time of publication, there 
has been only one previous GWAS of Achilles tendon injuries published, and this study 
failed to replicate results reported by candidate gene studies, which used a candidate 
gene approach (Kim et al., 2017). In the current study, we also attempted replication 
of findings from previous studies, which utilised a candidate gene approach and a 
cross-sectional replication of GWAS results between Kim et al. publicly available data. 
The results of the current GWAS differed from any previous findings of the candidate 
gene approach studies and the attempted replication of GWAS results from Kim et al., 
did not support their findings. Additionally, the most significant SNPs identified in this 
study were not found to be significant in the Kim et al data. However, the 
characteristics of populations and the cause of Achilles tendon injuries studied by Kim 
et al. and our research group differed. Our study was focused on Achilles tendon 
injuries that resulted from physical activity overload, specifically running. Kim et al. 
indicated that cases of Achilles tendon injuries in their study were of unknown nature 
and may not have been associated with physical activity. This was acknowledged as 
a limitation of their study and could explain discrepancies in the findings with our 
results and candidate gene approach studies, which predominantly used physically 
active people as cases. Putative replication of the rs12722 and rs1110495 SNPs was 
observed in our analyses, however, these results should be interpreted with caution 
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due to the imputed nature of the replicated data and low statistical significance. Further 
confirmation by direct genotyping is required to verify these findings. 
This issue of failed replication of the results demonstrates the importance of 
consistency in the studied trait definition and characteristics, together with other critical 
requirements for successful GWAS. A large sample size is an essential requirement 
of studies seeking genetic associations with complex traits such as injuries. 
Additionally, the opportunity to perform a meta-analysis and expand the sample size 
may increase the chances of stronger associations.  
4.4.3 Limitations of the study 
A sample size with sufficient statistical power is critical to the success of GWAS to 
detect genetic associations for human complex diseases. The minimum required 
sample size for a case-control study with 80% power depends on multiple parameters: 
disease prevalence, genotype RR, MAF, LD and type of inheritance (Pfeiffer & Gail, 
2003; Scherag, Müller, Dempfle, Hebebrand, & Schäfer, 2003). These factors are 
difficult to control and could be modulated by the employment of the sufficient sample 
size. The sample size calculation helps to avoid either larger sample size and 
therefore, additional costs, or smaller sample size and therefore, increased risk of 
false-negative rates (Hong & Park, 2012). 
In the initial planning stages of this study, we aimed to recruit a minimum of 800 
participants with each type of injury (cases) and 800 or more uninjured controls. These 
numbers were initially based on the popularity of this form of physical activity (Section 
1.2) and the previously reported relatively high prevalence (10%) of both injury types 
(Section 1.4.2 and Section 1.5.1). Using these sample sizes our initial power 
calculations (80% power; prevalence=10%; p<5x10-8) showed that common SNPs 
with a MAF >0.3 and an RR=1.5 would be within the significance threshold (Section 
1.8.3). For comparison, the MAF of previously investigated polymorphisms varied 
between 0.05 and 0.5 (Table 4.6). However, in order to analyse SNPs with a lower 
MAF, for example, a MAF=0.05 at the same RR=1.5, the sample size of the study 
should be significantly increased and comprise approximately 5,000 participants in 
each group. Similarly, if RR=1.3 then the sample size must exceed 20,000 samples in 
each group to allow us to analyse SNPs with MAF<0.5. On the other hand, if RR=2 
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and a sample size is 1,000 participants in each group, then SNPs with MAF between 
0.05 and 0.5 could be included in the analyses.  
As previously discussed in Section 2.4.1, a 25-month extensive recruitment effort 
resulted in the engagement of 4,720 unique responses from recreational runners. 
However, only 35% (n=1,651) met the predetermined selection criteria (age, ethnicity, 
weekly running distance, and medical and health criteria) for inclusion in the genetic 
component of the study. As previously reported in Section 4.1.9, 70% (n=1,165) of 
eligible runners agreed to participate and provided a saliva sample. Quality control of 
the data eliminated 66 samples, with a total of 1,099 samples (94%) included in the 
final analyses.  
Despite our extensive efforts, sample numbers were considerably lower than the initial 
recruitment targets; 21.4% (171/800) with a prior AT injury and 95.9% (767/800) 
uninjured controls. Repeated power calculations of our final cases and control 
(170:770) recruitment showed that 80% power could only be reached for 
polymorphisms with average MAF=0.3 and a genetic RR of 2 and more (Figure 4.3). 
This high RR is very uncommon for polymorphisms associated with complex traits, 
such as overuse injuries. Genetic variants associated with multifactorial diseases such 
as type I and type II diabetes, cardiovascular disease, autoimmune, neuropsychiatric 
conditions and cancer have been successfully identified and replicated in diverse 
populations (Manolio, Brooks, & Collins, 2008). However, the majority of the identified 
polymorphisms had a modest effect with a risk (OR) varying between 1.2 and 1.5, and 
rarely exceeding a value of 2 (Manolio et al., 2008). This range of the OR is noticeably 
lower when compared, for example, to the risk of 3.2 identified in the association 
between apolipoprotein E ε4 allele and Alzheimer’s disease (Rubinsztein & Easton, 
1999). Importantly, utilisation of a GWAS and scanning of hundreds of thousands of 
SNPs also allowed identifying key pathways, which were not implicated previously in 
those multifactorial diseases. Therefore, mapping out genetic variants with relatively 
low risk and identification of their roles in the pathophysiology of multifactorial diseases 
still may contribute to the understanding of the diseases and search for preventive 
measurements and new therapeutic approaches.    
Overall, the main limitation of this study, a small sample size, may be resolved by the 
employment of additional recruitment strategies and collaborations involving data 
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pooling and meta-analyses. Although over 4,700 recreational runners provided their 
detailed data for the epidemiological analyses, 65% of them were not eligible for the 
genetic study due to further selection criteria: in particular age limit, minimal weekly 
running distance, ethnicity, chronic conditions, which affect the musculoskeletal 
system, and smoking status. The upper age limit of 50 years and minimal weekly 
running distance were crucial factors for the study as the purpose of the project was 
to investigate genetic variants associated with overuse injuries acquired through 
regular physical activity. Therefore, these two factors excluded potential confounding 
factors associated with ageing and physical inactivity, predominantly chronic 
conditions, which may lead to similar diagnoses, but of different origin. Additionally, 
recreational runners were asked about injuries which occurred only in the past two 
years, but not lifetime injury history. This decision was made in order to avoid an 
increased risk of inaccuracies in the retrospective self-reported injury data (Gabbe et 
al., 2003).  
The final GWAS sample size included approximately 170 cases of each type of injury 
and 767 uninjured controls, whereas original power calculations recommended the 
recruitment of at least five times more cases. Therefore, using the same selection 
criteria and recruitment strategies that did not target runners with the injuries of 
interest, 25,000 completed survey responses would be required to deliver the required 
number of cases of each injury. Based on the Australian population data and the 
popularity of running among Australians, there are approximately 900,000 recreational 
runners between 18 and 50 years of age (Australian Bureau of Statistics, 2015, 
2016b). If the average prevalence of bone stress injuries and Achilles tendon injuries 
were 10% each, then potentially approximately 90,000 of Australian recreational 
runners experienced one of these injuries. If we were to recruit 800 cases of each type 
of injury, this would require only 1% of the injured runners in Australia. Although the 
ethnic background was one of the eligibility criteria, it was not a particularly restrictive 
factor. In our study, 90%, of recreational runners who completed the survey were of 
Caucasian European or Mediterranean background (Manzanero et al., 2018). 
Moreover, current methods of bioinformatics allow researchers to control for ethnicity 
as a potential confounding factor. Therefore, the ethnic background could be excluded 
from the eligibility factors in the future. These crude calculations demonstrate that 
there are potentially the numbers of study participants available in Australia, therefore, 
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it is feasible that the employed recruitment strategies were not ideal for recruitment of 
that large sample size. Of course, it is important to take into consideration usually 
predetermined time limitations and financial expenditures, which may limit recruitment 
efficiency.  
An approach, which could increase the sample size, could be a collaboration with 
health practitioners who would encourage eligible runners to participate in the study. 
This could improve the quality of the collected injury data as participants injuries would 
be diagnosed by a professional and therefore decrease proportions of self-diagnoses. 
In addition, potential collaboration with medical professionals could give access to 
databases with lifetime diagnoses of research interest, hence the criterion of the injury 
report time limit of two years could be excluded. However, this approach would require 
expansion of communications and promotion of the project in the professional medical 
community, significant relationship development and a willing group of medical 
professionals with the time and capacity to be involved.  
A critical assessment of the sample size in multiple GWAS demonstrated that the 
optimal size is crucial for the achievement of the statistical power of 80%. In situations 
where the number of cases is limited, then 80% power can still be achieved by 
increasing the relative proportion of case-controls from 1:1 to 1:4 case: controls. Thus, 
in the study, a proportion of 600:2400 would allow us to investigate SNPs with 
MAF>0.3 and RR=1.5. Interestingly, 1:4 was the final proportion of cases and controls 
in this study (170:770), which supports a good chance of recruitment in the proposed 
proportion in the future. 
The final approach to substantially increasing a sample size is a collaboration with 
other research groups that collected similar phenotypic and genetic data. Certainly, 
collaboration and data pooling increase the chance of producing high-quality research 
based on a large sample size. Development of online data-sharing platforms, biobanks 
and meta-analyses makes collaboration more achievable and increases chances to 
identify genetic variants at the required significance level. Currently, the methodology 
of meta-analyses allows researchers to merge data. However, prior to data sharing 
and pooling some important factors should be taken into consideration: heterogeneity 
of data, differences in the injury definitions and diagnoses, selection criteria and 
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utilisation of different genotyping platforms and imputation software (Evangelou & 
Ioannidis, 2013).  
Collection of a sample size with sufficient statistical power is a common challenge for 
GWAS. It is crucial to calculate the correct sample size during the study design and 
consider all contributing factors such as disease prevalence, relative risk, and allele 
frequencies. Access to large patient databases and collaboration are the key solutions 
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Bone stress injuries develop as a result of the repetitive loading of the bone when 
intensive weight-bearing activity is involved, particularly marching, jogging and running 
(Mattila et al., 2007). Bone stress injuries usually begin as stress reactions, which may 
develop into stress fractures and then complete bone fractures (Warden et al., 2014). 
Typically, bone stress injuries associated with loading of lower limbs develop in the 
tibial shaft and metatarsal bones, whereas upper leg and knee are less common 
locations of these injuries (Mattila et al., 2007). According to a systematic review, one 
of the most prevalent running-related injuries was a specific bone stress injury - medial 
tibial stress syndrome (MTSS) (Dias Lopes et al., 2012). Risk factors which contribute 
to the development of bone stress injuries may be divided into two groups: factors 
modifying the load applied to a bone (anatomic and biomechanical characteristics, 
training habits), and factors affecting bone density and its ability to resist the load (sex, 
age, hormonal status, chronic conditions, diet, genetic factors) (Warden et al., 2014).  
Several factors affecting the load applied to a bone were associated with an increased 
risk of bone stress injuries. Abnormal static alignment and leg length discrepancy may 
affect movement patterns during a running session and contribute to the development 
of bone stress injuries (Bennell et al., 1999; Warden et al., 2014). The rapid increase 
in training load may lead to accumulation of microdamage in the bone and 
development of the injury, especially if the base level of physical conditioning was low 
(Välimäki et al., 2005; Warden et al., 2014). In contrast, a gradual increase in the load 
and training regimen with rest periods allow the bone to adapt to the load and decrease 
the risk of bone stress injuries (Bennell et al., 1999). A higher incidence of bone stress 
injuries in females was reported by several studies (Mattila et al., 2007; Newman et 
al., 2013; Protzman & Griffis, 1977) and also observed in the project’s recruited cohort 
(Chapter 3). Some of the factors that affect bone density are associated with sex. 
These factors, associated with female sex, included low bone mineral density (BMD), 
menstrual disturbances (hormonal status disruptions) and nutritional issues, leading 
to a negative energy balance (Korsten-Reck, 2011). Then a new term ‘Relative Energy 
Deficiency in Sport’ was introduced, and all these factors became applicable to both 
sexes (Mattila et al., 2007; Mountjoy et al., 2015). Increased BMI and a higher 
proportion of body fat were associated with bone stress injuries (Beck et al., 2015; 
Newman et al., 2013). Additionally, during childhood and teenage, the bone may be 
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more vulnerable to injuries due to its immature condition and development processes 
during those periods. Bone density also decreases with age, which may lead to a 
higher risk of bone stress injuries later in life. Therefore, age may be an important risk 
factor, especially when hormonal status and training loads are considered as co-
factors (Bennell et al., 1999).  
Two studies of bone stress injuries in monozygotic twins suggested genetic input to 
the development of bone stress injuries (Singer et al., 1990; Zmuda et al., 2011). In 
addition, another study on recurrence of these injuries in athletes also contributed to 
the investigation of genetic variants, which may contribute to the development of bone 
stress injuries (Bennell et al., 1996b). It was proposed that genetic variants associated 
with bone stress injuries would most likely be those that have previously been 
associated with BMD, bone formation and chronic disorders affecting bone strength, 
such as osteoporosis. Calcium and vitamin D are essential for bone mineralisation, 
and supplementation of calcium and vitamin D is an efficient means of bone stress 
injury prevention (Lappe et al., 2008). Using a candidate gene approach several 
polymorphisms in the vitamin D receptor (VDR) gene were found to be associated with 
changes in bone mineral density (Ferrari et al., 1998; Kehoe & Montgomery, 2006). 
Additionally, polymorphisms in the VDR gene and a gene encoding bone 
morphogenetic protein 2 (BMP2) were associated with osteoporosis (Raisz, 2005; 
Styrkarsdottir et al., 2003). Also, polymorphisms in the VDR gene and a calcitonin 
receptor gene (CALCR) were significantly associated with stress fractures in military 
personnel (Yanovich et al., 2012). The Wnt pathway has previously been shown to 
play an essential role in bone formation, with disruptions in this pathway linked to 
osteoporosis (Piters et al., 2008). Hence, investigation of polymorphisms in genes 
encoding proteins involved in the Wnt pathway, and proteins antagonising this 
pathway, was undertaken using a candidate gene approach. This study showed a 
significant association between polymorphisms in the LDL receptor-related protein 5 
(LRP5) and sclerostin (SOST) and changes in bone mineral density (Piters et al., 
2008). The RANK/RANKL/OPG pathway plays an important role in bone remodelling 
and adaptation. Genes encoding proteins in this pathway were examined, and 
polymorphisms in these genes were shown to be significantly associated with stress 
fractures in elite athletes (Varley et al., 2015). The same cohort of elite athletes was 
used to investigate polymorphisms in the gene encoding P2X7 receptor, which is 
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involved in osteoblast and osteoclast response to stress. This study identified two 
significant polymorphisms associated with stress fracture prevalence in elite athletes 
(Varley et al., 2016).  
Overall, the knowledge of genetic predisposition to bone stress injuries is limited to 
just a few studies and requires deeper research involving the recruitment of specific 
cases with bone stress injuries and employment of less biased molecular methods 
such as GWAS (as discussed in Chapter 4). Whilst at the time of publication, there are 
no GWAS focusing on bone stress injuries, several related studies have attempted to 
localise genetic markers associated with BMD and bone fractures. One large study 
included three different populations from Iceland, Denmark and Australia and identified 
four genomic regions associated with BMD: ZBTB40–WNT4, RANKL, osteoprotegerin 
(OPG) and estrogen receptor 1 (ESR1) (Styrkarsdottir et al., 2008). A large meta-
analysis of 17 GWAS investigating genetic markers in association with BMD and 
identified 32 novel genomic loci associated with BMD, involving multiple Wnt pathway 
factors (e.g. SOST, LRP4, WNT4, DKK1), a pathway, which is involved in 
mesenchymal cell differentiation (e.g., RUNX2, SOX4, SOX9), the 
RANK/RANKL/OPG pathway, and a pathway, which is responsible for foetal 
development of the skeleton (e.g. SPP1, ME2C, RUNX2, SOX6) (Estrada et al., 2012). 
Additionally, several genetic variants were identified as important factors for factures 
associated with BMD. This meta-analysis outlined a highly polygenic nature of genetic 
variation of BMD and bone fractures. Therefore, this part of the project aimed to 






Selection criteria for eligible participants, as previously described in Section 4.2.1. 
5.2.2 Sample collection 
Sample collection, as previously described in Section 4.2.2. 
5.2.3 DNA Extraction  
DNA extraction protocol, as previously described in Section 4.2.3. 
5.2.4 Genotyping and Quality Control 
Quality control of the genomic data was performed on all collected samples prior to 
their assignment to cases and controls, as previously described in Section 4.2.4. 
5.2.5 Statistical Analyses 
Statistical analyses of cases with reported bone stress injuries and uninjured controls, 
as previously described in Section 4.2.5. 
5.2.6 Imputation 
Imputation of additional genotypes as previously described in Section 4.2.6. 
5.2.7 Replication Analysis 
Previously identified SNPs described in Table 1.2 were further investigated to attempt 
replication of those results in the current study, and seeking identified significance 




5.3 Results  
5.3.1 Phenotypic characteristics of the participants 
5.3.1.1 Statistical comparison of BS genomic cohort and BS injury cohort 
Recruitment resulted in 4,720 unique responses from recreational runners. After the 
application of the predetermined filters, a bone stress (BS) injury cohort was formed 
and comprised 475 bone stress injury cases and 1969 uninjured controls, resulting in 
a total of 2,444 recreational runners. Out of 1,165 participants recruited for the genetic 
arm of the study, 1,099 passed all required quality control steps and comprised 767 
uninjured runners and 174 runners with bone stress injuries, resulting in a total of 941 
runners, which were included in the BS genomic cohort. The remainder of the 
genotyped runners reported Achilles tendon injuries and were analysed in Section 4.3.  
The physical characteristics and reported ethic background of the BS genomic cohort 
are displayed in Table 5.1, and the physical characteristics of the BS injury cohort are 
displayed in Table 3.9. 
Injury cases comprised 18.5% of BS genomic cohort, and this rate was similar to the 
rate of cases in the BS injury cohort of 19.4% (χ21=0.39, p=0.52). The BS genomic 
cohort had a significantly higher rate of females than BS injury cohort (59.5% versus 
56.5%, χ21=3.35, p=0.04). However, the compared cohorts did not differ by the rates 
of injured males and females (χ21=1.27, p=0.18; χ21=2.26, p=0.08, respectively). 
Moreover, the rates of injured males and females were similar in both BS genomic and 
BS injury cohorts (17% and 19.5% in males, 18.6% and 20.1% in females). The BS 
genomic cohort also contained a significantly higher rate of runners with normal BMI 
than the BS injury cohort (77.7% versus 74.4%, χ21=3.87, p=0.03).  
Participant age (between 18 and 50 years) was a specific selection criterion for the 
genomic component of the study. The BS injury cohort comprised 17.7% of runners 
aged over 50 years old. These older runners were excluded from the remaining 
analysis, and four age groups were formed: 18-24, 25-34, 35-44 and 45-50. The 
statistical comparison of BS injury cohort and BS genomic cohort by the age group 
distribution showed a significant difference between the two cohorts (χ23=13.58, 
p=0.004). The uninjured groups of BS injury cohort and BS genomic cohort also were 
statistically different by age groups (χ23=12.23, p=0.006). However, age group 
distributions were not statistically different between injured groups of BS injury cohort 
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and BS genomic cohort (χ23=1.59, p=0.65). The lower rates of younger runners in the 
BS genomic cohort than in the BS injury cohort could be explained by the unwillingness 
of younger runners to provide a sample for the genetic study.  
The reported ethnic background of four grandparents was a key criterion for the 
genetic arm of the study. A runner who reported at least 75% of Caucasian European 
or Mediterranean background were eligible for genetic analysis. Thus, 87.6% of BS 
injury cohort reported 100% or a combination of these two backgrounds. Among the 
runners who were included in the genetic analysis, 94.3% were of Caucasian 
European background, and the remaining 5.7% had a combination of backgrounds 
with a prevalence of Caucasian European and Mediterranean backgrounds.  
When BS genomic cohort was compared to BS injury cohort by training characteristics 
of recreational runners, there was no significant difference by weekly running distance 
(χ21=1.98, p=0.37), number of running sessions per week (χ23=0.79, p=0.85), running 
terrains (χ24=1.94, p=0.74), participation in other sports besides running (χ21=1.91, 
p=0.16), stretching in relation to running sessions (χ21=0.14, p=0.7), and wearing 
orthotics (χ21=0.1, p=0.75). The two compared cohorts were significantly different by 
years of running experience (χ23=177.46, p<0.001). However, when injured and 
uninjured groups of BS injury and BS genomic cohorts were compared independently, 
injured cohorts were not significantly different by years of running experience 
(χ23=3.86, p=0.28), whereas uninjured groups differed significantly (χ23=15.72, 
p=0.001). The BS genomic cohort also significantly differed from BS injury cohort by 
the reported race pace (χ24=14.48, p=0.005). However, injured groups of these two 
cohorts did not differ significantly by the race pace groups (χ24=2.04, p=0.72), whereas 
uninjured groups significantly differed by this variable (χ24=13.3, p=0.009). In 
summary, BS genomic cohort differed from BS injury cohort by proportions of females, 
BMI group distribution, frequencies of age groups, reported race pace and years of 
running experience.   
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5.3.1.2 Statistical comparison of injured and uninjured runners within the BS 
genomic cohort 
The BS genomic cohort consisted of 564 females (59.9%) and 377 males (40.1%). 
Among these 941 runners, the proportions of injured females (n=110, 19.5%) and 
males (n=64, 17%) were similar (χ21=0.96, p=0.33). The frequencies of age groups 
were significantly different between injured and uninjured groups (χ23=11.1, p=0.01), 
with higher rates of runners aged 18-34 in the injured group than in the uninjured group 
(42.5% versus 31.6%). However, injured and uninjured groups did not differ by 
frequencies of BMI categories (χ23=0.43, p=0.93).  
Table 5.1 Physical characteristics of runners with bone stress injuries and 
uninjured runners in the BS genomic cohort. 




n % n % 
Sex 
Male 64 36.8 313 40.8 
Female 110 63.2 454 59.2 
Age group* 
18-24 years 18 10.3 38 5 
25-34 years 56 32.2 204 26.6 
35-44 years 71 40.8 371 48.4 




kg/m2) 5 2.9 16 2.1 
Normal (18.5 to <25 
kg/m2) 135 77.6 596 77.7 
Overweight (25 to <30 
kg/m2) 31 17.8 141 18.4 




100% CE 159 91.4 728 94.9 
75% CE + 25% 
MT/Other 11 6.3 14 1.8 
50% CE + 50% 
MT/Other 4 2.3 19 2.5 
100% MT 0 0.0 5 0.7 
75% MT + 25% Other 0 0.0 1 0.1 
BSI – bone stress injury, CE – Caucasian European, MT – Mediterranean, * - 
statistically significant difference between injured and uninjured groups within the AT 
genomic cohort (p<0.05).  
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Training habits of injured and uninjured runners included in the BS genomic cohort are 
described in Table 5.2. There were significantly more runners who reported running 
over 40 km per week in the injured group than in the uninjured group (36.2% versus 
26%, χ22=8.02, p=0.02). The injured and uninjured groups also differed by frequencies 
of the reported years running experience (χ23=12.26, p=0.007). The injured group had 
approximately half the proportion of inexperienced runners (≤2 years) than the 
uninjured group (11.5% versus 22.4%). The compared groups did not differ by the 
frequencies of running sessions per week (χ23=2.59, p=0.46), race pace (χ24=3.56, 
p=0.46), preferred running terrain (χ26=11.49, p=0.07), participation in other sports 
(χ21=0.02, p=0.88), and stretching in relation to running sessions (χ21=2.96, p=0.09). 
However, injured runners were more likely to report wearing orthotics (33.3% versus 
14.1%, χ21=36.6, p<0.001).  
Overall, injured and uninjured groups differed significantly by the frequencies of age 
groups, reported weekly running distance, years of running experience and wearing 
orthotics.   
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Table 5.2 Training characteristics of runners with bone stress injuries and 
uninjured runners in the BS genomic cohort. 




n % n % 
Weekly running 
distance* 
15-20 35 20.1 205 26.7 
20-40 76 43.7 362 47.2 
40+ 63 36.2 200 26 
Running 
experience* 
≤2 years 20 11.5 172 22.4 
3-5 years 59 33.9 196 25.6 
6-9 years 32 18.3 127 16.6 
10+ years 63 36.2 271 35.3 
Running sessions 
per week 
1 session  0 0 2 0.3 
2 or 3 sessions 66 37.9 327 42.6 
4 or 5 sessions 85 48.9 358 46.7 
6+ sessions 22 12.6 74 9.6 
N/A 0 0 6 0.8 
Race pace 
<4 min/km 25 14.4 82 10.7 
4-5 min/km 66 37.9 278 36.3 
5-6 min/km 64 36.8 291 37.9 
6-7 min/km 15 8.6 95 12.4 
>7 min/km 4 2.3 18 2.3 
N/A 0 0 3 0.4 
Running terrain 
Bitumen 78 44.8 322 42 
Cement 48 27.6 256 33.4 
Grass 8 4.6 16 2.1 
Hard dirt/gravel 35 20.1 146 19 
Treadmill 2 1.1 20 2.6 
Sand 0 0 4 0.5 
Synthetic 3 1.7 3 0.4 
Participation in 
other sports 
Yes 132 75.9 583 76 
No 40 23 182 23.7 
N/A 2 1.1 2 0.3 
Stretching 
Yes 114 65.5 447 58.3 
No 60 34.5 318 41.5 
N/A 0 0 2 0.3 
Orthotics** 
Yes 58 33.3 108 14.1 
No 115 66.1 658 85.8 
N/A 1 0.6 1 0.1 
BS – bone stress, CE – Caucasian European, MT – Mediterranean, * - statistically 
significant difference between injured and uninjured groups within the AT genomic 
cohort (p<0.05), **- statistically significant difference between injured and uninjured 
groups within the AT genomic cohort (p<0.001). 
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5.3.1.3 Discussion of phenotypic characteristics of investigated cohorts 
Bone stress injuries are one of the most common running-related injuries, with annual 
incidence rates varying between 4-5% among adolescent runners and over 20% in 
elite collegiate runners (Tenforde, Kraus, & Fredericson, 2016). Previous studies of 
bone stress injuries in runners identified a higher incidence rate in female runners and 
female military conscripts than in male counterparts (Mattila et al., 2007; Newman et 
al., 2013). In this study, the two-year incidence of bone stress injuries in the large injury 
cohort, described in Chapter 3 (N=4,284) was 11.1% and was significantly higher in 
female runners than in male runners (12% versus 10%, χ21=4.19, p=0.04). However, 
after the exclusion of runners reported other types of injuries and formation of BS injury 
and BS genomic cohorts, bone stress injury rates were similar for males and females 
in both analysed cohorts. This may be an important observation because several risk 
factors of bone stress injuries were originally linked to female sex and a systematic 
review of MTSS showed an association between female sex and increased risk of an 
injury (Newman et al., 2013). However, it is important to acknowledge that male 
runners may be as prone to bone stress injuries as female runners and may be 
affected by the same risk factors, such as changes in hormonal status, dietary 
disorders and low bone mineral density (Mountjoy et al., 2015).  
Since age was an ambiguous factor and both adolescents and elderly people are 
prone to develop bone stress injuries, these age groups were excluded from the BSI 
genomic cohort. Observed statistical difference between the described cohorts by the 
age group distribution, particularly between uninjured subgroups, could be explained 
by the lower interest of younger people to participate in the genetic arm of the study 
(Manzanero et al., 2018).  
   
5.3.2 Genetic polymorphisms associated with bone stress injuries  
Following QC and filtering of the SNP arrays, logistic regression analysis was used to 
calculate p-values across 281,168 genetic polymorphisms. Firstly, observed and 
expected p-values were compared, the QQ plot showed that these values were similar, 
and none of the genotyped polymorphisms reached a statistical significance of 
p<5x10-8 (Figure 5.1). Obtained p-values were then visualised on a Manhattan plot 
across the 22 autosomal chromosomes (Figure 5.2). None of the genotyped SNPs 
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surpassed either the genome-wide (p<5x10-8) or suggestive (p<10-5) significance 
thresholds. We, therefore, decided to identify the top 20 most significant SNPs, which 
required the significance threshold to be reduced to p<9.4x10-5. As shown in Table 
5.3, using this lower threshold, the 20 most significant SNPs were predominantly 
located on chromosomes 5, 6 and 9.  
 
Figure 5.1 QQ plot for the bone stress injury of observed and expected p-values, 
-log10 transformed.  
The plot shows observed p-values plotted on the y-axis (black dots) and theoretical p-
values plotted on the x-axis (red line). The black dots align closely with the red line 






Figure 5.2 Manhattan plot of p-values calculated for the bone stress injury case-control analysis, -log-transformed.  
Y-axis shows –log10 p-value for association with a bone stress injury. The red line indicates the suggestive significance threshold of 
p<1x10-5, the blue line indicates the threshold of p<9.4x10-5, which identifies the top 20 most significant SNPs. Chromosome colour-
coded legend is located along the x-axis. The rs numbers for each of the top 20 SNPs are indicated on the plot.
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Table 5.3 Top-20 most significant genotyped SNPs, ordered by chromosomes and base-pair location. 
SNP Chr BP MAF Gene A1 OR SE p-value 
rs6681012 1 25188064 0.29 LOC105376876 A 1.64 0.12 6.62E-05 
rs11900448 2 149942519 0.45 LYPD6B A 1.64 0.12 5.16E-05 
rs16831765 3 173620010 0.19 NLGN1 G 0.46 0. 2 6.63E-05 
rs957858 4 45737256 0.47 Intragenic C 1.7 0.13 4.75E-05 
rs13135708 4 139464920 0.3 Intragenic A 1.75 0.14 8.55E-05 
rs865410 5 167905111 0.24 Intragenic C 1.77 0.13 2.12E-05 
rs582906 5 167916628 0.48 RARS A 1.71 0.12 1.23E-05 
rs2180314 6 52617731 0.46 GSTA2 G 1.67 0.13 3.61E-05 
rs2144698 6 52623807 0.13 GSTA2 A 1.75 0.13 1.08E-05 
rs2608629 6 52625794 0.22 GSTA2 G 1.65 0.13 6.78E-05 
rs6454802 6 90814199 0.23 BACH2 A 1.63 0.12 7.80E-05 
rs11757155 6 90941240 0.18 BACH2 A 1.63 0.12 8.14E-05 
rs1871816 8 3666456 0.13 CSMD1 A 4.03 0.33 2.25E-05 
rs10780697 9 87654393 0.4 LOC105376118 G 1.7 0.13 3.73E-05 
rs474899 9 87660797 0.32 Intragenic A 1.76 0.13 1.05E-05 
rs1893005 11 87006224 0.43 TMEM135 G 0.55 0.16 3.25E-05 
rs11062435 12 3076665 0.39 TEAD4 G 1.79 0.15 9.35E-05 
rs1367605 12 41684389 0.23 PDZRN4 G 1.71 0.13 6.14E-05 
rs11085336 19 20478535 0.34 LOC105372315 A 1.67 0.13 8.01E-05 
rs225327 21 43763206 0.36 Intragenic A 1.67 0.13 8.99E-05 
SNP – single nucleotide polymorphism, Chr – chromosome, BP – base pairs, MAF – minor allele frequency, A1 – effect allele, OR – 
odds ratio, SE – standard error, P – p-value.
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Chromosome 6 contained the highest density of significant SNPs, with three SNPs 
located in the GSTA2 gene (rs2180314, rs2144698, rs2608629) and two SNPs in the 
BACH2 gene (rs6454802, rs11757155). The remaining 13 SNPs were distributed 
across 11 different chromosomes, with seven of them located in the protein-coding 
genetic regions. Two SNPs were located in uncharacterised loci (LOC), and four SNPs 
belonged to intragenic regions, with the most statistically significant SNP (rs474899) 
located in an intragenic region of chromosome 9. However, as previously discussed 
in Section 4.3.4 this data should be interpreted with extreme caution as the use of a 
reduced significance threshold (p<9.4x10-5) greatly increases the probability of type I 
errors (statistically in the order of 28 false positives). In order to help control for this, 
the same approach from Chapter 4 was applied. Specifically, imputed data were 
utilised to support and identify those SNPs that were more likely to be associated with 
BSI and also to exclude unreliable signals. 
 
5.3.3 Imputation of additional SNPs and visualisation of GWAS results 
Imputation made available 23,699,623 additional genotypes to support the case-
control analysis and visualisation of the array genotyped results. Case-control analysis 
for the imputed data was implemented under the same criteria as for the array 
genotyped data and resulted in calculated p-values for 7,438,753 genotypes. The 
imputed data was then visualised using LocusZoom plots for the 20 previously 
described genotyped SNPs.  
Five of the selected top 20 SNPs were located on chromosome 6, three of these 
mapped to the GSTA2 gene (Figure 5.3A). Supporting imputed SNPs in GSTA2 were 
distributed across surrounding genes encoding other members of glutathione S-
transferase family: GSTA7P, GSTA5 and GSTA1. However, only a few of imputed 
SNPs were in high LD (r2>0.8). Two other SNPs on chromosome 6 mapped to the 
BACH2 gene (Figure 5.3B). Multiple imputed SNPs with high LD were located around 
these two signals and spread along the BACH2 gene. One of the genotyped SNPs 
(rs11757155) was surrounded by multiple supporting imputed SNPs in high LD. 
Therefore, due to the appearance of several signals in GSTA2 and BACH2, both 
genes were considered for discussion regarding their potential function in the risk of 
bone stress injuries. 
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Six of the remaining 20 genotyped SNPs appeared in peak shaped LD patterns with 
other supporting imputed SNPs (Figures 5.4 and 5.5). However, not many genotyped 
SNPs had supporting imputed SNPs in high LD. Moreover, only three of these six 
SNPs were located within genes, specifically LYPD6B (rs11900448), CSMD1 
(rs1871816) and TEAD4 (rs11062435). These three genes were included in the 
subsequent discussion of the potential link between their function and development of 
bone stress injuries. The other three SNPs were located in the uncharacterised or 
intragenic regions: rs6681012, rs11085336 and rs225327. Although, rs6681012 was 
located between two genes – CLIC4 and RUNX3, none of the imputed SNPs belonged 
to either of these genes. Similarly, the closest to rs11085336 coding region was 
MIR1270, however, none of the supporting imputed SNPs were located in this gene. 
Finally, rs225327 was surrounded by highly conservative family of TFF (trefoil factor) 
genes, which are expressed predominantly in the gastrointestinal tissue. Hence, these 
three SNPs in the intragenic regions were excluded from the subsequent discussion. 
One of two closely located signals on chromosome 5, rs582906 was located within the 
RARS gene (Figure 5.6C). The second genotyped SNPs (rs865410) was located in 
the intragenic region. Supporting multiple SNPs were widely distributed across 
neighbour genes, however, the majority of the imputed SNPs were in LD of r2<0.6, 
and only several SNPs were clustered around these two genotyped SNPs. Similarly, 
widely scattered imputed SNPs were observed on the plots for rs16831765, located 
on chromosome 3 in the NLGN1 gene, rs1367605 on chromosome 12 in the PDZRN4 
gene, and rs957858 on chromosome 4 in the intragenic region (Figure 5.6A, B and D). 
SNPs located in NLGN1 and PDZRN4 genes were supported by multiple imputed 
SNPs in high LD. Hence, these two genes and the RARS gene were included in the 
following discussion of their potential role in bone stress injury development.   
Three of the remaining four signals rs13135708 (Figure 5.7A), rs474899 and 
rs10780697 (Figure 5.7B) were located in the uncharacterised and intragenic regions. 
Although the first SNP had multiple imputed surrounding SNPs in high LD, not of them 
were located in the surrounding genes. Yet the latter two SNPs were in proximity to 
the NTRK2 gene, and some of the imputed SNPs were located in this gene. The last 
included in top 20 list signal rs1893005 belonged to the TMEM135 gene on 
chromosome 11. This SNP was poorly supported by the imputed SNPs as the majority 
of them were in LD of r2<0.6 (Figure 5.7C). These two genes – NTRK2 and TMEM135 
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were included for discussion, NTRK2 was in proximity of two identified signals and 
TMEM135 has previously been investigated in relation to osteoporosis (Scheideler et 
al., 2008). 
In summary, ten genes were included in the following exploratory investigation of their 
functions and potential involvement in the development of bone stress injuries: 





Figure 5.3 Locus Zoom plots for identified significant SNPs for bone stress injuries from chromosome 6.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 





Figure 5.4 Locus Zoom plots for identified significant SNPs for bone stress injuries from chromosomes 1, 2, 8 and 12. 
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 1 in the intragenic 





Figure 5.5 Locus Zoom plots for identified significant SNPs for bone stress injuries from chromosomes 19 and 21.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Regions where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 19 in the intragenic 




Figure 5.6 Locus Zoom plots for identified significant SNPs for bone stress injuries from chromosomes 3, 4, 5 and 12.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 5 in the RARS gene; 




Figure 5.7 Locus Zoom plots for identified significant SNPs for bone stress injuries from chromosomes 4, 9 and 11.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 3 in NLGN1 gene; B, 
C) signals in the intragenic regions on chromosome 4. 
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5.3.4 Replication analysis 
Imputed data was also utilised to attempt replication of the results from previously 
published studies, which used a candidate gene approach and identified genetic 
variants associated with the risk of bone stress injuries. P-values of eight significant 
SNPs located in six genes and described in the literature review were identified and 
summarised in Table 5.4. None of these previously identified SNPs reached statistical 
significance in this study. LocusZoom plots (Figure 5.9 and Figure 5.10) for these eight 
SNPs showed very low significance profiles in the areas of the candidate genes. 
Currently, there are no other published GWAS investigating genetic markers of bone 




Table 5.4 Summary of candidate SNPs from previous studies and their significance levels identified using imputed data. 
SNP Chr BP MAF Gene A1 OR SE p-value 
rs1548456 7 93192036 0.28 CALCR T 1.16 0.12 0.229 
rs2051748 7 93199574 0.38 CALCR G 0.76 0.12 0.0261 
rs4328262 12 48285648 0.38 VDR G 0.96 0.12 0.7136 
rs1718119 12 121615103 0.32 P2X7 (P2RX7) A 0.97 0.12 0.79 
rs3751143 12 121622304 0.21 P2X7 (P2RX7) C 0.87 0.16 0.373 
rs1021188 13 43116133 0.22 RANKL(TNFSF11) C 1.2 0.15 0.2285 
rs1877632 17 41799590 0.27 SOST A 1.01 0.13 0.961 
rs3018362 18 60082093 0.38 RANK (TNFRS11A) A 0.95 0.13 0.671 
SNP – single nucleotide polymorphism, Chr – chromosome, BP – base pairs, MAF – minor allele frequency, A1 – effect allele, OR – 





Figure 5.8 Locus Zoom plots of the SNPs from replication analysis for bone stress injuries from chromosomes 7 and 12. 
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A, B) signals on chromosome 7 in CALCR gene; 




Figure 5.9 Locus Zoom plots of the SNPs from replication analysis for bone stress injuries from chromosomes 12, 13, 17 
and 18.  
Each SNP was plotted with 400kb flanking on both sides. Plotted SNPs are displayed in purple colour and named, surrounding SNPs 
are coloured based on their correlation (r2) with genotyped SNP. An LD heat map is displayed in the r2 legend in the top left corner of 
each plot. Genes where plotted SNPs are located, and surrounding genes are displayed in the bottom of each plot. Arrows on the 
horizontal blue lines show the direction of transcription, and rectangles are exons. A) signals on chromosome 12 in VDR gene; B) 
signals on chromosome 13 in RANKL (TNFSF11) gene; C) signals on chromosome 17 in SOST gene; C) signals on chromosome 18 




Research of bone stress injuries in a study on twins and their high recurrence rates in 
athletes led to the investigation of genetic factors, which may contribute to the development 
of these injuries (Bennell et al., 1996b; Singer et al., 1990). However, the genetic 
contribution to bone stress injuries is represented by a limited number of studies and 
primarily based on findings from genetic studies on bone mineral density and disorders 
affecting bone health, such as osteoporosis and osteoarthritis. Thus, from the studies used 
a candidate gene approach, genes which protein products are involved in the metabolism 
of vitamin D and calcium, the Wnt signalling pathway and the RANK/RANKL/OPG signalling 
pathway were the main candidates. 
The GWAS approach presented in the current study analysed 174 cases of bone stress 
injuries and 767 uninjured controls. All included recreational runners reported running at 
least 15 km per week and were between 18 and 50 years of age. Case-control analysis of 
genetic data did not identify any statistically significant SNPs reaching p<5x10-8. Hence a 
greatly reduced threshold (p<9.4x10-5) was employed to identify the top 20 most associated 
SNPs. Interpretation of these SNPs was supported with imputed data resulting in the 
identification of ten genes, which may be important in the development of bone stress 
injuries, specifically LYPD6B, TMEM135, CSMD1, TEAD4, GSTA2, BACH2, RARS, 
NLGN1, PDZRN4 and NTRK2. These genes, included in the discussion, were assorted by 
their affiliation to a certain pathway of factors, which indirectly may influence processes in 
the bone. In addition, a study of gene expression in osteoblasts allowed us to compare 
expression levels of the selected genes and use them as supporting evidence for genes’ 
potential role in bone stress injuries (Moriarity et al., 2015).   
Two genes were linked to the Wnt pathway, which was previously identified as an important 
pathway in the regulation of bone metabolism (Krishnan, Bryant, & MacDougald, 2006). 
Transmembrane protein 135 (TMEM135) has been previously studied in relation to 
osteoporosis, and its expression has been identified in adipocytes and osteoclasts during 
their differentiation. TMEM135 has also been identified as an important factor for 
osteoblastogenesis from human multipotent adipose tissue-derived stem cells (Scheideler 
et al., 2008). A meta-analysis of GWAS in 13 cohorts, which investigated genetic 
polymorphisms associated with heel bone properties such as broadband ultrasound 
attenuation (BUA), the velocity of sound (VOS), bone mineral density (BMD) showed that 
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the TMEM135 gene was significantly associated with BUA and VOS (Moayyeri et al., 2014). 
In addition, it was shown that the structure of this transmembrane protein is homologous to 
a transmembrane region of frizzled-4, which is a component of the Wnt signalling pathway, 
previously identified as an important pathway in bone formation (Piters et al., 2008; 
Scheideler et al., 2008). However, the imputation results of this study showed that the SNP 
in TMEM135 was not highly supported by other surrounding SNPs in high LD, which 
suggests that the function and the role of this gene require further research. The second 
gene LY6/PLAUR domain containing 6B (LYPD6B) results in a product which belongs to a 
lymphocyte antigen-6/urokinase-type plasminogen activator receptor superfamily with 
specific structural features, yet high variability by their function (Loughner et al., 2016). A 
review of the proteins in this family described Lypd6b, and its homolog Lypd6, as 
neuromodulators in mammals and detailed their involvement in the embryonic development 
(Vasilyeva, Loktyushov, Bychkov, Shenkarev, & Lyukmanova, 2017). The function of the 
protein encoded by LYPD6B is poorly studied, however, it was shown to be a target gene of 
the Wnt signalling pathway (Paramonov et al., 2017; Zhang et al., 2017). Thus, the 
discovered link between LYPD6B and the Wnt signalling pathway may be another 
supporting factor of this pathway’s role in the bone stress injury susceptibility. However, the 
current limited knowledge of the function and regulation of this gene requires further 
investigation. Interestingly, the RNA expression study demonstrated that both of these 
genes were expressed in osteoblasts at the moderate level, which contributes to their 
potential for subsequent research. 
Cytokines play an important role in osteoclast development and, therefore, in bone 
resorption (Manolagas, 1995). BTB domain and CNC homolog 2 (BACH2) is a gene that 
encodes a transcription factor, which is abundantly expressed in hematopoietic tissues, 
particularly in B cells and has been associated with lymphomas (Ichikawa et al., 2014; 
Sasaki et al., 2000). BACH2 also plays a crucial role in T-cell mediated immune responses 
and controls production of interleukin-4 (IL4) (Kuwahara et al., 2016), which in turn was 
identified as one of the inhibitors of osteoclast development (Manolagas, 2000). In addition, 
BACH2 was identified as a locus associated with rheumatoid arthritis (Ruiz-Larrañaga et al., 
2016). This gene was also moderately expressed in osteoblasts (Moriarity et al., 2015). In 
the current study, imputation analysis demonstrated a high density of imputed supporting 
SNPs which were located in this gene. Therefore, although its function is not at present 
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directly linked to the functioning of bone cells, its involvement in cytokine regulation and 
immune response may justify the involvement of this gene is BSI susceptibility. 
Both osteoclasts and osteoblasts are equipped with adrenergic and neuropeptide receptors, 
which are used for communication with the nervous system (Togari & Arai, 2008). The 
sympathetic nervous system is involved in the regulation of bone formation via controlling 
leptin production (Takeda et al., 2002). Several of the genes identified are linked to nervous 
system functioning. CUB and Sushi multiple domains (CSMD1) is a gene which is 
abundantly expressed in the central nervous system and epithelial tissues (Sun et al., 2001). 
PDZ domain-containing ring finger 4 (PDZRN4) is a gene which encodes a family member 
of Ligand of Numb Protein-X and therefore, is implicated in the cell fate determination 
through the inhibition of the Notch signalling pathway (Katoh & Katoh, 2004). Neuroligin 1 
(NLGN1) is a splice site-specific ligand for β-neurexins and belongs to a family of neuronal 
cell surface proteins, which are involved in formation and remodelling of synaptic contacts 
in the central nervous system (Ichtchenko et al., 1995; Reissner, Klose, Fairless, & Missler, 
2008). Neurotrophic receptor tyrosine kinase 2 (NTRK2) encodes membrane-bound kinase, 
which regulates the functioning of brain‐derived neurotrophic factor (BDNF). BDNF is 
responsible for the key processes in neurological development such as neuronal birth, 
maturation, differentiation, migration and survival. This factor is essential for dendritic growth 
and synaptic plasticity (Huang & Reichardt, 2001). Additionally, genetic variation in the 
NTRK2 gene was investigated in association with various psychiatric comorbidities. All these 
four genes were predominantly investigated in association with various neurological and 
psychiatric disorders (Baranzini et al., 2008; Lewis et al., 2010; Nakanishi et al., 2017; 
Pandya, Kutiyanawalla, & Pillai, 2013; Ray, Weickert, & Webster, 2014; Spalek et al., 2017; 
Torres et al., 2017; Voegeli et al., 2016; Zhang et al., 2015). 
Glutathione S-transferase alpha 2 (GSTA2) is a gene associated with three of the top 20 
SNPs from this study. The key function of its protein product is to detoxify carcinogens, 
therapeutic drugs, toxins and products of oxidative stress by conjugation with glutathione. 
This gene belongs to the alpha class of five transferases clustered on chromosome 6. This 
family is highly versatile and abundantly expressed in liver, kidneys and adrenal tissue 
(Seidegård & Ekström, 1997). The function of this enzyme was extensively researched in 
association with cancer risk and utilisation of toxic drugs (McIlwain, Townsend, & Tew, 2006; 
Zhang, Modén, & Mannervik, 2010). Imputation analysis showed that supporting SNPs of 
these three genotyped SNPs were located in neighbour genes encoding other GSTA family 
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members. However, these supporting SNPs were in low LD with genotyped SNPs. In 
addition, expression of GSTA2 has not been observed in osteoblasts (Moriarity et al., 2015). 
All these findings suggest a contributory role of GSTA2 into bone metabolism. In addition, 
the presence of three SNPs in this genomic area may be taken into consideration for further 
research.  
The arginyl-tRNA synthetase (RARS) gene encodes for the cytoplasmic tRNA synthetase 
for arginine. This synthetase is part of a multienzyme complex, which plays a key role in 
translation and is expressed in all tissues and cells, including osteoblasts (Girjes, Hobson, 
Chen, & Lavin, 1995; Moriarity et al., 2015). Due to its essential presence in every cell, it is 
difficult to speculate on its specific role in bone cells and the contribution of this gene 
variation to bone stress injury development.   
The remaining gene, TEA domain transcription factor 4 (TEAD4), encodes a transcriptional 
enhancer factor (TEF) and is also known as TEF3. This gene is typically expressed in 
skeletal muscle cells, promoting myoblast differentiation and epithelial-mesenchymal 
transition (Benhaddou et al., 2012). This gene has no known role in relation to bone 
formation and to date has predominantly been studied in embryonic cells and in relation to 
a role in cancer (Shi et al., 2017; Skottman et al., 2005). 
In conclusion, the most interesting finding was an association of TMEM135 variation with 
bone stress injuries. This gene encodes a transmembrane protein which regulates the 
growth of osteoblasts and is identified as one of the genetic markers associated with heel 
bone properties (Moayyeri et al., 2014). TMEM135 and LYPD6B both were functionally 
associated with the Wnt signalling pathway, which allowed us to flag them as genes of 
interest for further research. In addition, a review of gene expression analysis (via RNA 
sequencing) in normal human osteoblast cells showed that some of the previously discussed 
genes had relatively high (RARS) or moderate (TMEM135, TEAD4 and LYPD6B) 
expression levels, whilst expression of GSTA2 and PDZRN4 were undetected (Moriarity et 
al., 2015). Among the reviewed genes, four were predominantly expressed in the neuronal 
system and responsible for neurological development, the functioning of the central nervous 
system and synaptic plasticity. Several mouse models with leptin deficiency demonstrated 
the existence of the regulation of bone formation by the central nervous system (Elefteriou, 
2008). Another study showed co-expression of NTRK2 and BDNF in the active phase of 
osteoblasts in a rat model, which suggested their regulatory role in bone remodelling 
(Yamashiro, Fukunaga, Yamashita, Kobashi, & Takano-Yamamoto, 2001). The nervous 
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system plays a major role in bone formation and remodelling, which supports the presence 
of genetic polymorphisms in PZDRN4 CSMD1, NTRK2 and NLGN1 associated with bone 
stress injuries. This provides additional evidence of the complex interaction between bone 
and nervous system.  
Research of multifactorial conditions is complicated by the interplay of genetic and 
environmental factors, their variation and their unclear proportions of contribution to the 
cause of the condition. Additionally, the effect of genetic factors of multifactorial conditions 
such as overuse injuries is usually very low and varies between 1.2 and 1.5 OR (Bodmer & 
Bonilla, 2008). Therefore, the risk of the condition between carriers and non-carriers of 
certain genetic variants may differ marginally. This issue may be compensated by a sample 
size large enough (typically in the thousands) to identify these low effect polymorphisms. 
However, the recruitment of a cohort of sufficient size for GWAS can be very challenging, 
as previously discussed (Section 4.4.3). In addition, the review of the functions and 
expression location of the selected genes suggest that the majority of genes in this study 
were not associated with the processes responsible for bone formation and metabolism. 
This could be explained by the high chance of false-positive results due to the decreased p-
value threshold. In addition, the attempted replication analysis demonstrated that none of 
the previously described genetic variants reached the significance level. Unfortunately, the 
genetics of bone stress injuries is currently poorly understood and requires additional data 
collection and recruitment of physically active people experiencing such injuries.  
Although the identified genetic variants may have a weak effect and low predictive value, 
exploration of their function in molecular pathways may potentially reveal previously 
unknown processes or biomarkers that contribute to the development of an injury. The 
GWAS approach may be an efficient and unbiased tool to explore genetic predisposition to 
bone stress injuries, yet, in the current study, will require a significant increase of the sample 
size either via additional recruitment or through collaboration with similar research projects 





















As the original project aimed to recruit approximately 10,000 Australian recreational runners, 
the initial data and sample collection methods were designed to be minimally invasive, using 
online survey software and remote collection of saliva samples. The survey was designed 
to collect detailed health and injury data from Australian recreational runners that allowed 
us to identify runners eligible for the genetic part of the project (Domaschenz et al., 2015). 
A GWAS approach was selected as an unbiased method for identification of genetic variants 
associated with the studied injury traits. This method allowed us to analyse a large sample 
size in a short period and utilise programming software with predetermined workflow for the 
subsequent analyses of the high-volume genetic data. As a large number of recruited 
participants was a critical factor in reaching the significance level in the genetic analysis, the 
recruitment phase was the longest part of the project, taking 25 months. Versatile 
recruitment strategies were employed throughout this period; including the online 
advertisement, paid Facebook promotion and attendance of running events (Manzanero et 
al., 2018). As a result of the recruitment efforts, data from 4,720 responses were utilised for 
epidemiological data analysis and 1,099 DNA samples were used for investigating genetic 
variants associated with overuse running-related injuries. Statistical analyses of the 
collected epidemiological data provided insights to the training and lifestyle habits, and injury 
history of Australian recreational runners. In addition, risk factors of the most common 
running-related injuries were identified and discussed. The genetic analysis allowed us to 
identify genetic variants associated with Achilles tendon injuries and bone stress injuries at 
the suggested significance level of p<1x10-3.9 and p<9.4x10-5, respectively, and then 
compare these associations previously published associations. 
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6.2 Conclusions from epidemiological data analyses 
Initially, the epidemiological data analysis aimed to describe physical, training and lifestyle 
characteristics of the Australian recreational runners (Chapter 2). The recruited recreational 
runners displayed lifestyle and training characteristics, which were associated with a range 
of beneficial health outcomes. The recreational runners included in the study reported 
running at least 15 km per week, and 70% of the respondents running more than 20 km per 
week within at least two running sessions. Moreover, three-quarters of the respondents also 
reported participating in sports other than running. Thus, we concluded that recreational 
runners in the studied cohort met physical activity guidelines suggested by the WHO (World 
Health Organisation, 2010). Interestingly, reports of smoking, excessive weight and 
hypertension were uncommon for the participants. These findings suggested that 
recreational runners predominantly avoided the key contributors to the burden of disease 
(Australian Institute of Health and Welfare, 2016b). The data also demonstrated that the 
commencement of a regular running program was associated with a significant weight loss 
irrespective of biological sex, participation in other sports and injury history. This association 
between recreational running and healthy characteristics may contribute to the promotion of 
recreational running as a regular exercise for its beneficial effects such as improvement in 
aerobic capacity, weight loss and maintenance of overall healthy lifestyle. In addition, the 
data analysis demonstrated differences in training characteristics of male and female 
runners, as male runners were more likely to run longer weekly distances at higher 
frequencies of the weekly running sessions than female runners. These differences in the 
running patterns, together with the previously reported different motivation reasons for 
exercise between men and women (Australian Sports Commission, 2016; Lauderdale et al., 
2015) may assist in targeted marketing of running among different groups of the population.  
The second study (Chapter 3) demonstrated injury occurrence rates and common types of 
injuries typical for Australian recreational runners. Thus, over 50% of the recruited 
recreational runners reported running-related injuries, which had occurred in the past two 
years. Statistical analyses of the collected injury data identified the two most common 
reported injuries among Australian recreational runners as Achilles tendon injuries and bone 
stress injuries. Achilles tendon injuries were more typical for male runners, whereas the 
rates of the reported bone stress injuries were similar for male and female runners. Multiple 
logistic regression analyses aimed to identify factors associated with the occurrence of 
running-related injuries in general, and Achilles tendon injuries and bone stress injuries 
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independently. The multiple logistic regression analysis identified factors associated with a 
general risk of running-related injuries, such as male sex, younger age, and stretching in 
relation to a running session. Factors associated with Achilles tendon injuries comprised 
male sex, age over 35 years, faster race pace of 4min/km and stretching in relation to a 
running session. The identified factors associated with the development of bone stress 
injuries were age under 35 years, high BMI of over 30 kg/m2 categorised as obese, the 
weekly running distance of longer than 40 km and stretching in relation to a running session. 
These findings demonstrated the diversity of the factors which should be considered in the 
training programs aiming to prevent injuries. Identified training-related factors associated 
with the development of these types of injuries may contribute to the further research of 
running-related injuries. In addition, better knowledge of these factors may assist with the 




6.3 Conclusions from GWAS of Achilles tendon injuries and bone stress injuries 
In this project, two GWAS were conducted in order to identify genetic variants associated 
with Achilles tendon injuries and bone stress injuries (Chapter 4 and Chapter 5, 
respectively). The statistical case-control analyses of the genomic data were conducted 
independently for each type of injury. The analysis of the genetic variants associated with 
Achilles tendon injuries was conducted on 171 cases and 767 uninjured controls. Although 
this limited sample size did not allow us to reach the standard GWAS significance threshold 
p<5x10-8, an exploratory examination of the 20 most significant genetic variants was 
performed, further supported by SNP imputation and protein function. Several of these 
genetic variants were located in the genes TCF7L1, DOCK4 and TLE1, whose functions are 
associated with the Wnt signalling pathway. The Wnt pathway regulates transcriptional 
pathways in stem cell activation, cell proliferation and differentiation. The Wnt pathway also 
targets MMPs, which regulate the homeostasis of the extracellular matrix in the tendon 
(Clevers, 2006). Our findings suggest that the Wnt signalling may be involved in the 
regulation of homeostasis of the tendon matrix and therefore further research of its function 
and the potential link to the pathological processes occurring in the tendon may assist in 
better understanding of the tendinopathy. In addition, the imputation of genetic variants 
allowed us to compare our finding to the results of a previously published GWAS, which 
investigated genetic variants associated with Achilles tendinopathy in more than 100,000 
hospital patients (Kim et al., 2017). This study also did not reach the stringent p<5x10-8 
significance threshold. An attempted cross-replication of this study’s results and the GWAS 
results performed by Kim et al. (2017) failed. Furthermore, this study also failed to replicate 
associations identified in previous candidate gene studies (Section 4.3.6.3). These analyses 
demonstrated that none of the genes involved in the collagen structure (COL5A1, 
COL11A1), apoptosis (CASP3, CASP8) and inflammation (IL1B, IL1RN, IL6) reached the 
suggestive significance level of p<1x10-3.9. This study’s failed replication of the previous 
candidate gene studies’ results is supported by Kim et al. (2017), who also failed to replicate 
these candidate gene associations (Kim et al., 2017).       
The GWAS of genetic variants associated with bone stress injuries was conducted on 174 
cases and 767 uninjured controls. This sample size made the study underpowered; 
therefore, the top 20 significant signals were investigated in a highly exploratory manner, 
following a p-value threshold reduction from p<5x10-8 to p<9.4x10-5. The functions of the 
genes in the list of top 20 most significant variants were highly variable and only one of the 
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explored genes – TMEM135, potentially had a function relevant to the development of bone 
stress injuries. This gene was characterised as an important factor for osteoblastogenesis 
and was previously investigated in association with another condition affecting bone health 
– osteoporosis (Scheideler et al., 2008). Another gene LYPD6B encodes a product, which 
is involved in the embryonic development, however, is poorly studied. Importantly, 
TMEM135 and LYPD6B genes were both associated with the Wnt signalling pathway. 
Although the Wnt signalling pathway’s functions are versatile, its malfunction was previously 
associated with osteopenia or osteoporosis. Therefore, the described association suggested 
further research towards a better understanding of the Wnt pathway in bone formation. 
Genetic markers of bone stress injuries were poorly studied, however, several candidate 
gene approach studies suggested that genetic variants of VDR, CALCR, P2X7, RANKL, 
RANK, SOST genes were associated with the bone stress injuries (Styrkarsdottir et al., 
2008; Varley et al., 2016; Yanovich et al., 2012; Zmuda et al., 2011). Therefore, we 
attempted to replicate these results using GWAS data. The genetic variants of the genes as 
mentioned above did not reach the suggested significance level of p<9.4x10-5. These results 
suggest that the genetics of bone stress injuries requires more research, which may enable 





6.4 Key findings 
1. Australian recreational runners demonstrated healthy lifestyle habits, including 
meeting physical activity guidelines recommendations (Section 2.4.1). 
2. Commencement of a running program was associated with a significant weight loss 
in the novice recreational runners (Table 2.9). 
3. Male and female runners had different characteristics in running programs, and 
therefore, the appropriate promotion of physical activity may depend on gender 
(Table 2.6). 
4. Achilles tendon injuries and bone stress injuries were two most commonly reported 
running-related injuries in the cohort of Australian recreational runners (Figure 3.1). 
5. Male recreational runners were more likely to report running-related injuries than 
female runners (Table 3.4). 
6. Faster running race pace, older age and stretching were the factors associated with 
the reporting of Achilles tendon injuries in the population of Australian recreational 
runners (Table 3.7). 
7. Longer running distance, younger age, obesity and stretching were associated with 
the reporting of bone stress injuries in the population of Australian recreational 
runners (Table 3.10). 
8. Genetic variants in genes linked to the Wnt signalling pathway (TCF7L1, DOCK4 and 
TLE1) may contribute to the occurrence of Achilles tendon injuries (Figure 4.4, Table 
4.4). This observation is highly exploratory and requires further research to 
substantiate. 
9. The study was unable to replicate genetic results from the previous candidate gene 
approach studies and one GWAS, which may suggest that associations of the certain 
genetic variants are likely to be study-specific (Table 4.5, Table 4.6). 
10. The study was unable to determine the genetic polymorphisms associated with bone 
stress injuries. Only two genes (TMEM135 and LYPD6B) suggested a link between 
the Wnt signalling pathway and the bone stress injury occurrence (Figure 5.2, Table 
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5.3). Given the impact of bone stress injuries on participation in physical activity, this 
requires further research to substantiate. 
11. The study failed to replicate results from the candidate gene approach studies, which 
suggested that several genes were associated with the development of bone stress 
injuries (Table 5.4). 
12. Although three polymorphisms were a putative replication: rs1110495 (16:51914974, 
p=0.0215), rs12722 (COL5A1 gene, p=0.0194) and rs2051748 (CALCR gene, 
p=0.0261), these results should be interpreted with caution due to imputed nature of 
the data (Tables 4.5, 4.6 and 5.4). 
13. The genetic data collected and analysed in this study may assist in further research 
of the genetic variation associated with running-related injuries through replication, 




This cross-sectional study was based on large-scale recruitment of Australian 
recreational runners. The recruitment campaign lasted for 25 months, which was the 
most prolonged phase of the project. The recruitment campaign employed multiple 
strategies as they aimed to collect data from thousands of recreational runners. The 
study was promoted as the ‘AIS Running Injury Study’, which was described as a study 
of running-related injuries in Australian recreational runners, and research of genetic 
variants associated with Achilles tendon injuries and bone stress injuries. Thus, 
recreational runners provided their personal, health and injury data, which were analysed 
in the epidemiological part of the study (Chapters 2 and 3). The collected survey data 
was of a self-reported retrospective nature, and previous studies demonstrated 
limitations in collecting sporting injury data retrospectively (Gabbe et al., 2003; Kolt & 
Kirkby, 1999). However, the utilised questionnaire had been demonstrated to provide 
reliable data for this project (Domaschenz et al., 2015). The final dataset comprised over 
4,700 completed responses, which was the largest known dataset of health and injury 
data collected from Australian recreational runners. As previously discussed (Section 
2.5.1), there were approximately 2.8 million recreational runners in Australia during the 
recruitment phase (Australian Sports Commission, 2016). Although this study was vastly 
promoted by the Australian Institute of Sport – a well-known sporting institution in 
Australia, the recruitment of initially planned 10,000 recreational runners was not 
achieved. Whilst several recruitment strategies across Australia were employed, 
including social and online media and attending running events in other states the 
highest participation rate (7x) per 100,000 was observed in the ACT, where the AIS is 
located. This clearly highlights the importance of multisite recruitment for future projects 
to further maximise participant recruitment. The genetic arm of the study aimed to 
investigate genetic variants associated with Achilles tendon injuries and bone stress 
injuries, which were more likely to occur due to running overload, stringent selection 
criteria were applied to the studied cohort. Only runners younger than 50 years of age, 
who avoided smoking, did not experience any fractures or chemotherapy, and were not 
diagnosed with any chronic conditions which affect the musculoskeletal system, were 
eligible to participate in the genetic analysis. Therefore, to reach the sample numbers of 
at least 800 cases and 800 controls required for GWAS was also a significant challenge. 
In addition, as respondents were requested to consent to provide genetic material for the 
following GWAS in the survey, we identified that younger runners were less likely to 
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agree to participate in the genetic component of the project (Manzanero et al., 2018). 
Interestingly, a similar trend was observed in another independent study (McQuillan & 
Porter, 2011). With the reluctance to provide genetic material for research among 
younger adults, possibly due to lower levels of trust in research and greater privacy 
concerns.  
Performing GWAS for complex diseases is challenging due to the multiple genetic and 
environmental factors involved. The GWAS performed in this presented study, required 
careful planning and design, including the estimation of disease prevalence and 
heritability, choice of genotyping chip, required a sample size and calculated study power 
(Spencer, Su, Donnelly, & Marchini, 2009; Zondervan & Cardon, 2007). At the 
commencement of this study there was no other large-scale genetic variant analyses of 
Achilles tendon injuries and bone stress injuries. Therefore, this study would be the first 
of its kind to investigate high-density genetic predisposition in these two injury types. This 
project was an initiative of the CRN-AESS, and similar to other genetic-based studies, 
there were challenges with recruiting sufficiently large numbers of participants. As 
previously demonstrated (Section 1.8.3), a large sample size would allow us to 
investigate SNPs with relatively low MAFs and effect size. The OR of a single associated 
SNP is typically small, with the majority of SNPs associated with multifactorial conditions 
varying between OR of 1.2 to 1.5 (Bodmer & Bonilla, 2008). As previously shown 
(Section 1.8.3) our initial power calculations based on recruitment of >800 cases, relied 
upon an OR=1.5 or greater. Therefore, this study would only be able to identify SNPs if 
their OR was at the upper end of this range. The probability of identifying SNPs with a 
lower OR was therefore substantially reduced using the standard, stringent statistical 
thresholds. Their identification relied on the recruitment of tens of thousands of 
participants, which was well beyond the scope and timeframe of this study. Therefore, 
these types of studies need to employ recruitment strategies that use multiple locations 
and international collaborations to have the greatest impact.  
Another limitation may be due to the selection criteria used in this study. These relatively 
strict selection criteria were employed to control for confounding factors and therefore 
focus on the examination of genetic variants associated with these two injuries in 
physically active, healthy individuals. However, the application of this stricter selection 
criteria significantly reduced the number of eligible study participants from our original 
survey population. Using more relaxed selection criteria would have more likely enabled 
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the recruitment of the target sample size of 2,400 participants (800 in each of three 
analysed groups). However, this larger recruited population would be more 
heterogeneous, and identification of statistically significant genetic variants may be 
confounded by other uncontrolled factors. 
As GWAS have become a standard research approach, their value increases when other 
research groups recruit similar cohorts, allowing data to be pooled, or results replicated. 
For example, GWAS by Kim et al. also failed to identify statistically significant 
associations with Achilles tendon injuries employing 5,000 cases and over 100,000 
controls (Kim et al., 2017). In addition, this large study also failed to replicate results from 
the previous candidate gene studies. However, as acknowledged by the authors of this 
study, their study participants were not controlled for physical activity levels, which may 
have had a strong confounding effect, diluting out any associations. Collectively this 
demonstrates a delicate balance between applying strict selection criteria and therefore 
limiting sample size, versus recruiting a large heterogeneous cohort, and the analysis 
being affected by multiple confounding factors. This is further evidenced by a GWAS that 
identified FTO as an obesity susceptibility gene, through the analysis of 2,000 cases with 
type 2 diabetes and 3,000 controls across five centres in the UK (Frayling et al., 2007). 
At first, a cluster of SNPs in the FTO gene was found to be associated with type 2 
diabetes (p=5*10-8). Several replication GWAS confirmed that genetic variants in the 
FTO gene were associated with susceptibility to obesity (Dina et al., 2007; Scuteri et al., 
2007). However, further replication of these results and adjusting for BMI as a confounder 
abolished this association (Loos & Yeo, 2014). This example demonstrates that such 
factors as sample size, multisite research, correctly controlling for confounders and 
replication of findings together would advance GWAS research and allow researchers to 
identify robust genetic associations.  
The present study was focused on exercise-related injuries in healthy individuals, which 
other than the Kim et al. (2017) study, restricted the opportunity to replicate results from 
other GWAS. In addition to attempted replications, the UK Biobank health resource, 
which provides access to GWAS data across multiple traits, was explored as a source 
of similar studies (UK Biobank, 2019). However, this resource did not contain any studies 
(other than Kim et al. (2107)) of genetic associations of tendon or bone injuries with 
exercise-related phenotype, which was the key component of this study design. 
200 
 
As this research project aimed to identify factors associated with the development of 
running-related injuries, the literature review and hypotheses of this study relied on the 
previous finding from the exercise and sport science. This field of science has developed 
in recent years and comprises several disciplines, such as physiology, biomechanics, 
nutrition, sports medicine (Halperin, Vigotsky, Foster, & Pyne, 2018). In addition to the 
previously discussed challenges of GWAS research, exercise and sports science 
research also has its methodological issues. A recent review by Halperin et al. (2018) 
outlines several of these problems and their possible solutions to improve the quality of 
results in sport science (Halperin et al., 2018). Specifically, that exercise and sport 
science research would benefit from more validation and replication studies, access and 
sharing of raw data and collaborations (Halperin et al., 2018). 
These indicated issues suggest that this interdisciplinary project had several limitations 
due to the existing challenges in exercise science and GWAS. In summary, we again 
acknowledge that the genetic associations and interpretations in this study are currently 
of an exploratory nature. As such, they should be interpreted with caution, due to the 






6.6 Future directions 
Research into the genetic factors of multifactorial conditions is complex due to the interaction 
of genetic and environmental factors, which may contribute to the development of these 
conditions to varying degrees. However, typically the effect of genetic variants to the 
development of multifactorial conditions is rather low (Bodmer & Bonilla, 2008). With the 
development of high throughput genetic technologies, in particular the GWAS approach, 
genetic research has become more accessible and cost-effective, allowing for the 
investigation of a wider range of multifactorial conditions. However, these studies require 
consistency in the collected data and distinct phenotypic characteristics, which may restrict 
the sample size. The challenge of recruiting large numbers of participants may be resolved 
by collaborative efforts across multiple research teams and consortia. Similarly, the sharing 
of phenotypic and genetic data, and merging datasets with similar characteristics would 
allow researchers to increase final sample size and perform data meta-analysis.  
As this project was a part of a large collaborative network, phenotypic and GWAS data from 
this study was made available to collaborating research teams and will be accessible to 
more research groups in the future. The GWAS data from this study has already been 
utilised as part of the control group for another project investigating necroptotic cell death 
(Hildebrand, 2019). This was a large collaborative project that utilised cell biology and 
GWAS to identify polymorphisms in the MLKL gene, and assist in the understanding of the 
underlying processes of paediatric autoinflammatory disease (Hildebrand, 2019). 
Furthermore, sharing GWAS data may contribute to the further research of Achilles tendon 
injuries and bone stress injuries by adding data value to the meta-analyses.  
Conversely, this study significantly benefited from the freely available GWAS data generated 
by Kim et al (Kim et al., 2017). Access to these data enabled the ability to perform replication 
of our study findings in a separate study cohort. Whilst replication of our data could not be 
achieved and vice versa, this emphasised another important issue regarding the genetic 
research of multifactorial conditions, namely the independent reproducibility of results. 
Therefore, the current explosion of direct-to-consumer genetic testing for exercise, nutrition 
and sports, including injury risk, should be considered with caution. These tests rely on the 
results from the candidate gene approach studies, which, for instance, identified 
associations between polymorphisms in COL5A1, TNC and MMP3 genes with the risk of 
Achilles tendon injuries. However, none of these independent replication studies could 
provide any evidence that these polymorphisms were predictive of the injury risk, and would 
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have similar effects across various ethnicities and both sexes. Extreme caution must 
therefore be taken when interpreting results from direct-to-consumer tests which claim to 
provide advice on injury risk (Vlahovich et al., 2017). A recent joint statement from the AIS, 
the International Federation of Sports Medicine and the Athlome Consortium concludes that 
there is no place for these tests in predicting injury risk. Similarly the AIS has taken a position 
on the use of these commercial tests in athletes, advising against doing so (Vlahovich, 
Fricker, Brown, & Hughes, 2016). In the future, when more research can provide satisfactory 
reproducible scientific evidence of genetic variants associated with the injury risk, these tests 
may benefit injury prevention, but currently the predictive power of these tests is negligible. 
Therefore, the genetic results, demonstrated in this study, may be utilised for the future 
attempts to compare genetic associations and reproduce these results. In order to gather 
more genetic data and explore the contribution of genetics to injury risk, effective 
collaboration and communication between research groups should be the key part of this 
type of research. This could improve the outcomes of the replication analyses, lead to better 
quality results produced by individual studies and collaborations, and provide more scientific 
evidence in this topic. 
This study was the first project involving GWAS research carried out by the AIS in 
collaboration within the CRN-AESS. This may provide the opportunity for the further genetic 
research in sports science and injury prevention. In conclusion, this project contributed to 
the understanding of running habits and injuries in Australian recreational runners and 
initiated GWAS analysis of Achilles tendon injuries and bone stress injuries in physically 
active, healthy individuals. Furthermore, these GWAS data are available for the further 
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As per Mokone 
et al. (2005) 
Polymorphisms 
rs71746744, rs16399, 
rs1134170 in COL5A1 3'-
UTR functional region 
are independently 
associated with chronic 
AT (p=0.008, OR=2, 
CI:1.2-3.3;  p=0.015, 
OR=1.7, CI:1.1-2.7;  
p=0.014, OR=1.8, CI: 1.1-
2.9 respectively). 
Polymorphism 
rs4919510 in MIR608 
gene is associated with 
chronic AT (p=0.023, 
OR=1.6, CI: 1.1-2.5).   
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rs3196378 and rs 
71746744 were found to 
increase risk of ATP and 
RUP (p=0.023, p=0.011). 
One of them was also 
significantly associated 
with the increased risk 
of TEN (p=0.011). 
Alternatively, the third 
inferred allele 
combination was shown 
to decrease risk of ATP 
and RUP (p=0.011, 
p=0.004). Inferred allele 
combinations were 
constructed from CASP8 
rs3834129 and 
rs1045485. One of them 
was significantly 
assocated with an 
increased risk of TEN 
(p=0.031). 
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(p=0.038) difference in 
the genotype 
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group. There was also a 
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distribution between 
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controls (p=0.038).  
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As per Mokone 
et al. (2005) 
FBN2 rs331079 variant 
was significantly 
associated with the risk 
of AT (p=0.035), but no 
association between the 
ELN rs2071307 variant 
and AT (p=0.795).  
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significantly associated 
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However, there was no 
association between this 
SNP and ATP. None of 
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ADAMTS2, ADAMTS5, 
ADAMTS14 and ADAM12 
genes were associated 
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AT subjects showed 
evidence of underlying 
dyslipidemia. They had 
higher triglyceride (TG) 
levels (P = 0.039), lower 
%HDL-C (P = 0.016), and 
higher TG/HDL-C ratio (P 
= 0.036) in comparison 
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regions visible in 
both the 
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Asymptomatic ATP was 
more evident in men 
(13%) than women (5%) 
(p = 0.007). Men with 
tendon pathology were 
older (50.9 ± 10.4, 36.3 ± 
11.3, p < 0.001), had 
greater WHR (0.926 ± 
0.091, 0.875 ± 0.065, p = 
0.039), higher 
android/gynoid fat mass 
ratio (0.616 ± 0.186, 
0.519 ± 0.142, p = 0.014) 
and higher upper-
body/lower body fat 
mass ratio (2.346 ± 
0.630, 2.022 ± 0.467, p = 
0.013). Men older than 
40 years with a waist 
circumference >83 cm 
had the greatest 
prevalence of tendon 
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Women with tendon 
pathology were older 
(47.4 ± 10.0, 36.0 ± 10.3, 
p = 0.008), had less total 
fat (17196 ± 3173 g, 
21626 ± 7882 g, p = 
0.009), trunk fat (7367 ± 
1662 g, 10087 ± 4152 g, 
p = 0.003) and android 
fat (1117 ± 324 g, 1616 ± 
811 g, p = 0.005). They 
had lower 
central/peripheral fat 
mass ratios (0.711 ± 
0.321 g, 0.922 ± 0.194 g, 
p = 0.004) than women 
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et al. (2005) 
MMP3 variant rs679620, 
rs3025058 was inferred 
and found to be 
associated with 
increased risk for AT 
within the SA group (p= 
0.012; OR: 2.88; 95%CI: 
1.4 to 6.1). The 6A-G-C-G 
haplotype, constructed 
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Age (yr) (mean 
± sd)  















from the investigated 
variants, was 
significantly associated 
with reduced risk for AT 
(29%CON vs. 20% TEN, P 
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As per Mokone 
et al. (2005) 
None of the three 
investigated 
polymorphisms within 
the COL11A1 (rs3753841 




associated with AT in the 
AUS, SA or combined 
cohorts. The main 
finding was the 
association of the TCT-
inferred 
pseudohaplotype, 
constructed from the 
three polymorphisms 
within COL11A1 
(rs3753841 T/C and 
rs1676486 C/T) and 
COL11A2 (rs17999079 
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Injury Definition Identified factors  
T/A), with an increased 
risk of AT (p<0.05). 
Longo, U. 




study/2b  85/94 
CON: 52.4 ± 
12.0; AT: 54.9 






was filled out by 
the participants 
in order to 
identify the 
presence of AT. If 
the score was 
less than 100, 
then they were 




There was no effect of 
gender on the presence 
of AT (p= 0.14). No 
significant track and field 
specialty effect upon the 
frequency of AT was 
found on the VISA-A 
questionnaire scores (p= 
0.32). There were no 
differences in age, 
weight, and height 
between athletes who 
did or did not suffer 
from Achilles 
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Appendix 2 – Summary table of studies of genetic polymorphisms 
associated with bone stress injuries 































of age N/A 100% F N/A 0 N/A 
Bone mineral 
density (BMD) 
BB genotype in VDR 
gene was associated 
with lower BMD in 
girls under 18 years 
of age (p=0.03) 






































CCAGGCAC (8 SNPs) 
haplotype of the 
VDR gene was 
associated with 
12.22-fold increased 
risk of SF (95%CI 
1.45-102.7, p = 
0.022). 
CGTTCTCCGA (10 
SNPs) haplotype of 
the CALCR gene was 
associated with 
1.93-fold increased 
risk of SF (95%CI 
1.11-3.50, p = 
0.00255). 
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Men Study 74±5.9 
100% 
M 27.6±3.9 0 N/A 
volumetric 
BMD (vBMD) 
Rs1877632 in SOST 
gene, rs1801197 in 
CALCR gene, 









in TGFBR3, MEPE, 
PTN, FGFR2, LEP, 
CSF1R and GNRH2 
were also 
associated with 
BMD in this study. 

























Ser37Ala variant of 
BMP2 gene was 
associated with 
osteoporotic 
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general 
population  
















































were  associated 
with stress fracture 
injuries and 
rs4355801(OPG) 
was associated with 
increased risk of 
multiple stress 
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In both MP and EA 
cohorts, rs3751143 





rs1718119 in P2X7R 
gene was associated 
with stress fractures 









Appendix 3 – Ethics application - Removed.
Appendix 4 – Ethics approval - Removed
Appendix 5 – Online Questionnaire  
The genetics of exercise-induced injuries in
tendon and bone
Page exit logic: Disqualify if user does not accept conditions
IF: Question "Do you accept to participate in this research study?" is one of the following
answers ("I DO NOT ACCEPT the conditions above") THEN: Disqualify and display:
You must accept the conditions of the survey to participate in this study. Thank you for your
time.
Principal Investigator
Dr David Hughes (Department of Sports Medicine, Australian Institute of Sport)
Co-Investigators
Dr Nicole Vlahovich, Dr Stacey Compton, Maria Kozlovskaia and Dr Renae Domaschenz (Department of Sports
Medicine, Australian Institute of Sport), A/Prof Bon Gray, A/Prof Lotti Tajouri, A/Prof Justin Keogh, A/Prof Mike
Climstein, Rebecca Grealy, A/Prof Kevin Ashton and Professor Nuala Byrne (Bond University), Professor Matthew
Brown and Dr Paul Leo (University of Queensland) and Professor Maria Fiatarone Singh, Dr Yorgi Mavros, Guy




You are invited to take part in this research project if you are:
A recreational runner
Aged 18 and over
Run over 15 km via 2-5 sessions per week
Please read the Participant Information Form carefully as this will tell you about the
research project and explain what is involved. This will help you decide if you want to
continue and take part.
Ask questions about anything that you don’t understand or want to know more about.
Before deciding whether or not to take part, you might want to talk about it with a relative,
friend or healthcare worker.
Participation
Participation in this study is entirely voluntary.
You’re not obliged to participate and if you do, you can withdraw at any time without
penalty or prejudice.
To participate, we would like you to complete this online questionnaire, providing details
of your medical history, injury history and running habits.
This survey should take no more than 30 minutes to complete.
You are able to exit the survey and complete at a later date using the link at the top of the
page.
Your participation, personal details and results will be strictly confidential and only the
principal researchers above will have access to this information
By ticking the 'I ACCEPT' option below you are telling us that you:
understand what you have read;
consent to take part in the research project;
consent to participate in the research processes that are described;
consent to the use of your personal and health information as described;
understand that you are free to not answer specific items or questions in interviews or
questionnaires;
understand that any data or answers to questions will remain confidential with regard to
your identity;
certify to the best of your knowledge and belief, you have no physical or mental illness or
weakness that would increase the risk of participating in this project;
are participating in this project of your own free will and have not been coerced in any way
to participate.
Do you accept to participate in this research study? *
Further information about the project is available in the Participant Information Form
Participant Information
I ACCEPT the conditions above
I DO NOT ACCEPT the conditions above
I wish to see more information about the project:
Page entry logic:
This page will show when: Question "Further information about the project is available in the
Participant Information Form" is one of the following answers ("I wish to see more information
about the project:")
What is the purpose of this study?
Identifying new genes or new mutations in known genes will help researchers to better
understand the relationship between lifestyle, health status and genetic profile and we hope
that this information will ultimately improve health and quality of life, prevent injury or disability,
and prevent or treat chronic diseases.
This research is being conducted by a collaboration between Bond University, the Australian
Institute of Sport, the University of Queensland and the University of Sydney.
What does participation in the research project involve?
Participation in this project involves the completion of an online questionnaire and the
agreement to be followed up by a researcher at the Australian Institute of Sport for the provision
of a saliva sample for genetic analysis. Not all participants will be followed up to provide a
genetic sample
What will happen to my questionnaire submission?
Your information will be stored in password protected databases. Information about you
including medical information that you provide will be treated in such a way that you cannot be
identified in publications, except with your permission. In any publication and/or presentation,
information will be provided in such a way that you cannot be identified, except with your
permission.
Any information obtained for the purpose of this research project that can identify you will be
treated as confidential and securely stored.  It will be disclosed only with your permission, or as
permitted by law.
What are the possible benefits to participating?
We cannot guarantee that you will receive any benefits from this research, but your participation
in the study may help doctors to better understand the relationship between lifestyle, health
status and genetic profile with the hope that this will ultimately improve health and quality of life,
prevent injury or disability, and prevent or treat chronic diseases.
What are the possible risks to participating in the study?
All medical information is stored in password protected databases.  It is possible, though very
unlikely, that someone could get access to this database without permission.  During the
research project, new information about the risks and benefits of the project may become known
to the researchers. If this occurs, you will be told about this new information and the researcher
will discuss whether this new information affects you.
If you become upset or distressed as a result of your participation in the research, the
researcher is able to arrange for counselling or other appropriate support. Any counselling or
support will be provided by staff who are not members of the research team. In addition, you
may prefer to suspend or end your participation in the research if distress occurs.
Can anyone participate in this study?
As long as you meet the criteria specified earlier, you are eligible to take part.  The research
team have allocated the research funding to areas in which the technology is most likely to find
new genes
 
Do I have to take part in this research project?
Participation in any research project is voluntary.  If you do not wish to take part then you don’t
have to.  If you decide to take part and later change your mind, you are free to withdraw at any
stage.  All information that you have provided can be destroyed at any time. You can withdraw
your consent to participate in this research project by emailing the Principal Investigator
at injurystudy@ausport.gov.au
Before you make a decision to participate in any follow up studies, a member of the research
team will contact you so that you can ask any questions you have about the project.  You can
ask for any information that you want. 
How will I be informed of results from of this research project?
In accordance with relevant Australian privacy and other relevant laws, you have the right to
access the information collected and stored by the researchers about you. You also have the
right to request that any information, with which you disagree, be corrected. Please contact one
of the researchers named at the end of this document if you would like to access your
information.
Is this research project approved?
This project will be carried out according to the National Statement on Ethical Conduct in
Research Involving Humans (2007) produced by the National Health and Medical Research
Council of Australia.  This statement has been developed to protect the interests of people who
agree to participate in human research studies.
The ethical aspects of this research project have been approved by the Bond University Human
Research Ethics Committee, protocol number RO1688B.
Will I get paid to participate in this study?
You will not be paid for participating in this study. Participation by completion of the online
survey will enable the participant to be entered into a draw to win a $50 voucher to a sporting
goods store or similar. This draw will be done randomly allowing for a 1 in 200 chance of
'winning' the voucher.
Who can I contact if I have any questions or problems in relation to this study?
If you wish to discuss further the experimental procedure or have any questions, please do not
hesitate to contact Dr Nicole Vlahovich or Dr Renae Domaschenz phone (02) 6214 1578 or
email injurystudy@ausport.gov.au 
If you have any concerns with respect to the conduct of this study, you may contact the
Secretary of the Bond University Human Research Ethics Committee Dr Lisa Marlow on (07)
5595 4194 or by email lmarlow@bond.edu.au
 
Your Personal Details
Page exit logic: Year of birth disqualification
IF: Question "What year were you born?" is greater than "1997" THEN: Disqualify and display:
We're sorry, you must be aged 18 or older to participate in this study. Thank you for your time.
1. Please enter your contact information here:
2. Please enter your personal details here














What year were you born? *






























































3. What is your country of birth?
4. What is your country of citizenship?
Height (cm) *
I give permission, if I am eligible, to be contacted in the future for related research *
Yes
No
I give permission, if I am eligible, to be contacted in the future to provide a saliva sample for













































6. Which is your dominate leg* (used for kicking a ball)? *If you are unsure please choose
according to whether you are left or right handed
7. How many years have you been running on a regular* basis? *Regular is defined as at least
weekly.
< 1 1 2 3 4 5 6 7 8 9 10 +
Years < 1 1 2 3 4 5 6 7 8 9 10 +
8. On average, how many km per week would you run?
<15 15-20 20-30 30-40 40-50 50-60 60 +
Km <15 15-20 20-30 30-40 40-50 50-60 60 +
9. Do you run every day?
10. For an average week, please indicate how many running sessions you participate in.
1 2-3 4-5 6+






11. What type of terrain is the majority of your running performed on?
12. What is your current race pace in min/km?
> 7 6-7 5-6 4-5 < 4
min/km > 7 6-7 5-6 4-5 < 4
13. Do you spend time stretching in association with your running session?
14. If Yes, when do you stretch?
Bitumen
Cement







 Hidden unless: Question "Do you spend time stretching in association with your running
session?" #13 is one of the following answers ("Yes")
Before running
After running




15. While running do you wear orthotics?
16. If Yes, which foot?
17. If Yes, are they custom made?
18. What proportion of your running is: (please ensure that total of all entries equals 100%)
*minimalist means with no support or cushioning, e.g. aqua shoes, vibram five fingers (does not




 Hidden unless: Question "While running do you wear orthotics?" #15 is one of the




 Hidden unless: Question "While running do you wear orthotics?" #15 is one of the
following answers ("Yes") Dynamically shown if "While running do you wear orthotics?" = Yes
Yes
No
with standard running shoes?
with minimalist running shoes?
barefoot?
0 out of 100 Total
19. In the last two years have you participated in any other sports or intentional exercise on a
regular basis (for example weekly during at least one season)?
20. If yes, what sports? (please list all)
Running Related Injuries
21. In the last 2 years have you had any injuries of the lower limbs, which have forced you to




 Hidden unless: Question "In the last two years have you participated in any other sports or
intentional exercise on a regular basis (for example weekly during at least one season)?" #19 is
one of the following answers ("Yes") Dynamically shown if "In the last two years have you
participated in any other sports or intentional exercise on a regular basis (for example weekly




22. If Yes, How many lower limb injuries have you been diagnosed with in the past 2 years?
Injury 1 - Your Most Recent Injury
Page entry logic:
This page will show when: (Question "In the last 2 years have you had any injuries of the lower
limbs, which have forced you to discontinue running for a period of 2 weeks or more?" #21 is
one of the following answers ("Yes") AND Question "If Yes, How many lower limb injuries have
you been diagnosed with in the past 2 years?" #22 is one of the following answers
("1","2","3","4 +"))
Please answer the following questions in relation to your most recent lower limb injury.
23. You indicated that you have been diagnosed with a lower limb injury within the past 2 years
How did this injury occur?
 Hidden unless: Question "In the last 2 years have you had any injuries of the lower limbs,
which have forced you to discontinue running for a period of 2 weeks or more?" #21 is one of
the following answers ("Yes") Dynamically shown if "In the last 2 years have you had any
injuries of the lower limbs, which have forced you to discontinue running for a period of 2 weeks







due to a fall
during participation in another sport
other
24. Was this injury diagnosed by a professional:
Yes No
Doctor? Yes No
Physical Therapist? Yes No
25. Was this injury diagnosed by imaging (x-ray/ultrasound/bone scan/CT scan/MRI)?
26. If imaging, what type of diagnostic imaging?
27. Do you have a copy of the report of the imaging findings?
Yes
No
 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone






 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone
scan/CT scan/MRI)?" #25 is one of the following answers ("Yes")
Yes
No
28. Was the injury an Achilles tendon injury?
29. If Yes, which leg?
30. Was the injury a bone stress injury below the knee?
31. If yes, which leg?
Yes
No









 Hidden unless: Question "Was the injury a bone stress injury below the knee?" #30 is one




32. Was your injury a different injury (other than an Achilles tendon or bone stress injury)?
33. What type of injury was it?
34. Please provide details of the signs and symptoms of the injury (tick all that apply):
 Hidden unless: (Question "Was the injury an Achilles tendon injury?" #28 is one of the
following answers ("No") AND Question "Was the injury a bone stress injury below the knee?"
#30 is one of the following answers ("No"))
Yes
No
 Hidden unless: Question "Was your injury a different injury (other than an Achilles tendon













35. When is/was your pain at its worst?
36. As a result of this injury, how many weeks did you discontinue running?
1 2 3 4 5 6 6 +
weeks 1 2 3 4 5 6 6 +
37. How and when did your symptoms start?
38. What type of treatment did you have in association with this injury?




unable to exercise due to pain
sudden onset after injury





39. What type of treatment did you have in association with this injury?
40. If medication please provide details
41. Had you made any changes to your regular training program just prior to the onset of injury?
(for example, increase in training load, change in footwear, change in terrain)
42. If yes, please provide details:
 Hidden unless: Question "What type of treatment did you have in association with this





 Hidden unless: Question "What type of treatment did you have in association with this
injury?" #39 is one of the following answers ("medication")
Yes
No
 Hidden unless: Question "Had you made any changes to your regular training program
just prior to the onset of injury?
(for example, increase in training load, change in footwear, change in terrain)" #41 is one of the
following answers ("Yes")
43. Had you begun or changed your participation in any new exercise other than running prior
to the injury?
(for example basketball, touch football, tennis, another sport etc.)
44. If yes, please provide details:
45. Please upload any associated medical reports in relation to this injury.
You may upload a scanned report/image or a smartphone picture of the report/image (accepted
file types include png, jpg, doc, xls, docx, xlsx, pdf, txt maximum file size 1 MB).
46. If you do not have the medical reports, do you give us permission to contact your health care
provider to obtain reports relevant to this injury?
Yes
No
 Hidden unless: Question "Had you begun or changed your participation in any new
exercise other than running prior to the injury?
(for example basketball, touch football, tennis, another sport etc.)" #43 is one of the following
answers ("Yes")




47. Please provide name and contact details of the medical provider who holds these records.
We will send you a permission slip to sign and a stamped envelope addressed to this medical
provider.
This is necessary for the release of your records to us for this survey.
Name of medical provider:
Address of medical provider:
Phone contact for medical provider:
Injury 2 - Your Second Most Recent Injury
Page entry logic:
This page will show when: (Question "In the last 2 years have you had any injuries of the lower
limbs, which have forced you to discontinue running for a period of 2 weeks or more?" #21 is
one of the following answers ("Yes") AND Question "If Yes, How many lower limb injuries have
you been diagnosed with in the past 2 years?" #22 is one of the following answers ("2","3","4
+"))
Please answer the following questions in relation to your second most recent lower limb
injury.
 Hidden unless: Question "If you do not have the medical reports, do you give us
permission to contact your health care provider to obtain reports relevant to this injury?" #46 is
one of the following answers ("Yes")
48. You indicated that you have been diagnosed with more than 1 lower limb injury within the
past 2 years
How did this injury occur?
49. Was this injury diagnosed by a professional:
Yes No
Doctor? Yes No
Physical Therapist? Yes No
50. Was this injury diagnosed by imaging (x-ray/ultrasound/bone scan/CT scan/MRI)?
while running
while walking
due to a fall




51. If imaging, what type of diagnostic imaging?
52. Do you have a copy of the report of the imaging findings?
53. Was the injury an Achilles tendon injury?
54. If Yes, which leg?
 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone






 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone










55. Was the injury a bone stress injury below the knee?
56. If yes, which leg?
57. Was your injury a different injury (other than an Achilles tendon or bone stress injury)?
58. What type of injury was it?




 Hidden unless: Question "Was the injury a bone stress injury below the knee?" #55 is one




 Hidden unless: (Question "Was the injury an Achilles tendon injury?" #53 is one of the
following answers ("No") AND Question "Was the injury a bone stress injury below the knee?"
#55 is one of the following answers ("No"))
Yes
No
 Hidden unless: Question "Was your injury a different injury (other than an Achilles tendon
or bone stress injury)?" #57 is one of the following answers ("Yes")
59. Please provide details of the signs and symptoms of the injury (tick all that apply):

















unable to exercise due to pain
61. As a result of this injury, how many weeks did you discontinue running?
1 2 3 4 5 6 6 +
weeks 1 2 3 4 5 6 6 +
62. How and when did your symptoms start?
63. What type of treatment did you have in association with this injury?
64. What type of treatment did you have in association with this injury?
sudden onset after injury





 Hidden unless: Question "What type of treatment did you have in association with this





65. If medication please provide details
66. Had you made any changes to your regular training program just prior to the onset of injury?
(for example, increase in training load, change in footwear, change in terrain)
67. If yes, please provide details:
68. Had you begun or changed your participation in any new exercise other than running prior
to the injury?
(for example basketball, touch football, tennis, another sport etc.)
 Hidden unless: Question "What type of treatment did you have in association with this
injury?" #64 is one of the following answers ("medication")
Yes
No
 Hidden unless: Question "Had you made any changes to your regular training program
just prior to the onset of injury?




69. If yes, please provide details:
70. Please upload any associated medical reports in relation to this injury.
You may upload a scanned report/image or a smartphone picture of the report/image (accepted
file types include png, jpg, doc, xls, docx, xlsx, pdf, txt maximum file size 1 MB).
71. If you do not have the medical reports, do you give us permission to contact your health care
provider to obtain reports relevant to this injury?
 Hidden unless: Question "Had you begun or changed your participation in any new
exercise other than running prior to the injury?
(for example basketball, touch football, tennis, another sport etc.)" #68 is one of the following
answers ("Yes")




72. Please provide name and contact details of the medical provider who holds these records.
We will send you a permission slip to sign and a stamped envelope addressed to this medical
provider.
This is necessary for the release of your records to us for this survey.
Name of medical provider:
Address of medical provider:
Phone contact for medical provider:
Re-occuring Injury
Page entry logic:
This page will show when: Question "If Yes, How many lower limb injuries have you been
diagnosed with in the past 2 years?" #22 is one of the following answers ("2","3","4 +")
73. You have indicated that you have had more than one lower limb injury.
Was the diagnosis of the 2nd injury the same as the first injury?
 Hidden unless: Question "If you do not have the medical reports, do you give us
permission to contact your health care provider to obtain reports relevant to this injury?" #71 is




74. If yes, was it the same foot/leg?




76. Were the symptoms of the second injury the same, better or worse than the first injury?
77. Was the treatment the same for both injuries?
 Hidden unless: Question "You have indicated that you have had more than one lower
limb injury.
Was the diagnosis of the 2nd injury the same as the first injury?" #73 is one of the following
answers ("Yes") Dynamically shown if "You have indicated that you have had more than one
lower limb injury.








78. Was the recovery longer, shorter or similar in duration?
79. Do you have a family history of exercise-related or other lower extremity injury?
80. If yes, was it:
Yes No
bone stress? Yes No
Achilles tendinopathy? Yes No







 Hidden unless: Question "Do you have a family history of exercise-related or other lower
extremity injury?" #79 is one of the following answers ("Yes") Dynamically shown if "Do you
have a family history of exercise-related or other lower extremity injury?" = Yes
81. What family member did it occur in?
- check as many as relevant
Injury 3 - Your Third Most Recent Injury
Page entry logic:
This page will show when: Question "If Yes, How many lower limb injuries have you been
diagnosed with in the past 2 years?" #22 is one of the following answers ("3","4 +")
Please answer the following questions in relation to your third most recent lower limb injury.
 Hidden unless: Question "Do you have a family history of exercise-related or other lower
extremity injury?" #79 is one of the following answers ("Yes") Dynamically shown if "Do you















82. You indicated that you have been diagnosed with more than 1 lower limb injury within the
past 2 years
How did this injury occur?
83. Was this injury diagnosed by a professional:
Yes No
Doctor? Yes No
Physical Therapist? Yes No
84. Was this injury diagnosed by imaging (x-ray/ultrasound/bone scan/CT scan/MRI)?
while running
while walking
due to a fall




85. If imaging, what type of diagnostic imaging?
86. Do you have a copy of the report of the imaging findings?
87. Was the injury an Achilles tendon injury?
88. If Yes, which leg?
 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone






 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone










89. Was the injury a bone stress injury below the knee?
90. If yes, which leg?
91. Was your injury a different injury (other than an Achilles tendon or bone stress injury)?
92. What type of injury was it?




 Hidden unless: Question "Was the injury a bone stress injury below the knee?" #89 is one




 Hidden unless: (Question "Was the injury an Achilles tendon injury?" #87 is one of the
following answers ("No") AND Question "Was the injury a bone stress injury below the knee?"
#89 is one of the following answers ("No"))
Yes
No
 Hidden unless: Question "Was your injury a different injury (other than an Achilles tendon
or bone stress injury)?" #91 is one of the following answers ("Yes")
93. Please provide details of the signs and symptoms of the injury (tick all that apply):

















unable to exercise due to pain
95. As a result of this injury, how many weeks did you discontinue running?
1 2 3 4 5 6 6 +
weeks 1 2 3 4 5 6 6 +
96. How and when did your symptoms start?
97. What type of treatment did you have in association with this injury?
98. What type of treatment did you have in association with this injury?
sudden onset after injury





 Hidden unless: Question "What type of treatment did you have in association with this





99. If medication please provide details
100. Had you made any changes to your regular training program just prior to the onset of
injury?
(for example, increase in training load, change in footwear, change in terrain)
101. If yes, please provide details:
102. Had you begun or changed your participation in any new exercise other than running prior
to the injury?
(for example basketball, touch football, tennis, another sport etc.)
 Hidden unless: Question "What type of treatment did you have in association with this
injury?" #98 is one of the following answers ("medication")
Yes
No
 Hidden unless: Question "Had you made any changes to your regular training program
just prior to the onset of injury?
(for example, increase in training load, change in footwear, change in terrain)" #100 is one of
the following answers ("Yes")
Yes
No
103. If yes, please provide details:
104. Please upload any associated medical reports in relation to this injury.
You may upload a scanned report/image or a smartphone picture of the report/image (accepted
file types include png, jpg, doc, xls, docx, xlsx, pdf, txt maximum file size 1 MB).
105. If you do not have the medical reports, do you give us permission to contact your health
care provider to obtain reports relevant to this injury?
 Hidden unless: Question "Had you begun or changed your participation in any new
exercise other than running prior to the injury?
(for example basketball, touch football, tennis, another sport etc.)" #102 is one of the following
answers ("Yes")




106. Please provide name and contact details of the medical provider who holds these records.
We will send you a permission slip to sign and a stamped envelope addressed to this medical
provider.
This is necessary for the release of your records to us for this survey.
Name of medical provider:
Address of medical provider:
Phone contact for medical provider:
Injury 4 - Your Fourth Most Recent Injury
Page entry logic:
This page will show when: Question "If Yes, How many lower limb injuries have you been
diagnosed with in the past 2 years?" #22 is one of the following answers ("4 +")
Please answer the following questions in relation to your fourth most recent lower limb
injury.
 Hidden unless: Question "If you do not have the medical reports, do you give us
permission to contact your health care provider to obtain reports relevant to this injury?" #105 is
one of the following answers ("Yes")
107. You indicated that you have been diagnosed with more than 1 lower limb injury within the
past 2 years
How did this injury occur?
108. Was this injury diagnosed by a professional:
Yes No
Doctor? Yes No
Physical Therapist? Yes No
109. Was this injury diagnosed by imaging (x-ray/ultrasound/bone scan/CT scan/MRI)?
while running
while walking
due to a fall




110. If imaging, what type of diagnostic imaging?
111. Do you have a copy of the report of the imaging findings?
112. Was the injury an Achilles tendon injury?
113. If Yes, which leg?
 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone






 Hidden unless: Question "Was this injury diagnosed by imaging (x-ray/ultrasound/bone










114. Was the injury a bone stress injury below the knee?
115. If yes, which leg?
116. Was your injury a different injury (other than an Achilles tendon or bone stress injury)?
117. What type of injury was it?




 Hidden unless: Question "Was the injury a bone stress injury below the knee?" #114 is




 Hidden unless: (Question "Was the injury an Achilles tendon injury?" #112 is one of the
following answers ("No") AND Question "Was the injury a bone stress injury below the knee?"
#114 is one of the following answers ("No"))
Yes
No
 Hidden unless: Question "Was your injury a different injury (other than an Achilles tendon
or bone stress injury)?" #116 is one of the following answers ("Yes")
118. Please provide details of the signs and symptoms of the injury (tick all that apply):

















unable to exercise due to pain
120. As a result of this injury, how many weeks did you discontinue running?
1 2 3 4 5 6 6 +
weeks 1 2 3 4 5 6 6 +
121. How and when did your symptoms start?
122. What type of treatment did you have in association with this injury?
123. What type of treatment did you have in association with this injury?
sudden onset after injury





 Hidden unless: Question "What type of treatment did you have in association with this





124. If medication please provide details
125. Had you made any changes to your regular training program just prior to the onset of
injury?
(for example, increase in training load, change in footwear, change in terrain)
126. If yes, please provide details:
127. Had you begun or changed your participation in any new exercise other than running prior
to the injury?
(for example basketball, touch football, tennis, another sport etc.)
 Hidden unless: Question "What type of treatment did you have in association with this
injury?" #123 is one of the following answers ("medication")
Yes
No
 Hidden unless: Question "Had you made any changes to your regular training program
just prior to the onset of injury?
(for example, increase in training load, change in footwear, change in terrain)" #125 is one of
the following answers ("Yes")
Yes
No
128. If yes, please provide details:
129. Please upload any associated medical reports in relation to this injury.
You may upload a scanned report/image or a smartphone picture of the report/image (accepted
file types include png, jpg, doc, xls, docx, xlsx, pdf, txt maximum file size 1 MB).
130. If you do not have the medical reports, do you give us permission to contact your health
care provider to obtain reports relevant to this injury?
 Hidden unless: Question "Had you begun or changed your participation in any new
exercise other than running prior to the injury?
(for example basketball, touch football, tennis, another sport etc.)" #127 is one of the following
answers ("Yes")




131. Please provide name and contact details of the medical provider who holds these records.
We will send you a permission slip to sign and a stamped envelope addressed to this medical
provider.
This is necessary for the release of your records to us for this survey.
Name of medical provider:
Address of medical provider:
Phone contact for medical provider:
General Health Questions
132. Have you ever smoked cigarettes?
133. If Yes, at what age did you start smoking?
134. Do you currently smoke?
 Hidden unless: Question "If you do not have the medical reports, do you give us
permission to contact your health care provider to obtain reports relevant to this injury?" #130 is




 Dynamically shown if "Have you ever smoked cigarettes?" = Yes
Show/hide trigger exists. Dynamically shown if "Have you ever smoked cigarettes?" = Yes
Yes
No
135. If Yes, how many cigarettes per day on average?
136. If No, at what age did you quit?
137. When you were smoking, on average how many cigarettes per day would you smoke over
the years until you quit?
138. Do you ever consume alcoholic drinks?
139. If yes, approximately how many standard drinks would you consume per week? Examples
of standard drinks include 100ml of wine, a bottle of mid-strength beer, a 285ml glass(midi) of
full strength beer or a 30ml nip of spirits.
1-3 4-6 7-10 10 +
drinks 1-3 4-6 7-10 10 +
General Health Questions
 Dynamically shown if "Do you currently smoke?" = Yes
 Dynamically shown if "Do you currently smoke?" = No




 Dynamically shown if "Do you ever consume alcoholic drinks?" = Yes
140. Have you ever been diagnosed with any of the following conditions/disorders?
Yes No
any type of cancer Yes No
chronic renal failure Yes No




cystic fibrosis Yes No
cerebral palsy Yes No
cardiac conditions Yes No
high blood pressure Yes No
anaemia Yes No
skin diseases Yes No
thyroid disease Yes No
gastrointestinal disease Yes No
depression Yes No
insomnia Yes No
respiratory conditions Yes No
neurological conditions Yes No
other Yes No




















Where was the fracture?
When did it occur?
What treatment did you receive?
145. Do you have a family history of osteoporosis?
146. To your knowledge, have you ever been treated using quinolone antibiotics (for example
ciprofloxacin, norfloxacin)?
147. If yes, were you treated using these antibiotics within the 6 months prior to your injury?








 Dynamically shown if "To your knowledge, have you ever been treated using quinolone




148. To your knowledge, have you ever been treated using anti-seizure or epilepsy medications
(for example clonazepam, gabapentin, lamotrigine, sodium valproate)?
149. To your knowledge, have you ever been treated using corticosteriod medication (for
example cortisone injection, prednisone tablets, prednisolone tablets, flixotide inhaler, pulmicort
inhaler, QVAR inhaler, seretide accuhaler, symbicort turbuhaler, steriod cream)?








Show/hide trigger exists. Dynamically shown if "To your knowledge, have you ever been
treated using corticosteriod medication (for example cortisone injection, prednisone tablets,
prednisolone tablets, flixotide inhaler, pulmicort inhaler, QVAR inhaler, seretide accuhaler,





151. Which type of inhaler?
General Health Questions
152. To your knowledge, have you ever been treated using calcium tablets as prescribed by a
medical doctor or taken it without a prescription?
153. Do you take calcium tablets on a regular basis?
154. If yes, please provide details of dose and brand:
Dose
Brand





Show/hide trigger exists. Dynamically shown if "To your knowledge, have you ever been




 Dynamically shown if "Do you take calcium tablets on a regular basis?" = Yes
155. To your knowledge, have you ever been treated using vitamin D supplementation as
prescribed by a medical doctor or taken it without prescription?
156. Do you take vitamin D supplementation on a regular basis?







Show/hide trigger exists. Dynamically shown if "To your knowledge, have you ever been




 Dynamically shown if "Do you take vitamin D supplementation on a regular basis?" = Yes
158. To your knowledge, have you ever
Yes No Unsure
been treated using bisphosphonates
(for example actonel, Didrocal, alendronate sodium, zoledronic
acid)?
Yes No Unsure
undergone chemotherapy? Yes No Unsure
undergone a bone marrow or organ transplant? Yes No Unsure
159. Are you regularly taking, or have you ever taken, any other regular medication as
prescribed by a medical doctor?
160. If yes, please list medications
161. Are you regularly taking, or in the past have you regularly taken any other over-the-counter




 Dynamically shown if "Are you regularly taking, or have you ever taken, any other regular
medication as prescribed by a medical doctor?" = Yes
Yes
No
162. If yes, please list any other medications/supplements
Dietary Habits
163. Would you say that food dominates your life?
 Hidden unless: Question "Are you regularly taking, or in the past have you regularly taken
any other over-the-counter medications, dietary supplements or sports supplements?" #161 is
















Currently suffer with or have you ever suffered in the past with an eating
disorder? Yes No
Make yourself sick because you feel uncomfortably full? Yes No
Worry you have lost control over how much you eat? Yes No
Believe yourself to be fat when others say you are too thin? Yes No
165. Have you recently lost more than 6kgs in a 3 month period?







167. If Yes, please indicate the amount of weight gained/lost
weight gain (kgs)
weight lost (kgs)
reason (if any known)
168. Do you follow any of the diets below:
Yes No
Vegetarian? Yes No




Low carb/High Fat? Yes No
169. Do you follow a gluten free diet?
 Dynamically shown if "Have you undergone any significant (greater than 5 kg) weight




170. If yes, please provide the reason why you follow this diet
171. Do you have any food allergies or avoidances?
172. If yes,
Food type Reason for avoidance
1
Food type Reason for avoidance
2
Food type Reason for avoidance
3
Food type Reason for avoidance
4
Food type Reason for avoidance
 Dynamically shown if "Do you follow a gluten free diet?" = Yes
Coeliac disease







 Dynamically shown if "Do you have any food allergies or avoidances?" = Yes
Female Health Questions
Page entry logic:
This page will show when: Question "Sex" is one of the following answers ("Female")
173. Are you currently taking or have you ever taken the contraceptive pill?
174. If yes, how long have you or did you take the contraceptive pill?
< 1 year 1-2 years 3-5 years 5 + years
Length of time < 1 year 1-2 years 3-5 years 5 + years
175. What was the name of the contraceptive pill you were taking?




 Dynamically shown if "Are you currently taking or have you ever taken the contraceptive
pill?" = Yes











178. What is the regular length of your menstrual cycle?
I don't have a period Irregular < 26 days 27 - 31 days > 31 days
Cycle
length








179. Please provide a reason why you don't have a period:
180. Have you gone through menopause?
 Dynamically shown if "Do you have any children?" = Yes
Show/hide trigger exists.





181. If yes, at what age did you go through menopause?
182. Was the menopause:
183. Have you experienced amenorrhea (absence of menstrual periods) or oligomenorrhea
(infrequent or irregular menstruation) or menorrhagia (excessive menstruation)?






























 Dynamically shown if "Have you gone through menopause?" = Yes





Thank You for Participating!
If you have indicated and are eligible, you may be contacted in the future to provide a saliva
sample for analysis.
You have been entered into the draw to win one of 50 vouchers to spend $50 high performance
sportswear from 2XU.COM.AU.
For more information on the Collaborative Research Network's research activities please visit the CRN
website.
If you have any further questions, please do not hesitate to contact Dr Nicole Vlahovich or Dr Renae
Domaschenz phone (02) 6214 7319 or email injurystudy@ausport.gov.au 
See terms and conditions for voucher giveaway.
Permit No ACT TP 14/03056















































Appendix 7 – Facebook advertisement example

Appendix 8 – Participant information about the genetic  research
Participant Number: AIS 
Participant Information Sheet/Consent Form 
A study to investigate the relationship between genes, physical activity and health 
status. 
Title The genetics of exercise-induced injuries 
involving tendon and bone 
Protocol Number RO21688B 
Project Sponsor CRN for Advancing Exercise & Sports Science 
Principal Investigator Dr David Hughes 
Associate Investigator(s) Dr Nicole Vlahovich, Maria Kozlovskaia 
(Department of Sports Medicine, Australian 
Institute of Sport), A/Prof Bon Gray, A/Prof Lotti 
Tajouri, A/Prof Justin Keogh, A/Prof Mike 
Climstein, Rebecca Grealy, A/Prof Kevin Ashton 
and Professor Nuala Byrne (Bond University), 
Professor Matthew Brown and Dr Paul Leo 
(University of Queensland) and Professor Maria 
Fiatarone Singh, Dr Yorgi Mavros, Guy Wilson 
and Jacinda Meiklejohn (University of Sydney). 
Location Australian Institute of Sport, Bond University & 
CRN partner organisations 
Introduction 
You are invited to take part in this research project because you completed the online survey 
for the study the genetics of exercise-induced injuries involving tendon and bone, agreeing 
to follow up genetic analysis and you are: 
 A recreational runner,
 Aged 18-50 years of age,
 Run greater than 15km per week, and
 Fall into one of the following categories:
o Uninjured* for the past two years (*no  injury below the knee due to running
that required you to discontinue running for a period of 2 weeks or more)
o Diagnosed with a below knee bone stress injury caused by running, by a
physician or physiotherapist and confirmed by diagnostic imaging, in the last
2 years
o Diagnosed with Achilles tendinopathy or Achilles tendinitis caused by running,
by a physician or physiotherapist in the last 2 years
The Participant Information and Consent Forms tell you about the research project. It 
explains the procedures involved. Knowing what is involved will help you decide if you want 
to take part in the research. 
 Participant Number: 
 
AIS 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or healthcare worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. 
You will receive the best possible care whether you take part or not. You’re not obliged to 
participate and if you do, you can withdraw at any time without penalty or prejudice and any 
samples that you have provided will be disposed of. 
 
If you agree to participate in this study, we would like you to complete the enclosed 
paperwork and provide a saliva sample according to the enclosed instructions. 
 
All aspects of the study including your personal details and results will be strictly confidential 
and only the principal researchers above will have access to this information.  
 
If you decide you want to take part in the research project, you will be asked to sign the 
consent section. By signing it you are telling us that you: 
 understand what you have read;  
 consent to take part in the research project; 
 consent to participate in the research processes that are described; 
 consent to the use of your personal and health information as described 
 certify to the best of your knowledge and belief, you have no physical or mental 
illness or weakness that would increase the risk to of participating in this 
investigation; 
 are participating in this project of your own free will and have not been coerced in any 
way to participate; 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
What is the purpose of this study? 
Identifying sequences or new mutations in known genes will help researchers to better 
understand the relationship between lifestyle, health status and genetic profile and we hope 
that this information will ultimately improve health and quality of life, prevent injury or 
disability, and prevent or treat chronic diseases. The genetic sequence information will 
provide new insights into the genetic factors associated with exercise-induced injuries in 
recreational and elite athletes.  
 
This research is being conducted by a collaboration between Bond University, the Australian 
Institute of Sport, the University of Queensland and the University of Sydney. 
 
What does participation in the research project involve? 
Participation is this portion of the project involves the provision of a saliva sample for genetic 
analysis. Enclosed are the consent forms to read and sign, a kit that will help you collect the 
specimen and return envelope to return your sample. This process should take 
approximately 10-15 minutes.  
 
What are the possible benefits to participating? 
We cannot guarantee that you will receive any benefits from this research, but your 
participation in the study may help doctors to better understand the relationship between 
lifestyle, health status and genetic profile with the hope that this will ultimately improve health 
and quality of life, prevent injury or disability, and prevent or treat chronic diseases.   
 
 Participant Number: 
 
AIS 
What will happen to my test sample and what are the possible risks to participating in 
the study? 
Please see the document The Ethics of Genetic Research 
 
What if new information arises? 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information 
and the researcher will discuss whether this new information affects you. 
 
Can anyone participate in this study? 
As long as you meet the criteria specified earlier, and have participated in the online survey, 
you are eligible to take part.   
 
Do I have to take part in this research project? 
If you do not wish to take part then you don’t have to.  If you decide to take part and later 
change your mind, you are free to withdraw at any stage.  All information that you have 
provided can be destroyed at any time. You can withdraw your consent to participate in this 
research project by emailing the Principal Investigator at injurystudy@ausport.gov.au 
 
Before you make a decision to participate in any follow up studies, a member of the research 
team will contact you so that you can ask any questions you have about the project.  You 
can ask for any information that you want.   
Is this research project approved? 
This project will be carried out according to the National Statement on Ethical Conduct in 
Research Involving Humans (2007) produced by the National Health and Medical Research 
Council of Australia.  This statement has been developed to protect the interests of people 
who agree to participate in human research studies. 
 
The ethical aspects of this research project have been approved by Bond University Human 
Research Ethics Committee; protocol number RO21688B, contact Dr Lisa Marlow, Research 
Ethics Manager on (07) 5595 4194.      
 
Will I get paid to participate in this study? 
You will not be paid for participating in this study but all costs such as expenses involved 
with any investigation, posting of forms, questionnaires and samples will be covered 
 
Who can I contact if I have any questions or problems in relation to this study? 
If you wish to discuss further the experimental procedure or have any questions, please do 
not hesitate to contact Dr Nicole Vlahovich phone (02) 6214 7319 or email 
injurystudy@ausport.gov.au 
If you have any concerns with respect to the conduct of this study, you may contact the 
Secretary of the Bond University Human Research Ethics Committee Dr Lisa Marlow on (07) 





Participant Number: AIS 
The genetics of exercise-induced injuries involving tendon and bone information 
sheet 
Genetic Sample and Data Consent 
Principal Investigator: Dr David Hughes 
Statement of Informed Consent for Genetic Sample and Data Collection 
I have read, or had read to me in a language that I understand, this Participant Information 
Sheet and I understand the purposes, procedures and risks of this research project as 
described within it.  I have had the opportunity to ask questions and I am satisfied with the 
answers I have received. 
I give permission for my anonymised sample and/or clinical information to be shared 
by the Investigators of this study with collaborating researchers who have ethically 
approved studies and are researching the relationship between genes, physical 
activity and health status. 
I give permission for my anonymised sample and/or clinical information to be part of 
the Biobank, to be shared with other researchers who have ethically approved 
studies and are researching the relationship between genes, physical activity and 
health status. 
I understand that there is a very small chance that this study could identify a genetic defect 
that increases my risk for an unrelated condition. 
I would like to be informed if a risk factor for a treatable condition is 
identified 
I would NOT like to be informed if a risk factor for a treatable condition is 
identified 
I understand that I will not receive genetic results for conditions where there is no known 
treatment at the time the result becomes available. 
I understand that, due to the type of genetic test being performed, participation in this 
research project will not provide me with a clearance from any genetic or heritable 
conditions.   
I freely agree to participate in this research project as described. 
Name of Participant  Date  Signature of Participant 
Name of Researcher  Date  Signature of Researcher  
Appendix   9 – The ethics of genetic research
The Ethics and Risks Associated with 
Genetic Research  
A study to investigate the relationship between genes, physical activity and health 
status. 
What is genetic research? 
Genes are made of DNA – the chemical structure carrying your genetic information that 
determines many human characteristics such as the colour of your eyes. Researchers study 
how genes are expressed in order to understand why some people differ in their response to 
exercise and to develop, improved and individualised approaches to exercise prescription. 
This will potentially provide new ways in which to reduce disease within the wider community 
What will happen to my test sample? 
Saliva samples will be used immediately or stored for future studies. Saliva samples will be 
used to extract your DNA.  DNA sequence and other information obtained in this research 
project will be stored securely, with each participant sample allocated a specific code 
number. All data processing will occur by use of this number and not the participant’s name. 
However all samples are potentially re-identifiable and must remain so to satisfy the aims of 
the research and also to identify participants if required for the return of genetic information.  
The samples will be tested using genome-wide association studies. These studies are 
increasingly being used to identify biological pathways and networks underlying complex 
diseases. This type of genetic test is very unlikely to identify mutations associated with 
heritable diseases as it will not provide information about the whole genome, only portions of 
the genome which are unlikely to contain genes relating to disease.  
Researchers from the Australian Institute of Sport (Canberra), University of Queensland 
(Brisbane), the University of Sydney and Bond University (Gold Coast, Queensland) are 
collaborating to study your DNA samples for research only.  We may also share some 
information about your clinical information in our research group but all identifiers will be 
removed. All medical information is stored in password protected databases. 
We will also be establishing a biobank – this is a way of collecting and storing anonymous 
biological material and information for further research.  If you consent, your DNA will be 
stored and then can be used by other researchers for future projects.   
What are the possible risks of participating in the study?
All medical information is stored in password protected databases.  It is possible, though 
highly unlikely, that someone could get access to this database without permission. All 
samples and participant data will be stored securely in locked facilities.  
This type of genetic test is very unlikely to identify mutations associated with heritable 
diseases.  However, as part of this study there is a small chance that we might coincidentally 
find a defect in a gene which, in the duration of the project, may be identified as being 
associated with an increased risk for a genetic condition. If the condition is treatable or 
preventable, you can specify on the consent form if you want to be informed about such a 
finding. Learning this information may be upsetting. It could also affect your ability to get life 
insurance.  The information could be used against you in the work setting. 
You may be asked to give us health information about your relatives. Any information you 
give us will be kept confidential. We will not contact your relatives without your permission. 
We may discuss with you the possibility of including your relatives in the research project in 
the future. You may learn information from your test result about inherited diseases or 
disorders that may affect others, such as your brothers or sisters. This could interfere with 
family relationships. You may be faced with the decision to make the family aware of the 
existence of genetic information. Family members may or may not wish to know this 
information. Therefore, although we think that there are benefits in having that information, 
individuals have to weigh up the risks and decide whether or not to receive that 
information.  In the unlikely event that a risk for an unrelated genetic condition is identified 
we will help to put you in contact with a local genetics service.  
If we identify that you could be at risk for a disorder, which is currently untreatable and 
unpreventable, we will not disclose this information. 
If you become upset or distressed as a result of your participation in the research, the 
researcher is able to arrange for counselling or other appropriate support. Any counselling or 
support will be provided by staff, who are not members of the research team. In addition, you 
may prefer to suspend or end your participation in the research if distress occurs. 
What if new information arises? 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information 
and the researcher will discuss whether this new information affects you. 
How will I be informed of results from of this research project? 
In relation to any genetic information generated from use of your DNA, you may elect to: 
1. Have no information returned to you.
2. If a risk factor for a treatable condition is identified, have information returned to you
to provide to your medical practitioner for consideration, verification testing and
possible clinical or other action.
If your preference is not to receive genetic information, a researcher will contact you 
following the completion of genetic testing to ensure that this preference still remains. 
What will happen to information about me? 
In accordance with relevant Australian privacy and other relevant laws, you have the right to 
access the information collected and stored by the researchers about you. You also have the 
right to request that any information, with which you disagree, be corrected. Please contact 
one of the researchers named at the end of this document if you would like to access your 
information. 
If you wish to discuss further the experimental procedure or have any questions, please do 
not hesitate to contact Dr Nicole Vlahovich phone (02) 6214 7319 or email 
injurystudy@ausport.gov.au  
If you have any concerns with respect to the conduct of this study, you may contact the 
Secretary of the Bond University Human Research Ethics Committee Dr Lisa Marlow on (07) 
5595 4194 or by email lmarlow@bond.edu.au  
Appendix   10 – Mail package with consent forms
Thank you for agreeing to participate in The genetics of exercise induced injuries 
involving tendon and bone.  
Please set aside 5 minutes to collect the sample and fill out the paperwork. 
Please follow the steps below, skipping a step could mean that your sample is 
unable to be included in the research: 
1. You must wait 30 minutes after eating, drinking or smoking before
providing a saliva sample.
2. Read the Participant Information Sheet and the document entitled The
Ethics of Genetic Research - ethically defensible plan. Contact the
researchers using the email/phone number provided if you have any
questions.
3. Once the information is read and understood, sign the consent form (the
form marked COPY is for you to keep for your own reference).
4. Open the Oragene – DNA kit and carefully read the instructions provided on
the next page, follow the five steps carefully. Please ensure that the sample
fills the tube to the line without any bubbles
5. Place the collection tube (but not the funnel) into the biohazard bag.
6. Place the following in the reply paid envelope:
a. Tube containing saliva sample in the biohazard bag
b. The signed consent form (single page only)
then seal and place the envelope in the post. 
Please do not hesitate to contact the AIS if you have any questions or issues. 
Kind regards, 
Nicole Vlahovich  




Read all instructions prior to collection
P Emergo Europe, Molenstraat 15, 2513 BH The Hague, The NetherlandsTel: (+31) (0) 70 345-8570     Fax: (+31) (0) 70 346-7299
Australian Sponsor: Emergo Australia, Level 20, Tower II, Darling Park, 201 Sussex Street, Sydney, NSW 2000 Australia
Oragene®•DNA is not available for sale in the United States.
®Oragene is a registered trademark of DNA Genotek Inc. 
Some DNA Genotek products may not be available in all geographic regions, contact your sales representative for details.
All DNA Genotek protocols, white papers and application notes, are available in the support section of our website at 
www.dnagenotek.com.
Patent (www.dnagenotek.com/legalnotices) 





M DNA Genotek Inc.





For In Vitro Diagnostic Use
Procedure:
Most people take between 2 and 5 minutes to deliver a saliva sample 
following steps 1 to 5. 
1 Spit into funnel until the amount of liquid saliva (not bubbles) reaches the 
 ll line shown in picture #1.
2 Hold the tube upright with one hand. Close the funnel lid with the other hand 
(as shown) by  rmly pushing the lid until 
you hear a loud click. The liquid in the 
lid will be released into the tube to mix 
with the saliva. Make sure that the lid is 
closed tightly.
3 Hold the tube upright. Unscrew the funnel from the tube.
4 Use the small cap to close the tube tightly.
5 Shake the capped tube for 5 seconds. Discard or recycle the funnel.
Collection precautions:
Do NOT eat, drink, smoke or chew gum for 
30 minutes before giving your saliva sample.
Do NOT remove the plastic film from 
the funnel lid.
Intended use: For the collection of human DNA 
from saliva samples.
Contents: Kit contains stabilizing liquid.  
Warnings and precautions: Wash with water if 
stabilizing liquid comes in contact with eyes or skin. 
Do NOT ingest. See MSDS at www.dnagenotek.com.
Small cap, choking hazard.
Storage: 15°Cl30°C
Summary and explanation of the kit:
Oragene•DNA is a self-collection kit that provides 
the materials and instructions for collecting and 
stabilizing saliva specimens.
Label legend:
i Consult package insert
H Collect saliva by (Use by)
V In vitro diagnostic medical device
h Catalog number
C CE Marking
















A study to investigate the relationship between genes, physical activity and health 
status. 
 
Title The genetics of exercise-induced injuries 
involving tendon and bone 
Protocol Number RO21688B 
Project Sponsor CRN for Advancing Exercise & Sports Science 
Principal Investigator Dr David Hughes 
Associate Investigator(s) 
 
Dr Nicole Vlahovich, Maria Kozlovskaia 
(Department of Sports Medicine, Australian 
Institute of Sport), A/Prof Bon Gray, A/Prof Lotti 
Tajouri, A/Prof Justin Keogh, A/Prof Mike 
Climstein, Rebecca Grealy, A/Prof Kevin Ashton 
and Professor Nuala Byrne (Bond University), 
Professor Matthew Brown and Dr Paul Leo 
(University of Queensland) and Professor Maria 
Fiatarone Singh, Dr Yorgi Mavros, Guy Wilson 
and Jacinda Meiklejohn (University of Sydney). 
Location  Australian Institute of Sport, Bond University & 
CRN partner organisations 
 
Introduction 
You are invited to take part in this research project because you completed the online survey 
for the study the genetics of exercise-induced injuries involving tendon and bone, agreeing 
to follow up genetic analysis and you are: 
 
 A recreational runner, 
 Aged 18-50 years of age, 
 Run greater than 15km per week, and 
 Fall into one of the following categories: 
o Uninjured* for the past two years (*no  injury below the knee due to running 
that required you to discontinue running for a period of 2 weeks or more) 
o Diagnosed with a below knee bone stress injury caused by running, by a 
physician or physiotherapist and confirmed by diagnostic imaging, in the last 
2 years 
o Diagnosed with Achilles tendinopathy or Achilles tendinitis caused by running, 
by a physician or physiotherapist in the last 2 years 
 
The Participant Information and Consent Forms tell you about the research project. It 
explains the procedures involved. Knowing what is involved will help you decide if you want 




Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, you 
might want to talk about it with a relative, friend or healthcare worker. 
 
Participation in this research is voluntary. If you don’t wish to take part, you don’t have to. 
You will receive the best possible care whether you take part or not. You’re not obliged to 
participate and if you do, you can withdraw at any time without penalty or prejudice and any 
samples that you have provided will be disposed of. 
 
If you agree to participate in this study, we would like you to complete the enclosed 
paperwork and provide a saliva sample according to the enclosed instructions. 
 
All aspects of the study including your personal details and results will be strictly confidential 
and only the principal researchers above will have access to this information.  
 
If you decide you want to take part in the research project, you will be asked to sign the 
consent section. By signing it you are telling us that you: 
 understand what you have read;  
 consent to take part in the research project; 
 consent to participate in the research processes that are described; 
 consent to the use of your personal and health information as described 
 certify to the best of your knowledge and belief, you have no physical or mental 
illness or weakness that would increase the risk to of participating in this 
investigation; 
 are participating in this project of your own free will and have not been coerced in any 
way to participate; 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
What is the purpose of this study? 
Identifying sequences or new mutations in known genes will help researchers to better 
understand the relationship between lifestyle, health status and genetic profile and we hope 
that this information will ultimately improve health and quality of life, prevent injury or 
disability, and prevent or treat chronic diseases. The genetic sequence information will 
provide new insights into the genetic factors associated with exercise-induced injuries in 
recreational and elite athletes.  
 
This research is being conducted by a collaboration between Bond University, the Australian 
Institute of Sport, the University of Queensland and the University of Sydney. 
 
What does participation in the research project involve? 
Participation is this portion of the project involves the provision of a saliva sample for genetic 
analysis. Enclosed are the consent forms to read and sign, a kit that will help you collect the 
specimen and return envelope to return your sample. This process should take 
approximately 10-15 minutes.  
 
What are the possible benefits to participating? 
We cannot guarantee that you will receive any benefits from this research, but your 
participation in the study may help doctors to better understand the relationship between 
lifestyle, health status and genetic profile with the hope that this will ultimately improve health 




What will happen to my test sample and what are the possible risks to participating in 
the study? 
Please see the document The Ethics of Genetic Research 
 
What if new information arises? 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information 
and the researcher will discuss whether this new information affects you. 
 
Can anyone participate in this study? 
As long as you meet the criteria specified earlier, and have participated in the online survey, 
you are eligible to take part.   
 
Do I have to take part in this research project? 
If you do not wish to take part then you don’t have to.  If you decide to take part and later 
change your mind, you are free to withdraw at any stage.  All information that you have 
provided can be destroyed at any time. You can withdraw your consent to participate in this 
research project by emailing the Principal Investigator at injurystudy@ausport.gov.au 
 
Before you make a decision to participate in any follow up studies, a member of the research 
team will contact you so that you can ask any questions you have about the project.  You 
can ask for any information that you want.   
Is this research project approved? 
This project will be carried out according to the National Statement on Ethical Conduct in 
Research Involving Humans (2007) produced by the National Health and Medical Research 
Council of Australia.  This statement has been developed to protect the interests of people 
who agree to participate in human research studies. 
 
The ethical aspects of this research project have been approved by Bond University Human 
Research Ethics Committee; protocol number RO21688B, contact Dr Lisa Marlow, Research 
Ethics Manager on (07) 5595 4194.      
 
Will I get paid to participate in this study? 
You will not be paid for participating in this study but all costs such as expenses involved 
with any investigation, posting of forms, questionnaires and samples will be covered 
 
Who can I contact if I have any questions or problems in relation to this study? 
If you wish to discuss further the experimental procedure or have any questions, please do 
not hesitate to contact Dr Nicole Vlahovich phone (02) 6214 7319 or email 
injurystudy@ausport.gov.au 
If you have any concerns with respect to the conduct of this study, you may contact the 
Secretary of the Bond University Human Research Ethics Committee Dr Lisa Marlow on (07) 







The genetics of exercise-induced injuries involving tendon and bone information 
sheet 
Genetic Sample and Data Consent 
 
Principal Investigator: Dr David Hughes 
 
 
Statement of Informed Consent for Genetic Sample and Data Collection 
 
I have read, or had read to me in a language that I understand, this Participant Information 
Sheet and I understand the purposes, procedures and risks of this research project as 
described within it.  I have had the opportunity to ask questions and I am satisfied with the 
answers I have received. 
 
I give permission for my anonymised sample and/or clinical information to be shared 
by the Investigators of this study with collaborating researchers who have ethically 
approved studies and are researching the relationship between genes, physical 
activity and health status. 
 
I give permission for my anonymised sample and/or clinical information to be part of 
the Biobank, to be shared with other researchers who have ethically approved 




I understand that there is a very small chance that this study could identify a genetic defect 
that increases my risk for an unrelated condition. 
 
I would like to be informed if a risk factor for a treatable condition is 
identified 
I would NOT like to be informed if a risk factor for a treatable condition is 
identified 
 
I understand that I will not receive genetic results for conditions where there is no known 
treatment at the time the result becomes available. 
 
I understand that, due to the type of genetic test being performed, participation in this 
research project will not provide me with a clearance from any genetic or heritable 
conditions.   
 













Name of Researcher                                            Date                     Signature of Researcher    
 
The Ethics and Risks Associated with 





A study to investigate the relationship between genes, physical activity and health 
status. 
 
What is genetic research? 
Genes are made of DNA – the chemical structure carrying your genetic information that 
determines many human characteristics such as the colour of your eyes. Researchers study 
how genes are expressed in order to understand why some people differ in their response to 
exercise and to develop, improved and individualised approaches to exercise prescription. 
This will potentially provide new ways in which to reduce disease within the wider community 
 
What will happen to my test sample? 
Saliva samples will be used immediately or stored for future studies. Saliva samples will be 
used to extract your DNA.  DNA sequence and other information obtained in this research 
project will be stored securely, with each participant sample allocated a specific code 
number. All data processing will occur by use of this number and not the participant’s name. 
However all samples are potentially re-identifiable and must remain so to satisfy the aims of 
the research and also to identify participants if required for the return of genetic information.  
 
The samples will be tested using genome-wide association studies. These studies are 
increasingly being used to identify biological pathways and networks underlying complex 
diseases. This type of genetic test is very unlikely to identify mutations associated with 
heritable diseases as it will not provide information about the whole genome, only portions of 
the genome which are unlikely to contain genes relating to disease.  
 
Researchers from the Australian Institute of Sport (Canberra), University of Queensland 
(Brisbane), the University of Sydney and Bond University (Gold Coast, Queensland) are 
collaborating to study your DNA samples for research only.  We may also share some 
information about your clinical information in our research group but all identifiers will be 
removed. All medical information is stored in password protected databases. 
 
We will also be establishing a biobank – this is a way of collecting and storing anonymous 
biological material and information for further research.  If you consent, your DNA will be 
stored and then can be used by other researchers for future projects.   
 
What are the possible risks of participating in the study? 
All medical information is stored in password protected databases.  It is possible, though 
highly unlikely, that someone could get access to this database without permission. All 
samples and participant data will be stored securely in locked facilities.  
 
This type of genetic test is very unlikely to identify mutations associated with heritable 
diseases.  However, as part of this study there is a small chance that we might coincidentally 
find a defect in a gene which, in the duration of the project, may be identified as being 
associated with an increased risk for a genetic condition. If the condition is treatable or 
preventable, you can specify on the consent form if you want to be informed about such a 
finding. Learning this information may be upsetting. It could also affect your ability to get life 
insurance.  The information could be used against you in the work setting. 
  
 
You may be asked to give us health information about your relatives. Any information you 
give us will be kept confidential. We will not contact your relatives without your permission. 
We may discuss with you the possibility of including your relatives in the research project in 
the future. You may learn information from your test result about inherited diseases or 
disorders that may affect others, such as your brothers or sisters. This could interfere with 
family relationships. You may be faced with the decision to make the family aware of the 
existence of genetic information. Family members may or may not wish to know this 
information. Therefore, although we think that there are benefits in having that information, 
individuals have to weigh up the risks and decide whether or not to receive that 
information.  In the unlikely event that a risk for an unrelated genetic condition is identified 
we will help to put you in contact with a local genetics service.  
 
If we identify that you could be at risk for a disorder, which is currently untreatable and 
unpreventable, we will not disclose this information. 
 
If you become upset or distressed as a result of your participation in the research, the 
researcher is able to arrange for counselling or other appropriate support. Any counselling or 
support will be provided by staff, who are not members of the research team. In addition, you 
may prefer to suspend or end your participation in the research if distress occurs. 
 
What if new information arises? 
During the research project, new information about the risks and benefits of the project may 
become known to the researchers. If this occurs, you will be told about this new information 
and the researcher will discuss whether this new information affects you. 
 
How will I be informed of results from of this research project? 
In relation to any genetic information generated from use of your DNA, you may elect to: 
 
1. Have no information returned to you. 
2. If a risk factor for a treatable condition is identified, have information returned to you 
to provide to your medical practitioner for consideration, verification testing and 
possible clinical or other action. 
 
If your preference is not to receive genetic information, a researcher will contact you 
following the completion of genetic testing to ensure that this preference still remains.  
What will happen to information about me? 
In accordance with relevant Australian privacy and other relevant laws, you have the right to 
access the information collected and stored by the researchers about you. You also have the 
right to request that any information, with which you disagree, be corrected. Please contact 
one of the researchers named at the end of this document if you would like to access your 
information. 
 
If you wish to discuss further the experimental procedure or have any questions, please do 
not hesitate to contact Dr Nicole Vlahovich phone (02) 6214 7319 or email 
injurystudy@ausport.gov.au  
 
If you have any concerns with respect to the conduct of this study, you may contact the 
Secretary of the Bond University Human Research Ethics Committee Dr Lisa Marlow on (07) 
5595 4194 or by email lmarlow@bond.edu.au  
The genetics of exercise-induced injuries involving tendon and bone information 
sheet 
Genetic Sample and Data Consent 
Principal Investigator: Dr David Hughes 
Statement of Informed Consent for Genetic Sample and Data Collection 
I have read, or had read to me in a language that I understand, this Participant Information 
Sheet and I understand the purposes, procedures and risks of this research project as 
described within it.  I have had the opportunity to ask questions and I am satisfied with the 
answers I have received. 
I give permission for my anonymised sample and/or clinical information to be shared 
by the Investigators of this study with collaborating researchers who have ethically 
approved studies and are researching the relationship between genes, physical 
activity and health status. 
I give permission for my anonymised sample and/or clinical information to be part of 
the Biobank, to be shared with other researchers who have ethically approved 
studies and are researching the relationship between genes, physical activity and 
health status. 
I understand that there is a very small chance that this study could identify a genetic defect 
that increases my risk for an unrelated condition. 
I would like to be informed if a risk factor for a treatable condition is 
identified 
I would NOT like to be informed if a risk factor for a treatable condition is 
identified 
I understand that I will not receive genetic results for conditions where there is no known 
treatment at the time the result becomes available. 
I understand that, due to the type of genetic test being performed, participation in this 
research project will not provide me with a clearance from any genetic or heritable 
conditions.   
I freely agree to participate in this research project as described. 
Name of Participant  Date  Signature of Participant 
Name of Researcher  Date  Signature of Researcher  
Participant COPY 
